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CHAPTER 1 
INTRODUCTION 
 
The Internet is a major source of information for health issues for the 
general public. According to the Pew Internet Project (2002), 62% of Internet 
users, or 73 million people in the United States, have gone online in search of 
health information. The growth of online direct-to-consumer advertising of 
prescription drugs in the United States is a growing phenomenon resulting in the 
proliferation of web sites for specific medical “conditions” and pharmaceutical 
“treatments.” As such, the dramatic increase in accessibility and availability of 
online information about prescription medications raises interesting questions 
about the Internet as a fluid marketing medium. In particular, consumer-targeted 
prescription drug advertising serves as an interesting lens through which we can 
begin to examine the portrayal of menopause in online drug advertisements. 
Therefore, the aim of this study was to explore the portrayal of menopause on 
web sites sponsored by pharmaceutical companies for hormone therapies (HT). 
Advertisements are one of the most important cultural factors molding and 
reflecting our lives (Williamson, 2002). Their very existence is more than a 
medium, advertising forms a “vast superstructure” with an immense influence to 
create structures of meaning (Williamson, 2002, p. 11). Direct-to-consumer 
advertising (DTCA) is defined as “any promotional effort by a pharmaceutical 
company to present prescription drug information to the general public through 
the lay media” such as popular magazines and television (Bradley and Zito, 
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1997, p. 86). Web sites are not merely just an informational venue rather they are 
another way that DTCA can reach consumers (Khim, 2009). In fact, 30% of 
Americans surveyed state that they have talked with a doctor about a specific 
medication as a result of some form of direct-to-consumer advertising (Kaiser 
Family Foundation, 2001). Because the selling of prescription drugs in the United 
States requires the cooperation of health care providers, direct-to-consumer 
advertisements contain messages that may function to motivate consumers to 
take action in the form of seeking out health care providers in order to obtain 
certain pharmaceutical products (Cline and Young, 2004).  
As Conrad and Leiter (2008) note, the Internet has become “another direct 
avenue from pharmaceutical companies to consumers, and one that is not limited 
to national boundaries” (p. 834). Broadly speaking, the Internet may provide 
unprecedented access to individuals and new opportunities for information 
retrieval, pharmaceutical marketing, and consumption (Fox, Ward, and O’Rourke, 
2006). Indeed, the Internet has further expanded the potential to reach specific 
audiences for pharmaceutical products. Therefore, how pharmaceutical web sites 
frame and construct messages is of particular interest because these messages 
play an important role in shaping cultural attitudes and beliefs. Interestingly, there 
are no specific regulations for Internet marketing in the United States and 
pharmaceutical web sites are expected to conform to the same guidelines 
established for any DTCA (Woodlock, 2005). Due to the lack of regulation 
pertaining to Internet marketing and DTCA, the role of direct-to-consumer 
3 
 
 
advertising of pharmaceuticals in a global information environment warrants 
further investigation.  
Previous research has examined the topics of women and menopause in the 
popular media, such as print, television, and radio advertisements. A standard 
definition of menopause found in the medical literature is the absence of 
menstrual periods for one year (Mansfield and Voda, 1997). The assumption that 
menopause will be accompanied by hot flashes, night sweats, vaginal changes, 
irritability, and depression has become ingrained in medical and popular culture 
in North America (Kaufert, 1996). Yet, research has shown that menopause is 
not a universal experience. Some women may experience difficulty during this 
transition while others will experience little, if any, discomfort (Mansfield and 
Voda, 1997). In this study, menopause is defined more broadly as a natural part 
of the aging process, rather than an event that limits women’s psychological or 
physical capacities (McCrea, 1983).  
The existing literature demonstrates that representations of menopause in 
newspapers and popular magazines as a hormone deficiency disease that can 
be easily “fixed” with drugs are common in the print media (Carlson, Li, and 
Holm, 1997; Cimons, 2008; Gannon and Stevens; 1998; Hust and Andsager, 
2003; Lyons and Griffin, 2003; Shoebridge and Steed, 1999). Previous research 
has also shown that hormone therapies (HT) have been frequently portrayed as 
the remedy for menopausal symptoms and even as an “elixir of life” in helping 
women to maintain youthfulness (Watkins, 2007, p.1). The term hormone 
therapies (HT) refers to when a woman takes supplements of hormones, such as 
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estrogen alone or estrogen with another hormone called progesterone (progestin 
in its synthetic form) for menopause (FDA, 2008b).  
Hormone therapies come in many forms and dosages, including skin patches, 
vaginal tablets or creams, and prescription pills. In addition, implants, shots, or 
vaginal ring inserts are also available (National Institute on Aging, 2009). As 
Conrad (2007) notes, early medical articles reported that estrogen could “reduce 
menopausal symptoms” (p. 121). In addition, some medical articles also claimed 
the preventive benefits of estrogen, such as preventing breast cancer (McCrea, 
1983). Other presumed benefits for women taking HT were thought to be a 
“lower risk of coronary heart disease, hip and spinal fracture, vaginal atrophy, 
urinary incontinence and, possibly, Alzheimer’s disease” (Kaufert and Lock, 
1997, p. 84).  Furthermore, magazines and newspapers periodically run articles 
about menopause and the results of major medical studies relating to HT are 
reported. As a result, menopause and HT have become popular topics in the 
print media.  
In 1997, hormone therapies were part of a large set of clinical trials called 
the Women's Health Initiative (WHI). These large, multi-center trials were part of 
the largest coordinated study of women's health ever undertaken by the National 
Institutes of Health. Although the WHI study began in 1997 and was expected to 
run at least 10 years, the National Institutes of Health abruptly terminated a major 
clinical trial in June 2002 when unexpected results indicated increased risks for 
heart disease, stokes, blood clots, and breast cancer for those using HT. In light 
of the landmark decision to stop the WHI clinical trial early, there has been an 
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explosion of “media attention leading to confusion among women and health 
professionals about the benefits, risks, and uncertainties” regarding hormone 
therapies (Rees, 2005, p. 287).  
Despite these risks, the HT industry continues to be a multi-billion dollar 
business “admonishing women to do everything within their power to resist 
hormonal decline and atrophy” (Perz and Ussher, 2008, p. 294). Existing 
research on direct-to-consumer marketing shows that HT was advertised heavily 
to health professionals via medial journals and featured drugs for hormone 
replacement. As such, advertisements for HT published in professional and trade 
journals portrayed menopause as a “deficiency disease” advocating for HT as a 
widespread treatment for women (Richter, 2002; Whittaker, 1998). Yet, little is 
known about online direct-to-consumer advertising strategies and campaigns for 
hormone therapies aimed directly at the general public. In fact, Worcester and 
Whatley (1992) speak of the importance of evaluating and critiquing the mass 
marketing of hormones. Furthermore, Worcester (2004) states that “consumer 
literacy and action related to demanding safe, effective products, marketed by 
ethical corporations, and administered by physicians who have accurate, 
science-based information is urgent” (p. 62). Thus, an important step in 
unraveling the DTCA strategies employed on pharmaceutical web sites is to 
explore the representation of menopause in online advertisements for hormone 
therapies.  Specifically, I am interested in exploring the information content and 
how menopause is portrayed on web sites for hormone therapies sponsored by 
pharmaceutical companies.  
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Purpose of Study 
 
To better understand the construction of menopause in online DTCA drug 
advertisements, the purpose of this study was to explore how menopause was 
being portrayed on web sites for hormone therapies sponsored by 
pharmaceutical companies. In examining the web sites, I was curious about the 
portrayal of menopause and information content presented on DTCA 
pharmaceutical web sites since the WHI. Given this, further research on the 
construction of menopause on contemporary web sites for hormone therapies 
sponsored by pharmaceutical companies eight years following the decision to 
stop the WHI clinical trial was warranted.    
 
Significance of the Study  
 
By analyzing how menopause is portrayed on web sites for hormone 
therapies sponsored by pharmaceutical companies, this study provides a missing 
piece in the understanding of representations of menopause in various media. In 
particular, my analysis addressed how menopause was constructed on 
pharmaceutical web sites in order to address the knowledge gap in relation to 
online representations of menopause. In examining these web sites, I was 
particularly interested in the messages that pharmaceutical companies were 
constructing and conveying about women and menopause. As Hust and 
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Andsager (2003) note, although media are only one venue for information, they 
are a “powerful means of transmitting ideas and shaping thought” (p. 116).  
Conrad and Leiter (2008) further state, DTCA establishes a direct and 
independent relationship between drug companies and consumers “encouraging 
self-diagnosis and requests for specific drugs” (p. 825).  
DTCA on the Internet has been called “one of the largest single threats to 
global healthcare safety” (Lorence and Churchill, 2007, p. 551). In fact, the 
advertising of prescription drugs to the general public is illegal in most countries. 
Legal DTCA is exclusive to New Zealand and the United States (Woodlock, 
2005). As online DTCA becomes increasing prevalent, a discussion of the 
implications of the broad reach of DTCA of hormone therapies on the World Wide 
Web was also warranted. Hence, both the growth and magnitude of DTCA 
prescription drug advertising on the Internet and its potential consequences for 
public health overall add to the importance of understanding its far-reaching 
influence. 
 
8 
 
 
CHAPTER 2 
LITERATURE REVIEW 
 
Introduction  
 
 Menopause has been theorized over the years by a range of medical, 
social science, and feminist researchers. In fact, a variety of differing 
perspectives on menopause exist and the paradigms through which menopause 
has been represented varies considerably (Lyons and Griffin, 2003). While the 
biomedical model views menopause as a “disease” that can be treated medically, 
other models have emerged offering alternate frameworks for understanding 
menopausal experiences. First, various models of menopausal research found in 
the literature will be discussed. Then, the rise in popularity of hormone therapies 
as a treatment for menopause is traced. Next, a brief history of the Women’s 
Health Initiative, the first major study to examine the effects of hormone 
therapies, is provided. Finally, federal regulations of direct-to-consumer 
advertising in the United States and the pharmaceutical industry’s involvement in 
marketing hormone therapies to physicians and consumers are discussed.  
 
Biomedical Model of Menopause 
 
According to Lyons and Griffin (2003), several paradigms of menopause 
research exist, of which the biomedical paradigm is the most dominant model. 
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Promoting a woman’s natural change of life as a medical condition of “estrogen 
loss” has a history dating back several decades (Moynihan and Cassels, 2005). 
In fact, the social construction of menopause as a “deficiency disease” has been 
well-documented in the sociological literature (for example, see: Bell, 1987; 
McCrea, 1983; Riessman, 1983; Posner, 1979). Negative biomedical definitions 
of menopause include portraying menopause as the “end of fertility, ovarian 
failure, or the loss of womanhood” (Dillaway, 2005, p. 400). Thus, meanings 
around the aging feminine body cemented in a biomedical approach to 
menopause center on “the loss of attractiveness, fertility, and function” (Lupton, 
1996, p. 92).  
Basically, the biomedical model assumes that menopause is “best understood 
in terms of the biology of disease mechanisms” (Derry, 2002, p. 20). In this 
prevalent model, menopause is considered to be pathological and abnormal 
(Bell, 1987). As noted above, the biomedical model regards menopause as an 
“estrogen deficiency disease for which estrogen replacement is the therapy of 
choice” (Kaufert and Gilbert, 1986, p. 8). Therefore, a biomedical perspective has 
constructed menopause as a negative event requiring medical intervention. As 
Derry (2008) notes, postmenopausal women “do produce estrogen in their 
bodies [and] these lower levels of hormone were assumed to be negligible” (p. 
722). 
Early medical reports suggested that estrogen could “reduce menopausal 
symptoms” (Conrad, 2007, p. 121). Articles in the scientific and medical literature 
also claimed the preventive benefits of estrogen, such as preventing breast 
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cancer (McCrea, 1983). Furthermore, Robert Wilson’s bestselling book entitled 
Feminine Forever (1966) declared a revolutionary breakthrough claiming that 
hormones would “cure” the disease of menopause and reverse signs of aging.  
Notably, the idea of menopause as a disease requiring medical treatment was 
popularized in a book entitled Feminine Forever (1966) by Robert Wilson, a New 
York physician and gynecologist. A central claim of the book was that 
menopause was a condition that required management by a medical 
professional. In this book, Wilson (1966) described menopausal women as 
diseased and proclaimed that their ovaries were dead. Wilson (1966) further 
asserted that menopause was an estrogen deficiency disease treatable with 
estrogen replacement therapy.  
Essentially, Wilson (1966) solidified the idea of “menopause as a disease,” 
employed terms which were primarily negative about women and aging, and 
focused on deficiency and deterioration which he claimed could be treated by the 
beneficial effects of estrogen. As a result, Wilson (1966) defined menopause as a 
biomedical event thereby laying the groundwork for treating menopause with 
hormones (Lyons and Griffin, 2003). Thus, the idea that menopausal women had 
an estrogen deficiency became widely accepted in society and established the 
foundation for a pharmaceutical “treatment” for menopause. 
The view of menopause as a disease necessitating medical treatment has 
been a dominate discourse in the scientific and medical literature (Voda, 1992). 
Rostosky and Travis (1996) also noted the predominance of articles in the 
scientific literature about menopause based on the biomedical paradigm. 
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According to Dickson (1993), menopause is frequently depicted by metaphors of 
disease or breakdown in the biomedical research. Additionally, Kaufert and Lock 
(1997) reported how the medical-scientific literature uses “graphs, tables, and 
histograms to demonstrate that women who take hormones are at a lower risk of 
coronary heart disease, hip and spinal fracture, vaginal atrophy, urinary 
incontinence, and, possibly, Alzheimer’s disease” (p. 84). Thus, advertisements 
and articles in the medical literature actively promote and disseminate a medical 
model of menopause.  
The biomedical perspective has also been dominant in popular media 
accounts of menopause (Lyons and Griffin, 2003). Interestingly, research 
indicates that women obtain much of their information about menopause from the 
media and other forms of popular culture, most notably a primary source of 
information is from women’s magazines (Clinkingbeard et al., 1999). Therefore, 
investigations into representations of menopause in the popular media are 
valuable.  
The growing interest in menopause is illustrated by the increasing number 
of articles published in the popular press (Carlson, Li, and Holm, 1997). An 
analysis of the “lay” literature on menopause over a 10-year period showed that 
most of the magazine articles blended opinion with fact, many of the authors of 
the articles did not state their credentials, and physicians were often quoted as 
experts about midlife women’s health (Carlson, Li, and Holm, 1997). Gannon and 
Stevens (1998) examined the portrayal of menopause in the British media over a 
15-year time period and found the articles emphasized this time of life as a 
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negative experience or as a disease needing medical treatment. Similarly, Hust 
and Andsager (2003) found that photos of women shown in magazines over a 
20-year period were predominately white and the coverage was narrowly focused 
on scientific developments related to fertility. Shoebridge and Steed (1999) also 
examined the print media in Australia. In particular, they assessed articles 
relating to menopause over a 10-year period in two daily newspapers and four 
women’s magazines finding that articles drew on and reinforced the biological 
nature and disease management aspects. Moreover, Lyons and Griffin (2003) 
analyzed four self-help texts and found that terms such as “symptoms, 
deficiency, and atrophy” were employed across all four of the texts about 
menopause (p. 1634).  
In sum, the biomedical model of menopause as a deficiency disease 
requiring medical treatment has dominated “both the popular and clinical 
domains” (Lyons and Griffin, 2003, p. 1631). The literature cited above 
demonstrates that the prevailing biomedical model is one that portrays 
menopause as a disease and offers a negative view of menopause. In addition, a 
biomedical approach has further been associated with the emergence of 
hormone therapies that can be prescribed to “treat” menopause.  
 
Socio-cultural and Feminist Models of Menopause 
 
One critique of the biomedical approach to menopause is that this perspective 
largely ignores “social and cultural aspects of the passage into menopause for 
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women in American society” (Bell, 1987, p. 539). Given this, some researchers 
have moved away from the biomedical perspective of menopause. In contrast, 
the socio-cultural paradigm views the experiences of menopause as a natural 
event in which social and cultural contexts and meanings are significant (Lyons 
and Griffin, 2003). The socio-cultural perspective of menopause was developed 
by sociologists, anthropologists, and others partly in response to the growing 
dominance of the biomedical model (Hunter and O’Dea, 1997). Arguing that 
women are “not diseased, defective, or disabled at menopause,” the socio-
cultural perspective considers menopause to be a natural process and normal 
event (Voda, 1992, p. 923). Essentially, the socio-cultural paradigm views 
menopause as a normal process and offers an alternative to the biomedical 
model. From this perspective, menopause is conceptualized as a natural part of 
the aging process, rather than an event that limits women’s psychological or 
physical capacities (McCrea, 1983).  
Another approach to understanding menopause found in the literature is a 
feminist paradigm which refutes the disease model. A feminist approach views 
menopause as a natural process and universal event for all women (Bell, 1987; 
Lyons and Griffin, 2003; Voda, 1992). According to this model, menopause is a 
significant landmark for women marking the normal “closure of menstrual life” 
(Voda, 1992, p. 923). Simply put, menopause is largely regarded in this model as 
a “natural life transition” (Zita, 1993, p. 61). Moreover, a feminist model considers 
menopause to be the point at which a woman ceases to menstruate and signifies 
the end of fertility (Lyons and Griffin, 2003). Some feminist researchers have also 
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highlighted positive aspects of menopause. For example, Zita (1993) notes while 
some women may experience this transition with difficulty, others may find it to 
be a positive and easy experience. Voda (1997) further elaborates that 
menopausal transition can be a time of personal growth and productivity.  
A feminist approach to understanding menopausal experiences offers a 
critique of the biomedical model of menopause. Bell (1987) argues that the 
biomedical model and negative constructions of menopause reinforce traditional 
ideas “of women as biologically different and inferior” (p. 538). In fact, the 
feminist model views menopause as “yet another biological experience [that has] 
been used to suppress women’s positions” in society (Lyons and Griffin, 2003, p. 
1630). As noted, the biomedical model suggests that menopausal symptoms are 
caused by a biological breakdown or malfunction, namely the lack of estrogen. 
As such, the definition of menopause as a disease derived from the biomedical 
model has “its origins in patriarchal views and beliefs of women as defective and 
imperfect” (Voda, 1992, p. 923). Derry (2004) further asserts a biomedical model 
of menopause directs attention to a simple variable, in this case estrogen, which 
can be modified in straightforward ways. Specifically, a biomedical model 
reduces the “problem [to] having the right amount of estrogen” (Derry, 2004, p. 
15). The basic reasoning, according to a biomedical model, remains that some 
kind of biological breakdown or malfunction can be altered with effective medical 
intervention.   
A feminist perspective also contends that the medical profession has helped 
to transform the “meaning of menopause and defined it as a medical problem 
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with a medical solution” (Bell, 1987, p. 539). According to medical reasoning, if a 
health care provider believed that menopausal symptoms resulted from a lack of 
estrogen, then estrogen replacement therapy was promoted as the logical 
solution (Bell, 1987). If the disease definition of menopause is accepted, then 
women should report any change or symptom to their physician to be medically 
managed. Thus, physicians (usually male) reinforced their dominant social status 
as they also reinforced the subordination of women by “giving expert advice 
about how to grow old gracefully” (Bell, 1987, p. 540). As a result, a feminist 
model regards this as one way in which the medical profession has been able to 
assert control over women’s experiences of menopause (Coney, 1994; Kaufert 
and Gilbert, 1986).  
For these reasons, feminist researchers and women’s health advocates 
contend that medicine does not have the right to “alter, manipulate, and control 
the life course of women” (Voda, 1992, p. 931). As Derry (2002) states, 
“menopause is larger than a medical event” (p. 22). Feminist approaches to 
menopause may also give voice to female experiences of menopause that have 
either been “silenced or erased by the medical gaze that sets it sights on the 
horrifying dangers” of menopause (Zita, 1993, p. 66). As such, a feminist view of 
menopause attempts to offer a broader model exploring the “social, cultural, and 
psychological variables that influence the experiences of menopausal women” 
(Derry, 2002, p. 21).  
Overall, various models of menopausal research exist in the literature. These 
models provide a framework through which we can begin to understand how 
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menopause has largely been defined and promoted as a medical problem 
requiring a medical solution. Clearly, the biomedical model of menopause has 
been the dominant discourse surrounding menopause and has permeated the 
scientific and popular literature. However, other models of menopause have 
emerged, such as the socio-cultural and feminist paradigms, seeking to refute 
the biomedical model by offering alternative perspectives through which 
menopause experiences can be understood. Nevertheless, the dominant 
discourse remains to be “menopause as a deficiency and disease” which is 
based on a biomedical paradigm firmly grounded in a medical approach to 
menopause.       
 
History of Hormone Therapies  
 
As noted above, the prevailing biomedical notion that menopausal symptoms 
are caused by a lack of estrogen helped to set the stage for a medical treatment 
for menopause. Accordingly, estrogen therapy could replace this biological 
deficiency. To fully appreciate the widespread use and acceptance of hormone 
therapies for the “treatment” of menopause, a brief history of the rise in popularity 
of hormone therapies in the last few decades is provided. The term hormone 
therapies (HT) refers to when a woman takes supplements of hormones, such as 
estrogen alone or estrogen with another hormone called progesterone (progestin 
in its synthetic form) (FDA, 2008b). It was presumed that “women who take 
hormones are at lower risk of coronary heart disease, hip and spinal fracture, 
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vaginal atrophy, urinary incontinence and, possibly, Alzheimer’s disease” 
(Kaufert and Lock, 1997, p. 84).  It is also important to note that these hormone 
therapies come in many forms and dosages, including skin patches, vaginal 
tablets or creams, and prescription pills. In addition, implants, shots, or vaginal 
ring inserts are also available (National Institute on Aging, 2009).  
As Conrad (2007) points out, early medical articles reported that estrogen 
could “reduce menopausal symptoms” (p. 121). In addition, some medical 
articles also claimed the preventive benefits of estrogen, such as preventing 
breast cancer (McCrea, 1983). Furthermore, Robert Wilson’s bestselling book 
entitled Feminine Forever (1966), which was discussed above, declared that 
hormones would “cure” the disease of menopause and reverse signs of aging. 
Although some of the proclaimed benefits of HT lacked scientific evidence, two 
symptoms in particular appear “to be related to declining levels of estrogen 
during the menopausal transition” (Mansfield and Voda, 1997, p. 59). Therefore, 
HT may be effective in helping to moderate hot flashes and vaginal dryness.  
As Derry (2004) noted, the “enthusiasm for hormone use” probably had many 
roots (p. 214). In the 1930s and 1940s, American medical professionals started 
using DES, a synthetic estrogen, to treat menopause (Bell, 1987). During this 
time period, medical professionals started investigating the use of this synthetic 
estrogen, raising the possibility of treating so-called hormone deficiencies in 
women with hormone therapies. Subsequently, this became the first widely used 
estrogen replacement therapy and it was approved for marketing in 1941 (Bell, 
1987).  
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Treatment with estrogen replacement therapy continued to grow. In the 
1960s, there was a surge of interest in estrogen therapy and estrogen sales 
soared. As previously noted, Dr. Wilson (1966) first popularized the notion that a 
wonder drug (estrogen) could prevent the aging process in women in the book 
Feminine Forever (Worcester and Whatley, 1992). In this book, the idea that 
estrogen could keep women young forever and prevent the “decaying” process of 
aging was promoted (Worcester and Whatley, 1992). As a result, idea of 
menopause as an “estrogen deficiency disease” became widely accepted in our 
society and laid the foundation for a medical “treatment” of menopause with 
hormone therapies (HT). 
By the mid-1970s, a series of research papers confirmed a link between 
estrogen and endometrial cancer (Mansfield and Voda, 1997). In reaction to this 
news, sales of estrogen dropped drastically. Yet, this did not deter 
pharmaceutical marketing efforts to promote hormones. This was followed by 
research attempts to find a way to protect a woman’s uterus from developing 
cancer.  In the 1980s, this research paid off and estrogens were re-introduced to 
consumers in combination with a progestin (Voda and Ashton, 2006). By adding 
a progestin to estrogen, the medical thought was that the uterine lining would be 
protected. The new combination treatment, in which a woman was given both an 
estrogen and a progestin hormone, meant that women would need to take 
hormones every day (Voda and Ashton, 2006). Needless to say, menopausal 
and postmenopausal women represented a huge potential market for the drug 
industry. 
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Also in the 1980s, a new marketing strategy focused on the prevention of 
heart disease and osteoporosis. In particular, pharmaceutical manufacturers 
aggressively advertised the preventative benefits of hormones to both health 
care providers and consumers. This was evident in mass marketing efforts that 
“encouraged all women over thirty-five years to consider taking estrogens to 
prevent osteoporosis” (Worcester and Whatley, 1992, p. 4, italics in the original). 
By linking osteoporosis with menopause, the implication was that “osteoporosis 
practically [became] identified as a symptom of menopause” (Worcester and 
Whatley, 1992, p. 9). As a result of this marketing campaign, women not only 
heard about osteoporosis but they were also “frightened by the seeming 
inevitability of postmenopausal hip fractures or of becoming like the elderly 
woman with the severely bent spine” they saw in drug advertisements (Worcester 
and Whatley, 1992, p. 4).  
The use of HT for protection against heart disease in women was another 
strategy employed by pharmaceutical companies to further generate interest in 
hormones. Despite solid clinical evidence supporting the preventative benefits of 
HT related to heart disease, this technique aimed to raise anxiety “to the point at 
which a new group of women [would] actively seek” hormone prescriptions 
(Worcester and Whatley, 1992, p. 4). As a consequence, HT became symbolic of 
“the pattern of untested, unneeded products being marketed to healthy women 
for pharmaceutical-company inspired ‘medical conditions’” (Worcester, 2004, p. 
57).  
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According to Worcester (2004), when drug companies started promoting HT 
for the prevention of heart disease and osteoporosis, “they hoped to hook women 
into a product they would stay on for the rest of their lives” (p. 63). Obviously, this 
strategy had consequences for women. A major ramification was that women 
would be using hormones “for the rest of their lives and dependent upon 
expensive medical services to monitor how their bodies adjust to these products” 
(Worcester and Whatley, 1992, p. 16).  
In the 1990s, researchers explored the possibility that estrogen loss may 
contribute to the development of Alzheimer's disease. As such, this fostered the 
idea that estrogen replacement therapy may be useful for preventing or delaying 
the onset of this dementia (Paganini-Hill and Henderson, 1994). At the same 
time, there was a growing awareness of a variety of health risks associated with 
hormone use, including gallbladder disease, elevated blood pressure, and blood 
clots (Mansfield and Voda, 1997). In addition, evidence began to surface about 
the relationship between estrogens and breast cancer. Not surprisingly, many 
women became reluctant about using hormones and had concerns regarding the 
long-term safety and effectiveness of hormone therapies.  
Given the growing concerns about the side effects and risks associated with 
hormones, women began questioning the benefits of using hormones. According 
to Mansfield and Voda (1994), the control of hot flashes and sleep disturbances 
were cited by women as primary reasons for continuing to use hormones. In 
addition, women also stated that they decided to take hormones because their 
health care provider recommended hormone therapy. Yet, some women cited 
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reasons for not using hormones which included that they did not perceive 
menopause as a condition needing treatment, as well as their ongoing concerns 
about risks or unpleasant side effects (Mansfield and Voda, 1994).  
Attitudes towards menopause and hormone use also vary between women in 
different social groups. For example, research has demonstrated that rates of 
hormone use are typically lower among African-American and Hispanic women in 
the United States (Kaufert and Lock, 1997). This pattern of hormone use is 
reflective of previous research also showing that attitudes towards menopause 
and aging differed across ethnic groups, with African American women having 
more positive views than those expressed by Caucasian women (Sommer et al., 
1999).  In fact, healthy, white middle-class women have typically been the usual 
subjects of hormone-related menopausal research (Kaufert and Lock, 1997). 
In light of the growing concerns over the potential risks associating with using 
hormones, the U.S. National Institutes of Health began a set of clinical trials in 
1997 to test hormone therapies known as the Women’s Health Initiative (WHI). 
Although the WHI study began in 1997 and was expected to run at least 10 
years, the National Institutes of Health halted a major clinical trial in June 2002 
when unexpected results indicated increased risks for heart disease, stokes, 
blood clots, and breast cancer for those using HT. Next, I turn to a discussion of 
the history of the WHI. 
 
History of the Women’s Health Initiative (WHI) 
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A large set of clinical trials known as the Women's Health Initiative (WHI) 
began in 1997. The WHI was a massive initiative of the U.S. National Institutes of 
Health (NIH) pertaining to the health of postmenopausal women and included 
several studies designed to evaluate the effects of prescribed hormone therapies 
(HT) on the incidence of heart disease. The first study evaluated the effects of 
daily use of a combination therapy consisting of estrogen plus progestin and this 
arm of the study became known as the Combination Hormone Therapy Study 
(Voda and Ashton, 2006). The second arm of the study, known as the Estrogen 
Hormone-only Study, evaluated the effect of Estrogen on heart disease (Voda 
and Ashton, 2006). Taken together, these large multi-center trials were part of 
the largest coordinated study of women's health ever undertaken by the National 
Institutes of Health. 
One component of the WHI was a clinical trial designed to test whether the 
combined therapy of estrogen plus progestin was safe and effective for the 
primary prevention of coronary heart disease and was ended prematurely in July 
2002 (Derry, 2004). As originally designed, subjects involved in this clinical trial 
were to be followed for 8.5 years. However, WHI researchers announced that the 
study was going to be halted after an average of 5.2 years of follow-up after an 
excess number of subjects developed breast cancer (Derry, 2004). 
As Voda and Ashton (2006) have pointed out, the “theoretical underpinning of 
the WHI” was embedded in a biomedical model that defined menopause as a 
state of estrogen deficiency that could lead to disease (p. 402). To help further 
illustrate this point, a separate clinical trial of the WHI examined whether 
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estrogen alone was safe and effective for heart disease prevention. This second 
arm of the WHI was also halted earlier than originally planned, in 2004, when 
study participants had an increased risk of stroke (Derry, 2004). Thus, the WHI 
clinical trials provided “strong clinical trial evidence that postmenopausal HT does 
not prevent heart problems” (Derry, 2008, p. 731). 
As a result of the WHI findings, the FDA concluded that HT should be used 
only for treatment of hot flashes, vaginal dryness, and possible osteoporosis at 
the lowest dose and for the shortest period of time (FDA, 2003). In brief, risks to 
health such as stroke and breast cancer were found, the studies were 
prematurely discontinued, and acclaimed benefits of hormone use were not 
supported (Voda and Ashton, 2006). Indeed, the WHI findings had a “seismic 
effect on menopausal women’s health care in the U.S. and the rest of the 
Westernized world” (Voda and Ashton, 2006, p. 402).  
Yet, the idea that hormone therapy is “a valuable and powerful agent” to treat 
menopausal symptoms has not subsided resulting in campaigns from 
pharmaceutical companies to resurrect hormone therapies (Voda and Ashton, 
2006). As a result, HT are being strategically re-introduced to health care 
providers and consumers with an emphasis on improving the “quality of life” of 
menopausal women (Voda and Ashton, 2006, p. 410).  Presently, women are 
again encouraged to take hormones, only now it is for symptom relief. This 
“resurrection” is being witnessed in the promotion of HT as a viable treatment for 
“debilitating” menopausal symptoms, such as hot flashes, burning, itching, and 
painful urination (Derry, 2006, p. 406). Still implicit in this approach in the belief 
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that women are “hormone deficient [and…] the right combination of hormones 
can be found to prescribe” for any so-called menopausal symptom (Derry, 2004, 
p. 408). Ultimately, this thinking continues past practices and beliefs of 
menopause as a deficiency disease treatable with hormone therapies. In 
particular, direct-to-consumer advertising is one way that pharmaceutical 
companies are aggressively marketing hormone therapies to potential 
consumers for their products.    
 
Direct-to-Consumer Advertising 
 
Direct-to-consumer advertising (DTCA) is a growing area of pharmaceutical 
marketing activity (Berger et al., 2001). DTCA is defined as “any promotional 
effort by a pharmaceutical company to present prescription drug information to 
the general public through the lay media” such as popular magazines and 
television (Bradley and Zito, 1997, p. 86). The FDA further states that direct-to-
consumer advertisements are “published in magazines and newspapers that are 
distributed to a general audience rather than to healthcare providers such as 
doctors, nurses, and pharmacists [and] can also be broadcast through television 
or radio” (FDA web site: 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdverti
sing/ucm072025.htm. Retrieved: August 22, 2010). Currently, DTCA is only 
permitted in the United States and New Zealand (Conrad and Leiter, 2008). In 
the United States, DTCA is unique because prescription pharmaceutical products 
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cannot be purchased without a physician's prescription and DTCA is also 
regulated by the FDA (Huh and Langteau, 2007).  
In light of increasing direct-to-consumer advertising efforts, it is helpful to 
understand several advertising principles involved in the naming, labeling, and 
packaging of pharmaceuticals. Drug companies use several criteria for selecting 
a brand name. First and foremost, the name of the drug “must be easy to 
remember” (Kenagy and Stein, 2001, p. 2036).  The name of the drug should 
also be easy to spell (Gundersen, 1998). Ideally, the drug name should be one 
that physicians and consumers will not confuse with another product. The use of 
color in the product packaging may help to differentiate the pharmaceutical 
product from other competitors (Kenagy and Stein, 2001). In addition, drug labels 
should be easy to read and the name of the drug should be the most prominent 
feature (Kenagy and Stein, 2001). Taken together, these key principles constitute 
the common practices involved in the naming and marketing of prescription drug 
products. 
 
FDA Regulations of DTCA 
 
Between the years of 1906-1980 in the United States, advertising of 
prescription medications was restricted to physicians only (Conrad and Leiter, 
2008). Specifically, the pharmaceutical industry promoted HT to physicians in 
multiple ways. First, the pharmaceutical industry purchased advertising space in 
medical journals. Although prescription drug advertising is not a new 
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phenomenon with the medical community, advertisements in medical journals 
functioned as a way to introduce HT to physicians. Advertisements for HT, which 
were placed in these journals specifically to influence doctors and their 
prescribing patterns, contain “concepts and ideas that are prevalent across the 
history of medical journals ads” (Richter, 2002, p. 16). For instance, advertising 
messages in medical journals portrayed menopause as an illness and reinforced 
the authority and patriarchal role of physicians (Richter, 2002).    
In addition, the ads also reinforced the prescribing of estrogen products to 
midlife and older women. In particular, ads for HT emphasized the physician’s 
ability to help women (Watkins, 2007). For instance, ads showed images of both 
distraught women and cheerful women signifying before medication and after 
medication (Watkins, 2007). Furthermore, these portraits contributed to the 
negative images of midlife and older women in American society (Whittaker, 
1998).   
Moreover, HT advertisements in medical journals expanded from focusing 
on short-term “symptoms” of menopause to include indications for long-term use.  
By promoting HT for the prevention of the “long-term ravages of aging,” 
pharmaceutical companies tapped into the potentially enormous market of older 
women in America (Watkins, 2007, p. 54). In fact, some advertisements in 
medical journals approached the length of journal articles, including four-page 
spreads offering references and results of clinical studies to help make the case 
for the efficacy of HT (Watkins, 2007).  
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Forging alliances with physicians in preventing diseases was another 
strategy employed by pharmaceutical companies to create a potential captive 
market. In particular, Dukes (1997) states “osteoporosis was clearly a central 
target if the physicians were to be won” (p. 185). Therefore, pharmaceutical 
company-funded patient booklets were produced and distributed to physicians. 
These patient booklets and leaflets emphasized the benefits of HT, such as relief 
from hot flashes, night sweats, and the reversal of bone loss, and were readily 
available to women in waiting rooms at doctors’ offices. As a result, HT was 
constructed by the pharmaceutical industry as a “preventive measure” for 
osteoporosis (Worcester and Whatley, 1992). In fact, Moynihan and Cassels 
(2005) refer to this alliance between parts of the medical profession and 
pharmaceutical companies as the “menopause industry” (p. 48).  
The promotion of drugs to physicians has been “one of the reasons for the 
success” of HT (Katz, 2004, p. 931). Existing research has elucidated how 
pharmaceutical companies embarked on a crusade through an array of 
marketing techniques to promote HT to physicians. Through several strategies, 
the pharmaceutical companies effectively promoted HT as a “blanket therapy for 
all women” (Dukes, 1997, p. 185). Strategies used by the pharmaceutical 
industry to shape medical opinion included purchasing advertisement space in 
medical journals, forging alliances with physicians in preventing osteoporosis, 
and producing patient information booklets to be distributed to women in waiting 
rooms. Indeed, the pharmaceutical industry’s campaign to convey messages to 
physicians in order to expand the market for HT has been strategic and 
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calculated. From these advertisements, physicians received the message that 
unflattering and undesirable “symptoms” of menopause, as well as aging in 
general, were treatable by HT.  
 
DTCA and Print Media 
 
In the 1980s, pharmaceutical companies started expanding DTCA to the 
general public in magazines and newspapers. The dramatic growth in DTCA can 
be traced to 1985 when the FDA lifted restrictions on advertisements of 
prescription medications aimed at consumers. In 1985, the FDA determined that 
existing regulations in place for advertisements to physicians were sufficient to 
cover print advertisements aimed at consumers (Perri, Shinde, & Banavali, 
1999). As a result, the FDA permitted the pharmaceutical industry “sufficient 
latitude to allow a broader engagement with print ads for prescription drugs” 
(Conrad and Leiter, 2008, p. 834). Since then, the growth of DTCA of prescription 
drugs has “grown exponentially” (Cline and Young, 2004, p. 132). 
In addition to strategies used by pharmaceutical companies to shape medical 
opinion about HT, the drug industry also employed a number of DTCA tactics to 
shape public opinion. These DTCA strategies included consumer awareness 
campaigns designed to “build a collective consciousness regarding estrogen 
therapy for menopausal and postmenopausal women” (Palmlund, 1997, p. 159). 
As a result, a new brand of DTCA was witnessed in the form of consumer 
awareness education programs.  Frequently, newspaper ads failed to mention 
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that drug companies were funding the campaigns (Moynihan and Cassels, 2005). 
The hidden company sponsorship of such consumer awareness campaigns has 
been criticized as “marketing masquerading as education” (Moynihan and 
Cassels, 2005, p. 55). Nonetheless, “consumer education” efforts saturated 
advertisements in newspapers and popular magazines informing women that 
they should demand their doctors prescribe HT for menopausal symptoms 
(Cimons, 2008).  
Whittaker (1998) also conducted an analysis of HT advertisements in 
magazines and found that information in popular magazines relied heavily on the 
importance of doctors prescribing HT for the woes of menopause and aging. 
Interestingly, Whittaker (1998) found that women in the HT advertisements were 
generally portrayed with “naked or near naked bodies that were in most 
instances impossibly youthful for the age group they were representing” (p. 78). 
Moreover, the images implied that women taking HT would “not succumb to 
exhaustion, diminution, deficiency or decay” as a result of menopause 
(Whittaker, 1998, p. 80). Thus, traditional definitions and idealized notions of 
femininity, youth, and beauty prevailed in the DTCA advertisements for HT. The 
advertisements cemented the idea that “menopause is an inevitable but 
unnatural and undesirable process” (Richter, 2002, p. 2). 
 In addition, DTCA in popular women’s magazines conveyed the 
“consistent message of the necessity” of hormone therapies (Watkins, 2007, p. 
70). Women were advised to seek medical counsel, even if they did not have any 
symptoms (Watkins, 2007). Thus, popular information about menopause and HT 
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in newspapers and magazine DTCA followed the medical model and echoed 
what women were hearing from the medical establishment (Watkins, 2007). This 
is troubling given the fact that previous research has reported women cited 
popular magazines as a primary source of information they consulted for 
information about menopause (Clinkingbeard et al., 1999). Consequently, 
advertisements for HT in popular magazines aimed at women perpetuated 
messages that menopause was “difficult to come to terms with because [women] 
are supposedly physically, sexually and emotionally in decline” (Whittaker, 1998, 
p. 80).  
The use of high-profile celebrities was another means used by 
pharmaceutical companies to promote HT directly to women. Widely recognized 
celebrities, such as Lauren Hutton, singer Patti LaBelle, and actress Cheryl Ladd 
appeared in magazine advertisements as health advocates on an important 
mission to educate the public about menopause and the “medical condition of 
estrogen loss” (Moynihan and Cassels, 2005, p. 45). By reinforcing public fears 
about menopause and aging, celebrity campaigns promoting the use of HT were 
effective in helping to transform the way the general public viewed common 
ailments. After all, the goal of these company-funded celebrity campaigns was to 
“drive patients into doctors’ offices to seek treatment” (Moynihan and Cassels, 
2005, p. 44). 
In order to further expand markets for their products, pharmaceutical 
companies also created DTCA capitalizing on fear. Another DTCA strategy to 
promote HT to women was the promotion of fear and anxiety about “future ill-
31 
 
 
health in healthy individuals” (Mintzes, 2006, p. 0461). For many years, drug 
companies actively marketed HT for the prevention of heart disease (Katz, 2003). 
As seen with the marketing of HT to physicians to prevent osteoporosis, selling 
HT directly to women also linked osteoporosis as a “symptom” of menopause in 
such a way to create fear. Specifically, Wyeth-Ayerst advertisements featured 
postmenopausal hip fractures and images of older women with severely bent 
spines (Worcester and Whatley, 1992).  Furthermore, HT advertisements 
encouraged all women over thirty-five years to consider taking hormones for 
osteoporosis as a “preventive measure” (Worcester and Whatley, 1992, p. 9). 
Thus, defining menopause as a risk for other conditions further illustrated how 
pharmaceutical companies were able to target menopausal and postmenopausal 
women intentionally with a manufactured idea intended to create a “social 
demand” for hormone products (Palmlund, 1997, p. 162).   
Consequently, the information women received from DTCA in newspapers 
and magazines was biased towards the use of hormones. As a result, women 
“learned to view menopause in terms of increased health risks that could be 
prevented” with HT (Mintzes, 2006, p. 0462). By redefining the use of HT for 
menopause in terms of prevention, osteoporosis became a mechanism for the 
pharmaceutical industry to provoke undue anxiety in order to expand their 
marketing of HT as a preventive measure (Mintzes, 2006).  
A review of the literature helps to establish a picture of how 
pharmaceutical companies utilized DTCA to promote HT to women. The selling 
of HT directly to women was accomplished through pharmaceutical company-
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based “consumer awareness programs,” which largely consisted of 
advertisements in newspapers and popular magazines informing women to ask 
their doctors about HT. Furthermore, the use of celebrity spokespeople helped to 
transform the way the general public viewed menopause. Thus, women learned 
about the existence of HT and the claims made for the potential benefits, 
including its anti-aging effects (Watkins, 2007). In addition, information in popular 
magazines depicted negative images of menopause and supported following the 
advice of a medical expert. In particular, DTCA in newspapers and magazines 
transmitted the notion that menopause was best navigated and “managed” with 
guidance of a physician. Through the use of celebrities and advertisements in 
print media, the pharmaceutical industry presented women with a positive image 
of hormone therapies, made claims for its potential healing effects, and 
supported physicians as the experts in “treating” women’s reproductive health 
experiences.   
 
Revised DTCA Regulations and Implications 
 
In 1997, the FDA published revised guidelines that had major implications for 
direct-to-consumer advertising beyond print ads. Pharmaceutical companies 
could now market product-specific prescription medications, allowing both the 
name and use of a medication to be mentioned, directly to consumers through 
broadcast advertisements on television and radio. Essentially, this policy change 
made it easier for pharmaceutical companies to advertise via broadcast media, 
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such as television and radio, because it eased the type of risk disclosure needed. 
Previously, regulations required drug companies to furnish a summary of the 
product label, including all of the risk-related information in a product’s package 
labeling, in any promotional materials (Gellad and Lyles, 2007). Under these new 
guidelines, the drug companies were no longer required to provide all of the risk-
related information in their promotional materials. The FDA would allow product-
specific DTCA if “adequate provision” was provided regarding information on the 
manufacturer’s safety and efficacy claims (Gellad and Lyles, 2007). Since this 
change in 1997, pharmaceutical companies could now tell consumers where to 
find additional information, such as by referring them to an Internet web site or 
providing a toll free telephone number.  
Consequently, the updated 1997 FDA guidelines led to widespread print and 
broadcast DTCA (Conrad and Leiter, 2008). In fact, spending on advertising in 
medical journals to physicians decreased while DTCA spending for prescription 
drugs increased rapidly (Berger et al., 2001). Since the FDA’s relaxation of its 
regulation in 1997, pharmaceutical industry spending on DTCA has more than 
tripled reaching $4.2 billion in 2005 for American broadcast DTCA efforts 
(Conrad and Leiter, 2008). In 2004, the FDA further announced that print 
advertisements no longer had to include full prescribing information thereby 
raising important questions about the consistency and completeness of 
information contained in DTCA (Hollon, 2005, p. 2030). Ultimately, DTCA has 
provided pharmaceutical manufacturers with “a new avenue for increasing the 
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rate of diffusion and adoption of new drugs” (Perri, Shinde, & Banavali, 1999, p. 
1806).  
To further complicate matters surrounding DTCA, the Internet has become 
“another direct avenue from pharmaceutical companies to consumers, and one 
that is not limited to national boundaries” (Conrad and Leiter, 2008, p. 834). As 
researchers have noted, the pharmaceutical industry is in a position to “benefit 
commercially from environmental changes such as the Internet” (Fox, Ward, and 
O’Rourke, 2006, p. 323). For instance, the Internet may provide access to 
individuals and new opportunities for information retrieval, pharmaceutical 
marketing, and consumption (Fox, Ward, and O’Rourke, 2006). Indeed, the 
Internet has further expanded the potential to reach specific audiences for 
pharmaceutical products. According to Khim (2009), web sites are another way 
that DTCA can reach consumers. Yet, there are no specific regulations for 
Internet marketing in the United States and pharmaceutical web sites are 
expected to adhere to the same guidelines set for any DTCA (Woodlock, 2005). 
Therefore, the role of direct-to-consumer advertising of pharmaceuticals in a 
global information environment warrants further investigation.  
To date, no research exists on the representation of menopause and 
information content on DTCA pharmaceutical web sites for hormone therapies. 
However, a few studies of Internet web sites of pharmaceutical products exist in 
the literature. Such examples provide direction for future research exploring 
DTCA pharmaceutical web sites for HT.  
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In a study examining several antidepressant web sites, Woodlock (2005) 
found that depression, anxiety, eating disorders, and low self-esteem, were 
classified as “illnesses” and the information on the web sites was based on 
biological models with little attention to possible social reasons for the disorders. 
Additionally, a vast majority of the images on the antidepressant web sites were 
of young to middle aged, white women (Woodlock, 2005). Similarly, another 
study of the portrayal of depression on Selective Serotonin Reuptake Inhibitors 
(SSRIs) web sites found that the symptoms of depression listed on the 
pharmaceutical web sites conveyed that the disorder was likely to be permanent 
without treatment (Gawley, 2007). Specifically, the likelihood of depression being 
a chronic condition and the danger of leaving any mental disorder untreated were 
emphasized in the depression web sites sponsored by pharmaceutical 
companies (Gawley, 2007). These two studies demonstrated the ways in which 
prescription medications for mental health issues, such as depression, were 
being marketed to consumers on the Internet and highlight the need for further 
studies to look at how drug companies are marketing their drugs to women 
(Woodlock, 2005). As noted, there is a lack of research on the representation of 
menopause and information content on DTCA pharmaceutical web sites for 
hormone therapies. According to Worcester and Whatley (1992), evaluating and 
critiquing the mass marketing of hormones is of great importance. 
 
Summary 
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In this chapter, several theoretical perspectives were described, including 
biomedical, socio-cultural, and feminist models. Although a biomedical view of 
menopause tends to be the dominant discourse found in the scientific literature 
and popular media accounts, other models have emerged offering alternatives to 
the biomedical model. Yet, the biomedical model persists. Thus, the dominant 
biomedical discourse of menopause as a “disease” caused by an estrogen 
deficiency has resulted in menopause being largely regarded as a biomedical 
breakdown of malfunction in need of medical treatment (Lyons and Griffin, 2003). 
Despite the pervasiveness of the biomedical model found in the scientific 
literature and popular media accounts, a biomedical approach does not 
adequately reflect social and cultural aspects which can have an influence on 
women’s complex menopausal experiences. 
A review of the existing literature also provided possible explanations for the 
rise in popularity of HT. From early proclaimed benefits of protection against 
heart disease to the re-introduction of HT for symptoms relief, reasons for 
hormone use had many origins. Within this context, a large set of clinical trials 
known as the Women's Health Initiative (WHI) began in 1997 to evaluate the 
effects of prescribed hormone therapies (HT) on the incidence of heart disease. 
In short, the WHI studies were prematurely discontinued, risks to health such as 
stroke and breast cancer were found, and proclaimed benefits of hormone use 
were not supported (Voda and Ashton, 2006). Yet, the pharmaceutical industry 
continues to strategically find ways to re-introduce HT as a viable option. Indeed, 
“post-WHI risks to women’s health persist” (Voda and Ashton, 2006, p. 410) 
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This chapter also examined regulations of DTCA in the United States and 
characterized the pharmaceutical industry’s involvement in DTCA of hormone 
therapies to physicians and consumers. A central focus of the existing research 
is on how the pharmaceutical industry has promoted HT to physicians through 
professional publications. Furthermore, research has examined how 
pharmaceutical companies have targeted women directly through DTCA in 
newspapers and magazines promoting the widespread use of HT as a universal 
remedy for menopause and aging.  
Lorence and Churchill (2007) state the growth of direct-to-consumer 
marketing of pharmaceuticals in the United States has “spawned the generation 
of web sites for consumer information” (p. 551).  Despite this, little is known 
about DTCA on pharmaceutical web sites for HT. As the Internet presents 
pharmaceutical companies with a way to expand their advertising to potential 
audiences for their prescription medications, a key concern is the ongoing 
“invisible and unregulated attempts to change public perceptions about health 
and illness to widen markets for new drugs” (Moynihan et al., 2002, p. 890). 
Future research needs to explore online DTCA aiming to stimulate profits from 
women’s reproductive experiences. Therefore, this study examined how 
menopause was being portrayed on pharmaceutical web site advertisements for 
hormone therapies to address this void in the literature. The following set of 
research questions helped to address the gaps in the existing literature: 
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1. What is the prominent discourse about menopause on the 
pharmaceutical web sites? Did it vary across the web sites? If the 
biomedical perspective is used in the portrayal of menopause, then 
menopause will be presented as a medical event to be medically 
managed. Furthermore, “deficiency” will be a common theme if the 
biomedical perspective is accepted. If a feminist perspective is 
used in the portrayal of menopause, I would expect to see an 
alternative discourse that rejects the medical construction of 
menopause as requiring medical treatment and supervision by a 
health care professional.  In addition, I will explore how symptoms 
are presented and if the symptoms are the same across the web 
sites.  
2. How is the Women’s Health Initiative (WHI) framed on the 
pharmaceutical web sites? Likewise, I will also examine if evidence 
of actual clinical studies, such as the WHI or others, are referenced 
on the pharmaceutical web sites. 
3. Who is/are the intended target audience(s) of the web sites? To 
help determine if the web sites are geared towards a specific 
audience, I will examine the language and/or visual cues employed 
on the pharmaceutical web sites. 
4. Is the information presented differently for various audiences, and if 
so, how? (i.e. health professionals, consumers, etc.). For example, 
I will investigate if the advertising slogans differ depending on the 
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target audience. In addition, I will examine what (if anything) is 
absent or lacking on the web sites. 
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CHAPTER 3 
THEORETICAL FRAMEWORK 
 
Overall, the concept of medicalization has been widely used by social 
scientists to examine how processes come to be perceived and treated as 
illnesses. Essentially, medicalization is a process that entails the transformation 
of human conditions into treatable disorders (Zola, 1991). Thus, the existing 
literature has tended to focus on “how diagnostic categories emerge, evolve, and 
are phenomenologically experienced in particular health contexts” (Timmermans 
and Haas, 2008, p. 663). Notable examples of medicalization described by 
sociologists include hyperactivity in children (Conrad, 1975), aging and disability 
(Zola, 1991), pregnancy (Oakley, 1984; Riessman, 1983), and menopause 
(McCrea, 1983). Next, I describe the process of medicalization and take a closer 
look at the specific social contexts in which the different dimensions of 
medicalization arise. 
 
Medicalization 
 
Conrad (2007) defines medicalization as the process by which non-
medical problems are defined and treated as medical problems. For Conrad, the 
“key to medicalization is definition” (2007, p. 5). In particular, medicalization 
occurs “when human problems or experiences become defined as medical 
problems, usually in terms of illnesses, diseases, or syndromes” (Conrad and 
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Barker, 2010, in press). Hence, the process of medicalization includes defining a 
problem in medical terms, adopting a medical framework, and treating a problem 
with medical interventions (Conrad, 2007).   
Originally, the concept of medicalization was associated with the notion of 
professional dominance (Freidson, 1970). Early sociological studies focused on 
the creation of “new medical categories with the subsequent expansion of 
medical jurisdiction” (Conrad, 2007, p. 8). In this context, the power and authority 
of the medical profession was “evident in the medicalization” of hyperactivity in 
children and childbirth (Conrad, 2007, p. 9). In addition, “deviant” behaviors, such 
excessive alcohol consumption and homosexual behavior, also came to be 
regarded and treated as medical conditions (Conrad and Schneider, 1992). As 
noted by Zola (1991), several natural processes, including aging, have also been 
transformed into diseases.  As such, the increasing trend of medicalization of 
natural processes and “deviant” behaviors were linked to the growing authority of 
the medical profession. Beginning with the extension of medicine’s jurisdiction, 
medicalization was viewed as a process whereby natural occurrences in 
everyday life came “under medical domination, influence, and supervision” (Zola, 
1983, p. 295).  
Conrad and Schneider (1980) further suggest that there are three levels to 
medicalization. First, the conceptual level entails the use of medical language to 
define a problem. Second, the institutional level consists of medical collaboration 
with authorities to gain legitimacy over management of the problem. The third 
level consists of the interaction between physicians and the patient where the 
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problem is defined and managed with medical treatments (Conrad and 
Schneider, 1980). Thus, these various levels of medicalization illustrate how the 
medical profession has been able to assert social control over natural processes 
and “deviant” behaviors. 
As noted, early formulations of the concept of medicalization considered 
the extension of medicine’s jurisdiction over “normal” life events as the major 
catalyst driving this phenomenon. However, Conrad (2007) elaborated and 
identified three emerging forces also contributing to medicalization. These forces 
are the pharmaceutical industry, consumers, and managed care. Thus, several 
new forces are seen as providing momentum for further medicalization. 
Specifically, the rise of pharmaceutical advertisements “marketing diseases and 
then promoting drugs to treat those diseases” is now common practice (Conrad, 
2007, p. 135). Given these changes in the health care landscape, Conrad argues 
that the physicians’ role in medicalization in decreasing while the role of 
pharmaceutical companies is increasing (Conrad, 2007). As Conrad states, 
“while physicians are still the gatekeepers for many drugs, the pharmaceutical 
companies have become a major player in medicalization” (Conrad, 2007, p. 
134).  As Riessman notes, this process has had “far-reaching consequences” for 
women (1983, p. 3). As a result, the process of medicalization has transformed 
several reproductive experiences, such as childbirth and menopause, into 
medical-technical problems necessitating medical intervention.  
 
Medicalization of Women’s Reproductive Experiences 
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According to Riessman (1983), a “plethora of female conditions” have 
been re-conceptualized as illnesses (p. 9). In fact, research on medicalization 
has shown that women’s issues have been disproportionately medicalized 
(Conrad, 2007; Lorber, 1997; Riessman, 1983; Riska, 2003). For example, 
childbirth has been medicalized (Barker, 1998; Brubaker and Dillaway, 2009; 
Riessman, 1983). With childbirth, there has been an increase in the use of 
medical technology (Williams and Umberson, 1999). As such, women are 
admitted as patients to a hospital and hooked up to monitors (Riessman, 1983). 
As a result, one consequence is the expectation of women to be under medical 
supervision during childbirth and to relinquish some control over the childbirth 
process.  
Furthermore, menstruation has also been medicalized (Chrisler and Levy, 
1990). Negative consequences of medicalizing menstruation include that women 
are seen as angry, moody, irritable, and irrational during menstruation (Chrisler 
and Levy, 1990). Such labels have implications and suggest that women are 
unable to fulfill their social roles and obligations. As such, the transformation and 
labeling of these natural processes into diseases has severe consequences for 
women.  
Indeed, childbirth and menstruation are two examples of natural 
processes and reproductive experiences that have been medicalized. Through 
this widespread medicalization of gendered reproductive experiences, women 
have received messages that their bodies are a “burden, particularly during the 
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hormonal and physiological changes associated with menstruation, pregnancy, 
and menopause” (Whittaker, 1998, p. 80). Consequently, reproductive 
experiences among women have been medicalized resulting in the expansion of 
medical jurisdiction over women’s bodies. 
 
Medicalization of Menopause 
 
In addition to menstruation and childbirth, menopause has also been 
medicalized further illustrating how definitions “of health and illness are socially 
constructed” (McCrea, 1983, p. 111). As noted, although menopause is a part of 
the natural aging process, it has been socially constructed by clinical 
communities and pharmaceutical companies as a pathological and abnormal 
“condition” in need of medical intervention (Dillaway, 2005; Ferguson and Parry, 
1998; McCrea, 1983; Riessman 1983). This standpoint stems from the 
widespread acceptance and adoption of a biomedical model of menopause 
which regards menopause as an “estrogen deficiency disease for which estrogen 
replacement is the therapy of choice” (Kaufert and Gilbert, 1986, p. 8). Hence, a 
biomedical perspective has constructed menopause as a negative event 
requiring medical intervention. As Derry (2008) notes, postmenopausal women 
“do produce estrogen in their bodies [and] these lower levels of hormone were 
assumed to be negligible” (p. 722). Moreover, McCrea (1983) suggests such 
medical definitions of menopause as a “deficiency disease” have resulted in 
many women to feel morally obligated to accept medical intervention. Thus, all 
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midlife and older women are being defined as “hormonally deficient” and in need 
of medical intervention (Meyer, 2001, p. 770). As a result, the medicalization of 
menopause allows for the “widespread acceptance of hormone use as a primary 
prevention strategy” for menopause (Meyer, 2001, p. 779). Furthermore, the 
medical label of “hormone deficiency” decreases the status and autonomy of 
women while increasing the status and power of the physician (Bell, 1990; 
Coney, 1994; Lupton, 1996; McCrea, 1983). In summary, the reproductive aging 
experiences of women have been particularly susceptible to medicalization in our 
society.  
 
Importance of Framework 
 
The process of medicalization allows for a researcher to recognize and 
understand the levels of medicalization operating within the constructions of 
menopause in online drug advertisements. Within this study, medicalization 
provides a useful framework for understanding the degree to which any process 
of medicalization is present in portrayals of menopause on the web sites for 
hormone therapies. Conrad (2007) identifies “diagnostic expansion” as one way 
in which medicalization can occur (p. 47). Hence, the expansion of established 
diagnosis and definitional boundaries to include new problems or new markets 
beyond what something was originally designated for provides an opportunity to 
investigate how this aspect of medicalization operates (Conrad, 2007).   
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Additionally, Kaufert and Gilbert (1986) describe several tests for 
medicalization that can be used to determine if the process of medicalization is 
occurring. One sign is when the decline of estrogen production has become a 
central theme.  When menopause becomes defined exclusively as an estrogen 
deficiency or disease-like requiring medical management, proposed treatment 
options for menopause will involve the use of hormone therapies to supplement 
or balance this loss of hormones. Another indication is when women are told that 
they should depend on a physician to have their menopausal status recognized 
and defined, rather than relying on their own judgment (Kaufert and Gilbert, 
1986). Taken together, these “tests for medicalization” will be helpful to help 
ascertain if the process of medicalization is occurring or advanced across the 
DTCA web sites for HT. Furthermore, this theoretical grounding allows for greater 
insight and understanding of the wider social processes shaping the 
medicalization of menopause, such as the availability of new technologies and 
pharmaceutical products for profit which provide further potential for 
medicalization.  
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CHAPTER 4 
METHODOLOGY 
 
The primary focus of this qualitative investigation was on how menopause 
was portrayed on web sites for hormone therapies sponsored by pharmaceutical 
companies. Because of this focus, a qualitative and interpretive approach was 
most appropriate. In particular, qualitative content analysis focuses on the 
content and contextual meaning of text (Creswell, 2007).  Furthermore, a 
qualitative content analysis also emphasizes the interaction among the 
researcher and the data to “develop a theory or pattern of meaning” (Creswell, 
2007, p. 21). Within this tradition, I employed an interactive and reflexive 
approach to data collection and analysis in order to develop a fuller 
understanding of the phenomenon under investigation.  
By exploring the constructions of menopause in online advertisements for 
hormone therapies, I sought to generate rich insight into subjective meanings 
that are negotiated and situated both socially and historically. As stated earlier, 
exploring the online messages that pharmaceutical companies were conveying 
about women and menopause was of particular interest in this study. As a result, 
this qualitative investigation contributes to the “critical analysis of social texts” 
(Denzin and Lincoln, 1994, p. 101). 
Within my review of the existing literature, I identified several key issues that 
were relevant for developing an understanding of how menopause is constructed 
in online DTC advertisements for hormone therapies. These key issues included: 
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understanding how menopause is portrayed on web sites for hormone therapies 
sponsored by pharmaceutical companies, identifying intended target audiences 
of the web sites, determining whether the information is presented differently for 
these various target audiences, and assessing if anything is silent or missing on 
the web sites. As such, the core research questions were generated with these 
issues in mind to allow for exploration of these key dimensions. 
As noted, previous research of DTC advertising on the Internet provided a 
useful foundation for this study of web sites for hormone therapies. In particular, 
Gawley (2007) examined the medicalization of depression on Selective Serotonin 
Reuptake Inhibitors (SSRIs) web sites and found that medicalization had a strong 
impact on the portrayal of depression on the web sites. In particular, the 
likelihood of depression being a chronic condition and the danger of leaving any 
mental disorder untreated were emphasized in the depression web sites 
sponsored by pharmaceutical companies. Furthermore, symptoms of depression 
listed on the pharmaceutical web sites conveyed that the disorder was likely to 
be permanent without treatment (Gawley, 2007). Specifically, the dataset for the 
study by Gawley (2007) was comprised of online DTC advertisement web sites 
for SSRI antidepressants. Modeled after this study, I used a list of FDA-approved 
drug products for treating postmenopausal symptoms and identified relevant web 
sites sponsored by pharmaceutical companies for analysis to explore how 
menopause was portrayed in the online advertisements.  
 
The Sample 
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This study was a cross-sectional observation and the dataset was comprised 
of a sample of online DTC advertisement web sites for hormone therapies. 
Specifically, the web sites marketed prescription “treatments” for menopause as 
a primary focus and acknowledged a sponsorship or affiliation with a 
pharmaceutical company. The sampling frame consisted of web sites for 
Estrogen and Estrogen-Progestin products approved by the U.S. Food and Drug 
Administration (FDA). In particular, the web sites were identified by using a list of 
FDA-approved estrogen- and progestin-containing drug products used for 
treating postmenopausal symptoms as of January 16, 2008 (see Table 1). Thus, 
the sample of English-language web sites were selected because of their wide 
circulation on the World Wide Web, accessibility to the researcher, authorship 
(i.e. created by a pharmaceutical company), FDA-approved products, and target 
audience or audiences. The units of analysis were the printed textual web pages. 
In accordance with University policies, I applied for exemption from the Wayne 
State University Human Investigation Committee since this study entailed 
analyzing data available from publically available web sites and human subjects 
were not involved in the research. In June 2009, exemption was granted (see 
Appendix B) from the Wayne State University Human Investigation Committee 
for this study. 
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Table 1: FDA-Approved Estrogen and Estrogen-Progestin Products* 
HT Web Site Date of Last Update on 
Web Site 
 
1. Alora (N/A) 
2. Angeliq (http://www.angeliq-us.com) 
3. Climara (N/A) 
4. Climara Pro (N/A) 
5. Combipatch (http://www.combipatch.com)     
6. Delestrogen (N/A) 
7. Enjuvia (http://www.enjuvia.com) 
8. Estraderm (N/A) 
9. Estrasorb (http://www.estrasorb.com) 
10. femhrt 
(http://www.wcrx.com/products/femhrt) 
11. Femring 
(http://www.wcrx.com/products/femring) 
12. Prefest (N/A) 
13. Premarin (http://www.premarin.com)       
14. PREMPRO (http://www.prempro.com)    
15. Vivelle-Dot (N/A)  
 
 (Source: FDA, 2008a.)  
*Information current as of January 16, 2008. 
1. N/A 
2. Not Stated 
3. N/A 
4. N/A 
5. 2006 
6. N/A 
7. 2008 
8. N/A 
9. 2008 
10. Not Stated 
 
11. Not Stated 
 
12. N/A 
13. 2006 
14. 2006 
15. N/A 
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The criteria for the online DTC advertisement web sites for hormone therapies 
were:  
 
1. FDA-approved Estrogen and Estrogen-Progestin products as of January 
2008 (presented in Table 1). 
2. The FDA-approved prescription products (mentioned above) must have a 
web site. 
3. Web sites promoting alternatives for menopause, such as herbs, 
supplements, and alternative therapies, were excluded. 
 
In this study, menopause was defined as a natural part of the aging process, 
rather than an event that limits women’s psychological or physical capacities 
(McCrea, 1983). Furthermore, this study concentrated on advertisements for 
hormone therapies for women who reached menopause naturally, as opposed to 
those who had surgical menopause (i.e. removal of the ovaries or the uterus). 
This study uses the term hormone therapies to refer to when a woman takes 
supplements of hormones, such as estrogen alone or estrogen with another 
hormone called progesterone (progestin in its synthetic form) (FDA, 2008b). It is 
also important to note that these hormone therapies come in many forms and 
dosages, including skin patches, vaginal tablets or creams, and prescription pills. 
In addition, implants, shots, or vaginal ring inserts are also available (National 
Institute on Aging, 2009). Thus, the overall focus of this study was on the direct-
to-consumer online advertisements of various FDA-approved hormone therapies, 
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defined as estrogen or estrogen plus progestin products, for menopausal and 
postmenopausal women. 
Initial data collection took place over a two-week period (July 11-25, 2009). 
During this time, each pharmaceutical web site was printed out in its entirety over 
the course of one day. I also went back to the web sites in January 2010 to use 
the online symptom tools found on four of the pharmaceutical web sites 
(ANGELIQ, ENJUVIA, PREMARIN, and PREMPRO) for an experiment, which is 
described in Chapter 7. As indicated in Table 1, there were 15 FDA-approved 
Estrogen and Estrogen-Progestin products but only eight had web sites active 
during this time period and these comprised the study sample (N=8). I began on 
the home page (or main page) and systematically followed each link and menu 
item. Once printed, the pages were organized by the web site, labeled, and 
numbered. For instance, each web page was printed out and labeled using the 
following convention: Premarin1, Premarin2, and so forth. Moreover, each web 
site was coded from beginning to end in order to develop a fuller understanding 
of the overall content of each web site, tone, and key features. In addition, web 
sites are constantly evolving and changing. To address this, the URL of each 
web site and the date the data was retrieved was noted.   
As Gawley (2007) notes, web sites are more than text. Often, web sites 
include diagrams, cartoons, and photographs. As such, the full-text of the printed 
web pages was analyzed with a focus on the content and contextual meaning of 
the text and visual elements. In addition, content analysis involves subjective 
judgments. In order to make the study as reproducible and systematic as 
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possible, I developed a coding instrument to help characterize the online drug 
advertisements. 
       
Analysis Procedures 
 
The advertising of hormone therapies by pharmaceutical companies via web 
sites offered rich data for content analysis. For the analysis, I used a qualitative 
content analysis approach for data analysis which is an ongoing process 
involving continual reflection and asking analytic questions. The analysis was 
guided by the core research questions. First, I answered the first research 
question concerning the portrayal of menopause on web sites for hormone 
therapies. I also examined the framing of the Women’s Health Initiative on the 
pharmaceutical web sites. Next, I examined the apparent target audience or 
audiences for the web sites. Further, I investigated if and how the information 
was presented differently for various target audiences and addressed what, if 
anything, was missing or silent on the web sites for hormone therapies.  
 
My data analysis plan consisted of the following steps: 
 
1. Look for broad themes (open coding) 
2. Axial coding (recode #1, major categories emerged from data) 
3. Relational / selective coding (recode #2, began to establish core 
categories) 
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4. Pattern analysis (conclusion, developed explanation, used relevant 
theories in discussion section and compared with other findings of 
similar studies) 
 
When coding, I began by looking at several dimensions of the web sites 
for hormone therapies. As I started analyzing, I examined the various features of 
the web sites, such as online quizzes to test one’s knowledge, checklists or 
guides for patients to talk with their physician, and self-diagnostic tools to assess 
menopausal “symptoms.” I also looked at the words, meanings, metaphors, and 
color schemes. Furthermore, features such as personal testimonials proved 
fruitful for analysis.  
The size and positioning of visual elements were also of particular interest, 
such as how women were positioned in images (i.e. if the women were active or 
passive). If a person was presenting a message, I also looked at the gender, 
estimated age, and race of the person delivering the message. In addition, I was 
also curious to discover if possible side effects of the hormone therapies were 
highlighted and if the Women’s Health Initiative was mentioned. Although these 
were some areas that I intended to consider whenever I began my coding and 
analysis, I expected to expand the coding sheet and categories as new or 
interesting aspects emerged during coding and analysis. Indeed, this was the 
case as I added more categories to the coding sheet whenever I analyzed the 
images of the characters in the online advertisements for HT. In this way, I 
expanded the code sheet (Appendix A) to capture the primary location, primary 
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behavior, and attire for the characters being depicted in the online 
advertisements to help provide a richer context.  
 
Analytic Approach  
 
The analysis is divided into five chapters which include an overview of the 
web site characteristics, textual and visual elements of the web sites, the 
portrayal of menopause, and the presentation of benefits and side effects of 
hormone therapies (HT). In particular, Chapters 5 and 6 focus on the 
characteristics of the direct-to-consumer web sites for HT. In these chapters, I 
examine the menu options, slogans, color schemes, and imagery employed on 
the web sites for both consumers and health care professionals. Two questions 
are explored in these chapters. In particular, I identify two main audiences for the 
HT web sites and I also investigate how the online information is presented 
differently for these two potential markets.  
Chapter 7 explores the portrayal of menopause on the web sites for HT, 
examining how menopause was being portrayed in the online advertisements by 
analyzing the definitions of menopause, descriptions of menopausal “symptoms,” 
and self-diagnosing symptom tools found across the HT web sites in the study 
sample. Chapter 8 analyzes the presentation of benefits and side effects of HT. 
This chapter also helps to illuminate what was deficient or missing in the online 
drug advertisements for HT.  Chapter 9 provides a discussion of the results and 
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compares key findings with other findings of similar studies. Finally, Chapter 10 
discusses policy implications of my findings and ideas for future research.  
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CHAPTER 5 
OVERVIEW OF PHARMACEUTICAL WEB SITES 
FOR HORMONE THERAPIES 
 
This chapter provides an overview of the direct-to-consumer (DTC) 
pharmaceutical web sites for FDA-approved prescription hormone therapies and 
is divided into several sections. First, the names of the various hormone 
therapies (HT) and what these product names may symbolize are examined. 
Next, the overall layout and organization of the web sites for HT are described to 
help elucidate how the information content about the HT products was presented 
to web site users. Finally, the chapter concludes with a comparison of menu 
options for consumers and health care professionals observed on the web sites 
for HT. 
 
Description of HT Products 
 
To provide a foundation for analyzing the HT products in the study sample, I 
started by examining the name of the pharmaceutical manufacturer, the type of 
the HT product (i.e. tablet, patch, or lotion form), and the brand name of the HT 
products. Table 2 shows the name of the pharmaceutical manufacturer for each 
of the HT products and the type of HT product in the sample (N=8). As seen in 
Table 2, the study sample contained HT products from six different 
pharmaceutical manufacturers. Two of the HT products in the sample (femhrt 
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and Femring) were manufactured by Warner Chilcott. In addition, two of the HT 
products (PREMARIN and PREMPRO) were from Wyeth Pharmaceuticals (now 
part of Pfizer Inc.)  Out of the four remaining HT products in the sample, one 
each was from the following pharmaceutical manufacturers: Bayer HealthCare 
Pharmaceuticals (ANGELIQ), Novogyne Pharmaceuticals (CombiPatch), 
Duramed Pharmaceuticals (ENJUVIA), and Graceway Pharmaceuticals 
(Estrasorb). 
 
Table 2: Description of HT Products 
Name of HT Product Manufacturer 
 
Type of HT Product 
ANGELIQ Bayer HealthCare 
Pharmaceuticals 
  
Tablets 
 
CombiPatch Novogyne Pharmaceuticals Patch 
 
ENJUVIA Duramed Pharmaceuticals Tablets  
 
Estrasorb Graceway Pharmaceuticals Lotion 
 
femhrt Warner Chilcott Tablets  
 
Femring Warner Chilcott Vaginal Ring 
 
PREMARIN Wyeth Pharmaceuticals 
(now part of Pfizer Inc.) 
   
Tablets 
 
PREMPRO Wyeth Pharmaceuticals 
(now part of Pfizer Inc.) 
   
Tablets 
 
 
 
Table 2 further shows the type of the HT products in the sample. In most 
cases (n=5), the HT product was available in tablet form. The HT products 
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available in tablet form included ANGELIQ, ENJUVIA, femhrt, PREMARIN, and 
PREMPRO. It should be noted that PREMARIN and PREMPRO were also 
available as vaginal creams; however, the PREMARIN and PREMPRO web sites 
reflected information about HT product in the tablet form. Therefore, information 
about these two HT products in tablet form was included in the analyses. 
Additionally, one of the HT products (CombiPatch) was available as a 
combination patch containing both estrogen and a progestin. According to the 
CombiPatch web site, the product is an alcohol-free patch that “releases both 
estrogen and progestin continuously through your skin” (CombiPatch web site: 
http://www.combipatch.com. Retrieved: July 13, 2009). The HT product known as 
Estrasorb was available as a “topical estrogen delivered in a moisturizing, soy-
based lotion” (Estrasorb web site: http://www.estrasorb.com. Retrieved: July 15, 
2009). Furthermore, one of the HT products was provided as a vaginal ring. The 
Femring web site described the product as “an off-white, soft, flexible vaginal ring 
with a center that contains an estrogen” (Femring web site: 
http://www.wcrx.com/products/femring. Retrieved: July 17, 2009). As made 
evident by the product name Femring, the form of the HT product was sometimes 
embedded in the product name. Therefore, next I examined the names of the 
various HT products. 
As noted in an earlier chapter, there are several advertising principles 
involved in the naming, labeling, and marketing of pharmaceutical prescription 
products. According to Gundersen (1998), the brand name for a prescription drug 
is “owned solely by the manufacturer […and] choice of the brand name is 
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motivated by marketing considerations” (p. 678). Considerations that play a role 
in a company’s decision include a brand name that is easy to spell and one that 
consumers and health care providers will remember (Gundersen, 1998).  
Among the HT product names, two brand names were unique in the sense 
that the form of the HT product was incorporated directly into the product name. 
For example, Femring can be viewed as a combination of “feminine” and “ring,” 
or alternatively, “female” and “ring.”  Another example was CombiPatch where 
the name of the product captured the essence of the product which was a 
combination patch containing both estrogen and a progestin. Here, it is likely that 
the naming choices of these two HT products reflected a common advertising 
technique of selecting a brand name for a drug that is easy to remember (Kenagy 
and Stein, 2001). 
For other drug names in the sample, interesting word associations were 
embedded into the brand names of the HT product. The name ANGELIQ in and 
of itself may suggest something being angelic, ethereal, celestial, or saintly. The 
name ENJUVIA closely resembled the word rejuvenate and may imply the 
possibility to make young again or restore to youthful vigor. Both the brand 
names ANGELIQ and ENJUVIA are examples of how HT products may be 
marketed by likening them to positive words and their possible associations. 
Additionally, the name PREMARIN referred to origin of drug. According to 
Vance (2007), the name PREMARIN was “coined from pregnant mare urine, 
from which the estrogen complex was isolated” (p. 282). Furthermore, Estrasorb 
could be viewed as a play on words suggesting that the HT product works by 
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absorbing the estrogen cream into the skin. These are possible interpretations of 
the brand names and what they may signify. Although these are interpretations, 
an analysis of the brand names has been productive for understanding several 
key points.  
First, the brand names of the HT products reflected common DTCA 
techniques. Two of the HT products, CombiPatch and Femring, incorporated the 
form of the product into the name. This technique can help potential consumers 
and health care providers to remember the drug name (Kenagy and Stein, 2001, 
p. 2036).  Additionally, such strategic naming choices for prescription products 
may also help distinguish the product so that physicians and consumers will not 
confuse it with another HT product on the market.  
Second, certain words were embedded into the HT product names to evoke 
positive associations and feelings about the HT products. In this sense, the 
product name of ANGELIQ is an example used to connote particular qualities or 
desires, such as suggesting something is angelic. Next, I examined the layout 
and organization of the HT web sites to help demonstrate how information about 
the HT products was presented to web site users. 
  
Web Site Layout and Organization 
 
To help understand the construction of menopause in online drug 
advertisements for HT, an examination of the overall organization of the web 
sites in the sample was warranted. Table 3 illustrates the layout of the HT web 
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sites. There are many common elements on a web site; such as links, logos, and 
textual content. Navigation systems, presented to web site visitors in the form of 
menu options and links, are typically found on the left side or across the top of 
web sites. As shown in Table 3, all of the web sites in the sample (N=8) provided 
links for navigating content on the left side and across the top of the web sites.  
 
Table 3: Layout of HT Web Sites 
Name of HT 
Product 
Navigation 
Links on 
Left 
 
Navigation 
Links 
Across Top 
 
Logo in Top 
Left Corner 
Textual 
Content 
Centered 
 
ANGELIQ Yes 
 
Yes Yes Yes 
CombiPatch Yes 
 
Yes Yes Yes 
ENJUVIA Yes 
 
Yes Yes Yes 
Estrasorb Yes 
 
Yes Yes Yes 
femhrt Yes 
 
Yes Yes Yes 
Femring Yes 
 
Yes Yes Yes 
PREMARIN Yes 
 
Yes Yes Yes 
PREMPRO Yes 
 
Yes Yes Yes 
 
Another common element of web site design includes the positioning of 
logos in the upper left corner of web sites. Here again, logos were observed in 
the upper left corner on each of the HT web sites (N=8). Furthermore, another 
common web site design technique is to center or display the primary textual 
content in the middle of the web page as a focal point. In the online 
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advertisements for HT, all of the web sites (N=8) adhered to these conventions. 
Within these online advertisements, the placement of logos was in the top left 
corner, navigation links were positioned on the left side and across the top, and 
main textual content was centered on the web page. 
Hence, this analysis is important for illustrating how the layout and 
organization of the pharmaceutical web sites provided a structure to help guide 
web site users through information about the HT products. These basic web site 
design techniques offered a consistent way for the pharmaceutical companies to 
present information about their HT products to potential markets. Next, I take a 
closer look at the information content found across web site portals designed 
specifically for two potential markets: consumers and health care providers.  
 
Consumer and Health Care Provider Portals 
 
In this study, all of the web sites for HT (N=8) provided information about 
their products to two discernable yet distinct audiences, consumers and health 
care providers. In fact, specific sections of the web sites were clearly labeled for 
each intended audience. Specifically, Table 4 illustrates how the various web site 
portals for health care providers were labeled. A total number of 608 printed 
pages of web site content were analyzed in this study from the eight HT web 
sites (N=8). As illustrated in Table 4, 134 of printed pages were geared towards 
health care providers. In comparison, there were 474 of printed pages of web site 
content for consumers demonstrating the amount of information aimed at 
consumers.  
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Table 4: Label for Section of Web Site and Number of Printed Pages of Web Site 
Content for Health Care Providers 
 
Name of HT Product Label for Health Care 
Provider Portal 
 
Number of Printed 
Pages of Web Site 
Content for Health 
Care Providers 
  
ANGELIQ Physician Information 
 
1 
CombiPatch For Health Care 
Professionals 
 
37 
ENJUVIA Healthcare Professionals 
Click Here 
 
43 
Estrasorb Healthcare Professionals 
 
11 
femhrt Full U.S. Prescribing 
Information 
 
1 
Femring Full U.S. Prescribing 
Information 
 
1 
PREMARIN Health Care Professionals’ 
Info 
 
20 
PREMPRO Health Care Professionals’ 
Info 
 
20 
 
As shown in Table 4, five of the HT web sites (n=5) provided information 
for health care providers in a section of the web site labeled with the words 
“health care professionals.” Two of the HT web sites (femhrt and Femring) simply 
provided “Full U.S. Prescribing Information” for health care professionals. In one 
instance, the ANGELIQ web site used the label “physician information.”  
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Interestingly, the ENJUVIA web site provided information for pharmacists in 
addition to physicians. By including information aimed at pharmacists, 
pharmaceutical manufacturers were able to extend their reach to other health 
providers thereby widening their potential market for their products. 
Nevertheless, a web site visitor was transported to an entirely different set of 
content on all of the HT web sites (N=8) by selecting one of the web site portal 
options intended for health care professionals. Next, a comparison of the type of 
menu options provided for consumers and health care providers is discussed.   
 
Menu Options for Consumers  
 
Menu options were important indicators of how information about the HT 
products was presented to web site visitors. In this section, I examine the type 
and amount of menu options available on the web sites for consumers, which 
were presumably female consumers. Table 5 shows the number of menu options 
for consumers provided on each of the HT web sites. As shown in Table 5, the 
number of menu items provided across all of the web sites for consumers totals 
134. The number of menu items ranged from five menu items provided on the 
femhrt web site to 24 menu items for consumers on the ANGELIQ web site.  
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Table 5: The Number of Menu Options for Consumers 
HT Web Site 
 
Number of Menu Options for 
Consumers 
 
ANGELIQ 24 
 
CombiPatch 22 
 
ENJUVIA 22 
 
Estrasorb 8 
 
femhrt 5 
 
Femring 8 
 
PREMARIN 23 
 
PREMPRO 22 
 
Total 134 
 
 
A variety of menu options were presented to consumers across the HT 
web sites. Table 6 details the menu options observed for consumers across all of 
the HT web sites in the sample. In every instance, information for consumers 
about the HT product was located under a menu option entitled “About” followed 
by name of the particular HT product (N=8). For example, information about 
ANGELIQ was observed under the menu option entitled “About ANGELIQ” on 
the HT web site (ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 
13, 2009). Likewise, this trend was observed in another example in which web 
site visitors could learn more about CombiPatch by following the link titled “About 
CombiPatch” (CombiPatch web site: http://www.combipatch.com. Retrieved: July 
13, 2009). 
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Table 6: Menu Options for Consumers 
HT Web Site Menu Options for Consumers 
 
ANGELIQ About ANGELIQ 
• The Difference in DRSP (DRSP 
refers to drospirenone, a 
synthetic progesterone and a 
spironolactone analog) 
• Is ANGELIQ Right for me? 
• How do I Get ANGELIQ? 
• Discussion Guides for Talking 
with Your Health Care 
Professional 
Using ANGELIQ 
• What to Expect 
About Menopause 
• Understanding Your Symptoms 
• Treatment Options 
• Healthy Lifestyle Changes 
• Assess Your Symptoms 
About Hormone Therapy 
• Hormone Therapy in the News 
FAQ 
Tools 
• Quiz How Much Do You Know 
About Menopause 
• Guide for Talking with Your 
Health Care Provider 
• Assess Your Symptoms 
Patient Information 
Safety Information 
Refer a Friend 
Contact Us 
ANGELIQ Press Room 
 
CombiPatch New to CombiPatch? 
Already Using CombiPatch? 
About Menopause 
• Menopausal Symptoms 
• Natural vs. Surgical Menopause 
• Menopause FAQs 
• Menopause Resources 
Living with Menopause 
• Eating Right 
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• Keeping Fit 
• Sex After Menopause 
About Hormone Therapy 
• Risks/Benefits of Hormone 
Therapy 
• Myths About Hormone Therapy 
About CombiPatch 
• How It Works 
• How to Use It 
• Risks/Benefits of Using 
CombiPatch 
• Talking to Your Doctor 
• CombiPatch FAQs 
• Cyclic Therapy FAQs 
Contact Us 
 
ENJUVIA A Stage of Life Called Menopause 
• Surgical Menopause 
• Natural Menopause 
About ENJUVIA 
• ENJUVIA Is Demonstrated to 
Help 
• Taking ENJUVIA 
• Safety and Tolerability 
• Frequently Asked Questions 
Advice for Coping With Menopause 
• Little Steps that Can Make a Big 
Difference 
• Tip of the Month 
• Tips for Talking with Your 
Healthcare Professional About 
Menopause and Hormone 
Therapy 
Resources 
• Glossary 
• Assessing Your Symptoms: The 
Menopause Impact Tool 
• Mystified About Menopause? 
Want to Talk About It? 
• Related Web Sites 
• ENJUVIA Coupon 
Prescribing Information 
Important Safety Information 
Contact Us 
Assess Your Symptoms  
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Free Coupon for ENJUVIA 
 
Estrasorb About Estrasorb 
How to use Estrasorb 
About Menopause 
Estrasorb Experiences 
FAQ 
Important Safety Information 
Contact Us 
Women’s Health Resources 
 
femhrt About FEMHRT 
What is Menopause? 
What Are the Recent Concerns 
Regarding HRT? 
Important Safety Information 
Patient Product Information 
 
Femring About Femring 
About Menopause 
Hormone Therapy News 
Important Safety Information 
Femring Reminder Program 
FAQ 
Inserting Instructions 
Patient Acceptability 
 
PREMARIN Understanding Menopause 
• What is Menopause? 
• What to Expect During 
Menopause 
• Common Symptoms of 
Menopause 
• Menopausal Symptom Assessor 
About PREMARIN 
• What is PREMARIN? 
• Benefits of PREMARIN 
• Dosing and Time on Therapy 
• Side Effects and Safety 
Wellness Plan 
• Seeing Your Health Care 
Professional During Menopause 
• Taking Care of Yourself 
Women’s Stories 
• Connie 
• Jeanne 
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• Mary 
• Maureen 
• Rochelle 
Prescribing Information 
Important Safety Information 
Tell a Friend 
Contact Us 
 
PREMPRO Understanding Menopause 
• What is Menopause? 
• What to Expect During 
Menopause 
• Common Symptoms of 
Menopause 
• Menopausal Symptom Assessor 
About PREMPRO 
• What is PREMPRO? 
• Benefits of PREMPRO 
• Dosing and Time on Therapy 
• Side Effects and Safety 
Wellness Plan 
• Seeing Your Health Care 
Professional During Menopause 
• Taking Care of Yourself 
Women’s Stories 
• Carol 
• Debbie 
• Penny 
• Carolyn 
Important Safety Information 
Tell a Friend 
New Packaging 
Contact Us 
 
 
Further analysis regarding the breakdown of broad categories for the menu 
options for consumers is displayed in Table 7. In the online advertisements, all of 
the HT web sites (N=8) provided information about menopause for consumers. 
On four of the HT web sites, the menu option was labeled “About Menopause.”  
These four web sites included ANGELIQ, CombiPatch, Estrasorb, and Femring. 
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In addition, three of the HT web sites (femhrt, PREMARIN, and PREMPRO) 
highlighted information about menopause under the menu option entitled “What 
is Menopause.” Another example was found on the ENJUVIA web site and the 
menu option was called “a Stage of Life Called Menopause.”  Thus, all of the HT 
web sites furnished information about menopause for web site visitors. Common 
information under this menu option across all of the HT web sites (N=8) included 
a definition of menopause and information about menopausal symptoms.   
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Table 7: Breakdown of Categories of Menu Options for Consumers  
Menu Option Number of HT Web Sites 
with Menu Option 
 
HT Web Site 
 
About [HT Product] 8 ANGELIQ, CombiPatch, 
ENJUVIA, Estrasorb, 
femhrt, Femring, 
PREMARIN, PREMPRO 
 
About Menopause 8 ANGELIQ, CombiPatch, 
ENJUVIA, Estrasorb, 
femhrt, Femring, 
PREMARIN, PREMPRO 
 
Advice for Talking with 
Health Care Provider 
 
5 ANGELIQ, CombiPatch, 
ENJUVIA, PREMARIN, 
PREMPRO 
 
FAQs 4 ANGELIQ, CombiPatch, 
Estrasorb, Femring 
 
Women’s Stories 3 Estrasorb, PREMARIN, 
PREMPRO 
 
Refer a Friend  3 ANGELIQ, PREMARIN, 
PREMPRO 
 
Coupon 2  ANGELIQ, ENJUVIA 
 
Glossary of Terms 1 
 
ENJUVIA 
 
Moreover, five of the HT web sites in the sample provided advice to 
consumers for talking with their health care providers. These five web sites 
included ANGELIQ, CombiPatch, ENJUVIA, PREMARIN, and PREMPRO. 
Consumers could access the “Guide for Talking with Your Health Care Provider” 
on the ANGELIQ web site (ANGELIQ web site: http://www.angeliq-us.com. 
Retrieved: July 13, 2009). In addition, CombiPatch provided information for 
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“Talking with Your Doctor” (CombiPatch web site: http://www.combipatch.com. 
Retrieved: July 13, 2009). Visitors to the ENJUVIA web site could learn “Tips for 
Talking with Your Healthcare Professional about Menopause and Hormone 
Therapy” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009). 
According to the ENJUVIA web site, consumers may “find that this simple form 
will make it easier to talk with your healthcare professional [so] simply complete 
the form, print it, and take it with you to your next appointment” (ENJUVIA web 
site: http://www.enjuvia.com. Retrieved: July 14, 2009). Advice for what to expect 
during your first visit with your health care professional was provided on both the 
PREMARIN and PREMPRO web sites under the menu choices entitled “Seeing 
your Health Care Professional during Menopause.”  
On all five of the web sites that offered guidance to consumers, a list of 
recommended questions that consumers could ask their health care provider was 
presented. In these questions, consumers were first and foremost encouraged to 
ask their health care provider about HT treatment options. Undeniably, the 
positioning of this question implied the importance of inquiring about HT. 
Interestingly, two of the web sites (ANGELIQ and CombiPatch) suggested that 
consumers may also want to ask about non-medical options, such as diet 
modifications for reducing symptoms. However, this question was positioned at 
the very end of the recommended list of questions for consumers to ask their 
health care provider. Obviously, by positioning non-medical options as last on the 
list of questions to ask, the implication was that non-medical options were not as 
important. In addition, the ENJUVIA web site told consumers to “talk with your 
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health care professional before you begin any new exercise plan or diet” 
(ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009). In this 
case, non-medical options were being referred to a health care provider for 
medical supervision and guidance. As a result, the ENJUVIA web site implied 
that all options, HT and non-medical options, should be discussed, approved, 
and even supervised by a health care professional.  
Also under the guise of providing “advice,” consumers were reminded to 
see their physician on a regular basis and to obtain more medical tests. 
Mammograms and bone density tests were examples of recommended medical 
tests (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009). 
Thus, the advice to consumers emphasized that continued medical monitoring 
was important for staying healthy. The PREMARIN web site informed consumers 
that “achieving the best possible health during menopause means seeing your 
health care professional on a regular basis during this time of transition” 
(PREMARIN web site: http://www.premarin.com. Retrieved: July 17, 2009). In 
this statement, the role of the health care provider was linked to achieving 
positive health outcomes thereby encouraging consumers to consult medical 
treatment.  Consumers were also told on the ENJUVIA web site that talking with 
a health care professional was important because it “could lead to a more 
accurate assessment of your symptoms” (ENJUVIA web site: 
http://www.enjuvia.com. Retrieved: July 14, 2009). As a result, the so-called 
“advice” furnished to consumers on the pharmaceutical web sites privileged 
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medical authority and the physician’s role in providing a diagnosis was 
reinforced.  
In comparison, physicians were also provided with information about 
talking with patients. Yet here, information provided to health care professionals 
for talking with their patients emphasized their medical expertise and authority in 
“combating” misinformation about HT. One example was found on the 
CombiPatch web site in which health care providers were told that consumers 
will “look to you for guidance” (CombiPatch web site: 
http://www.combipatch.com. Retrieved: July 13, 2009). Specifically, health care 
providers were told they may need to help “combat the many misconceptions 
about HT” (CombiPatch web site: http://www.combipatch.com. Retrieved: July 
13, 2009). To help combat this confusion, the drug manufacturers supplied 
information for health care providers in case they were asked to provide a 
clarification for their patients.  
Continuing with my analysis of the menu options for consumers, four of the 
HT web sites provided Frequently Asked Questions (FAQs). These four web 
sites were ANGELIQ, CombiPatch, Estrasorb, and Femring. In addition, 
“Women’s Stories” were also observed as a menu option on three of the HT web 
sites (Estrasorb, PREMARIN, and PREMPRO), which will be explored further in 
Chapter 7.  Also, three web sites (ANGELIQ, PREMARIN, and PREMPRO) had 
a menu option where consumers could “Tell a friend” about the HT product.  In 
these three instances, web site visitors could type in the email address of a 
“friend” and send them information about the HT product. Interestingly, this email 
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“Tell a Friend” option capitalized on technology to further disseminate information 
about HT products to potential consumers. 
In the menu options for consumers, coupons and a glossary were also 
observed. Specifically, two of the HT web sites offered a coupon. A coupon found 
on the ANGELIQ web site informed consumers that they could “save up to $50 
on your first 3 prescriptions of ANGELIQ” (ANGELIQ web site: 
http://www.angeliq-us.com. Retrieved: July 13, 2009). Another coupon on the 
ENJUVIA web site could be printed out “to receive 30 tablets of ENJUVIA – 
Free!” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009). 
Upon further scrutiny of the coupon, it stated ”once your healthcare professional 
attaches this coupon to a completed, signed prescription form, you can take the 
prescription to your pharmacy and receive up to 30 tablets of ENJUVIA at no 
charge” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009). 
Here again, the importance of the health care provider providing a prescription in 
order to receive the “free” tablets was noted. Finally, the ENJUVIA web site 
provided an alphabetical glossary of terms for consumers. Some examples of 
terms found in the glossary include estrogen, hot flashes, night sweats, and 
osteoporosis.  
To summarize, the menu items provided for (female) consumers generally fell 
into three leading categories: First, an “About” section described the various HT 
products. Second, an “About Menopause” menu option identified several 
menopausal symptoms for web site users. Next, information was provided to 
consumers for talking with their health care provider. Taken together, the top 
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menu categories emphasized information about the HT products, information 
about menopause, and advice for talking with a physician focused on HT 
treatment and the need to consult a health care professional. For comparison, I 
examined the type of menu options available on the web sites for health care 
providers, which is discussed further in the next section of this chapter. 
 
 
Menu Options for Health Care Providers 
 
In contrast, the number of menu items on the HT web sites geared 
towards health care providers is shown in Table 8. In the online advertisements, 
the number of menu options for health care providers totaled 51 menu items. In 
particular, two of the HT web sites (Femring and ANGELIQ) provided only one 
menu option for health care providers which led to detailed prescribing 
instructions. On the other hand, 16 menu options were observed on both the 
CombiPatch and ENJUVIA web sites for health care providers.   
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Table 8: The Number of Menu Options for Health Care Providers 
HT Web Site Number of Menu Options for Health 
Providers 
 
ANGELIQ 1 
 
CombiPatch 16 
 
ENJUVIA 16 
 
Estrasorb 3 
 
femhrt 2 
 
Femring 1 
 
PREMARIN 6 
 
PREMPRO 6 
 
Total 51 
 
 
As shown next in Table 9, a range of menu options were presented to 
health care providers across the HT web sites. In every instance, prescribing 
information was provided for health care professionals (N=8). While all of the HT 
web sites provided prescribing information for health care providers, important 
differences existed between the web sites. For example, four of the HT web sites 
provided a menu option about dosage options. The four web sites providing a 
menu option for health care providers to learn more about various dosage 
strengths were CombiPatch, ENJUVIA, PREMARIN, and PREMPRO. In all four 
instances, this menu option led to information about various dosage options and 
was accompanied by colorful pictures of the HT products in their various dosage 
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strengths. On the PREMARIN web site, a picture of five colored tablets 
representing a “range of dosing options” was displayed (PREMARIN web site: 
http://www.premarin.com. Retrieved: July 17, 2009). Likewise, a “variety of 
dosage strengths for prescribing flexibility” was shown on the ENJUVIA web site 
complimented with a picture of five colored tablets (ENJUVIA web site: 
http://www.enjuvia.com. Retrieved: July 14, 2009). In addition, a picture of three 
colored tablets was observed on the PREMPRO web site (PREMPRO web site: 
http://www.prempro.com. Retrieved: July 17, 2009). Another example was 
present on the CombiPatch web site. In this case, pictures of two different sized 
patches were shown to depict the “two treatment regimens for CombiPatch” 
(CombiPatch web site: http://www.combipatch.com. Retrieved: July 13, 2009). 
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Table 9: Menu Options for Health Care Providers 
HT Web Site Menu Options for Health Providers 
 
ANGELIQ Physician Information 
 
CombiPatch About CombiPatch 
• How It Works 
• Why It’s Different 
• Dosage and Regimen Options 
• Choosing a Treatment Regimen 
• Clinical Trial Information 
• Transdermal Preference 
Talking to Your Patients 
• Risks/Benefits of Hormone 
Therapy 
• Myths about Hormone Therapy 
• Women’s Health Initiative 
Library 
• Online Resources 
• CME  
• Events 
CombiPatch Prescribing Information  
 
ENJUVIA Enjuvia Home  
Discover the ENJUVIA Effect 
• Discover the ENJUVIA Effect on    
Moderate-to-Severe 
Vasomotor Symptoms 
• Discover the ENJUVIA Effect on    
Moderate-to-Severe Vaginal 
Dryness and Pain With Sex 
• Low-Dose Efficacy with the 
ENJUVIA Effect 
• The ENJUVIA Delivery System 
• ENJUVIA Dosage Strengths 
• ENJUVIA Safety Profile 
• Frequently Asked Questions 
About ENJUVIA 
Resources 
Information for Pharmacists 
Menopause Impact Tool 
Prescribing Information 
Important Safety Information 
References 
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Contact Us 
 
Estrasorb Symptoms and Therapy 
Efficacy 
Delivery and Safety 
 
femhrt Full Prescribing Information 
Information for the Patient  
 
Femring Full Prescribing Information 
 
PREMARIN Premarin Home 
Premarin Family Name 
Practice Resources 
Patient Materials 
Important Safety Information 
Prescribing Information 
 
PREMPRO Prempro Home 
Practice Resources 
Patient Materials 
Important Safety Information 
Prescribing Information 
New Packaging for Prempro 
 
 
 
Further analysis of the categories of menu options provided to health care 
professionals across the HT web sites is shown in Table 10. As seen in Table 10, 
the most frequently observed menu choice for health care providers was 
prescribing instructions. As already noted, this menu option was provided across 
all of the HT web sites (N=8). This was followed by a menu option about the 
range of dosage options on four of the HT web sites (CombiPatch, ENJUVIA, 
PREMARIN, and PREMPRO). Additionally, a menu option leading to information 
that health care providers could distribute to their patients was also presented.  
The four web sites providing information for patients were CombiPatch, femhrt, 
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PREMARIN, and PREMPRO. Interestingly, a health care provider had to register 
first for a free account in order to access the patient education materials from the 
PREMARIN and PREMPRO web sites. However, information for patients was 
available on the CombiPatch and femhrt web sites and health care providers 
could easily print out the information from these two web sites and distribute it to 
their patients.  
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Table 10: Breakdown of Categories of Menu Options 
for Health Care Professionals 
Menu Option Number of HT Web Sites 
with Menu Option 
 
HT Web Site 
 
Prescribing Information 8 ANGELIQ, CombiPatch, 
ENJUVIA, Estrasorb, 
femhrt, Femring, 
PREMARIN, PREMPRO 
 
Dosage Options 4 CombiPatch, ENJUVIA, 
PREMARIN, PREMPRO 
 
Information for Patients 
 
4  
 
CombiPatch, femhrt, 
PREMARIN, PREMPRO 
How it Works 
 
3 CombiPatch, ENJUVIA, 
Estrasorb 
 
Events Calendar 
 
3 CombiPatch, 
PREMARIN, PREMPRO 
 
Efficacy 
 
2 ENJUVIA, Estrasorb 
 
CME 1 CombiPatch 
 
 
To continue with my analysis of the main categories of menu options for 
health care providers, next I observed a menu option about how the HT product 
worked on three of the web sites (CombiPatch, ENJUVIA, and Estrasorb). For 
example, health care providers could select the menu option labeled “How 
CombiPatch Works” to learn more about how hormones were delivered to 
patients using the product (CombiPatch web site: http://www.combipatch.com. 
Retrieved: July 13, 2009). Health care providers could also click on the menu 
choice titled “The ENJUVIA Delivery System” and watch an animated video that 
shows how ENJUVIA was released (ENJUVIA web site: http://www.enjuvia.com. 
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Retrieved: July 14, 2009). Likewise, a menu option entitled “Delivery and Safety” 
was provided to health care professionals on the Estrasorb web site (Estrasorb 
web site: http://www.estrasorb.com. Retrieved: July 15, 2009). 
Next, an event calendar was observed on three of the HT web sites. 
These event calendars were designed so that a health care provider could learn 
more about upcoming events and stop by a pharmaceutical booth “to learn more 
about [their] product portfolio or to speak with a representative” (PREMARIN web 
site: http://www.premarin.com. Retrieved: July 17, 2009). Two of the HT web 
sites also provided a menu option specifically discussing the efficacy of the HT 
product (ENJUVIA and Estrasorb). In fact, the word “efficacy” was used in the 
title of the menu option. For instance, health care providers were presented with 
a menu option simply entitled “Efficacy” on the Estrasorb web site (Estrasorb web 
site: http://www.estrasorb.com. Retrieved: July 15, 2009). Moreover, the menu 
option on the ENJUVIA web site was called “low-dose efficacy with ENJUVIA” 
(ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009). 
Furthermore, the CombiPatch web site was unique in the study sample 
because it was the only web site that provided continuing medical education 
(CME) opportunities for health care providers.  In this case, a list of five online 
continuing education resources, “designed to meet the Continuing Medical 
Education information needs of health care professionals” was provided 
(CombiPatch web site: http://www.combipatch.com. Retrieved: July 13, 2009). 
Interestingly, whenever a web site user would click on one of the online 
resources for CME, they were informed “you are now leaving the CombiPatch 
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web site and moving to an external web site independently operated and not 
managed by Novogyne Pharmaceuticals. Novogyne assumes no responsibility 
for the sites” (CombiPatch web site: http://www.combipatch.com. Retrieved: July 
13, 2009). All of the five online resources for CME were commercially-produced 
and anyone interested in obtain CME credits had to register and create an 
account with the company. The inclusion of such resources on the CombiPatch 
web site demonstrated that the pharmaceutical company recognized these online 
continuing education opportunities might be of particular interest to this target 
audience (i.e. health care professionals) visiting information about their HT 
product. 
In summary, menu options for health care professionals could be grouped 
into four main categories. First, a menu option linking to full prescribing 
information was observed on all of the HT web sites. Second, the next frequently 
observed menu option for health care providers was for the range of available 
dosage strengths. In all four instances, colorful pictures of the HT product were 
included to help illustrate the range of dosage options. As noted, the language 
used in the menu options was biomedical in nature and used easily recognizable 
language by the intended audience, such as prescribing information and dosage 
and regimen options.  Health care professionals were also supplied with 
information that could be distributed to their patients. In the information that 
health care provider could supply to patients, the physician’s medical authority 
and clinical expertise were reinforced.  Hence, a comparison of menu options for 
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consumers and health care providers illustrated how information was presented 
to targeted web site audiences for the HT products.  
 
Summary 
 
In this chapter, I presented an analysis of the overall layout and 
organization of the web site for HT. My analysis included an examination of the 
names of the HT products and I found that brand names either indicated the form 
that the product was available or played with word associations, such as 
rejuvenation and angelic, to link HT products with certain feelings or desires. In 
addition, I observed the presence of two web site portals on the HT web sites for 
different audiences. This analysis was valuable because it helped to demonstrate 
how information content on the pharmaceutical web sites was being presented to 
these two potential markets for HT products. As evident in the creation of distinct 
web portals for consumers and health care providers, this enabled the drug 
manufacturers to organize and present information to two potential markets for 
their products. By also utilizing web portals for distinct audiences and then 
labeling these sections for consumers and health care providers, drug companies 
were further able to furnish certain types of information tailored for different 
audiences.  
My analysis also revealed that the menu options presented to consumers 
varied from the content provided to health care providers. Leading menu options 
for consumers included an “About” menu option describing the HT products (i.e. 
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About ANGELIQ), an “About Menopause” menu option, and a menu option 
providing information to assist consumers in talking with their health care 
provider. Thus, the order of the menu options for consumers created a context 
where consumers first learned about a particular HT product, then they learned 
about menopause, and next they were given advice for talking with their health 
care provider. Within the advice provided on the web sites, consumers were 
encouraged to first ask about HT treatment options and were also told that 
seeing a health care provider on a regular basis during menopause was 
important to a healthy outcome. 
On the other hand, health care providers were presented with different 
menu options. Of these menu options, prescribing information, the range of 
available dosage strengths, and information for patients were prominent. 
Correspondingly, the menu options for health care providers utilized biomedical 
rhetoric, such as dosage and regimen options, likely because it was familiar to 
the target audience. Health care providers were told that patients would look to 
them for guidance thereby reinforcing their medical authority and expertise in 
helping combat misconceptions about HT that consumers may have. By 
presenting information to health care providers that emphasized their medical 
authority, and by also providing “advice” for consumers that clearly reinforced the 
importance of medical supervision and routine medical tests during menopause, 
we begin to see how a biomedical perspective of menopause was being adopted 
and articulated on the web sites for HT. 
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This chapter provided a foundation for understanding how information 
about the HT products was presented differently on the web sites depending on 
the target audience. As made evident by the menu options provided to 
consumers, information about the HT products, information about menopause, 
and advice for talking with a physician were prominent. When taken together, the 
menu options for consumers focused on HT treatment and the need for 
consumers to consult a health care professional.  
In sum, the pharmaceutical web sites introduced consumers to the 
importance of consulting with a health care provider about HT treatment options. 
In contrast, common menu options for health care providers utilized biomedical 
rhetoric, such as dosage and regimen options. Additionally, the information for 
physicians to distribute to their patients reinforced their medical authority and 
expertise in helping to combat consumer “misconceptions” about HT.  
In the next chapter, I delve more into the textual and visual elements 
observed on the web sites for HT. In particular, the advertising slogans found on 
the web sites are examined. In addition, an analysis of the color schemes and 
imagery observed across the HT web sites is presented.  
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CHAPTER 6 
TEXTUAL AND VISUAL ELEMENTS OF THE  
WEB SITES FOR HORMONE THERAPIES 
 
This chapter examines the textual and visual elements present on the 
direct-to-consumer (DTC) web sites for hormone therapies. First, the advertising 
slogans found on the web sites are analyzed. In particular, a comparison of 
advertising slogans aimed at consumers and health care professionals is 
presented. Next, an analysis of the color schemes and imagery observed across 
the HT web sites is provided. Finally, the chapter concludes with a discussion of 
multimedia elements present on several of the HT web sites.  
 
Advertising Slogans  
 
In general, corporations depend on a variety of advertising strategies to 
help achieve their marketing success. Pharmaceutical manufacturers of HT 
products are no exception and use carefully constructed online advertising 
slogans to promote a product and to generate interest in their products. In this 
study, advertising slogans are defined as those few words beneath, below, or 
beside the HT product name often found in the upper left corner on the web sites. 
These slogans appeared in the largest font on the HT web sites and were 
separated from the rest of the web site content for easy recognition. Therefore, 
their prominent placement on the web sites helped to draw attention to these 
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advertising slogans. In fact, these slogans were among the first words a web site 
visitor would likely see, following the product name and product logo, and were 
some of the most repeated words throughout the HT web sites. This key 
placement is in agreement with a key direct-to-consumer advertising principle in 
which the brand name of a drug should be the most prominent feature in 
advertisements (Kenagy and Stein, 2001).  
On seven of the HT web sites in this study (n=7), the main advertising 
slogan was repeated on subsequent web pages. Repetition of the advertising 
slogans from web page to page helped to unify a drug manufacturer’s message 
about its HT product. Hence, advertising slogans can help form an initial 
impression for web site visitors and assist with product name recognition. Next, I 
examined the advertising slogans aimed at consumers observed on the web 
sites for HT. 
 
Advertising Slogans for Consumers 
 
From a sociological perspective, advertising slogans are a useful data 
source that can be used to investigate the messages and meanings embedded in 
a drug company’s communications. As Table 11 indicates, seven of the HT web 
sites (n=7) presented advertising slogans aimed at consumers. Out of the seven 
slogans, a number of recurring key phrases or words were observed. In the 
online advertisements, the words “discover,” “relief,” and “treat” were repeated 
within the slogans.  
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Table 11: Advertising Slogans for Consumers on the HT web sites 
HT Web Site Advertising Slogans for Consumers 
 
ANGELIQ • Focus on You 
• Discover the Difference 
• Ask for ANGELIQ 
• Relief may be a once-a-day 
tablet away 
 
CombiPatch • The New Menopause 
 
ENJUVIA • Great Expectations 
• Discover ENJUVIA 
• ENJUVIA is Demonstrated to 
Help 
 
Estrasorb • Feel Good Again 
• Treat Yourself 
• Get Relief 
 
femhrt N/A 
 
Femring • Change Your Menopause Not 
Your Life 
 
PREMARIN • Treat Your Menopausal 
Symptoms 
 
PREMPRO • Relief from Hot Flashes, Night 
Sweats, and Vaginal Symptoms 
 
 
In particular, the word “relief” was noted in three of the slogans on the web 
sites (ANGELIQ, Estrasorb, and PREMPRO). The ANGELIQ web site proclaimed 
“Relief may be a once-a-day tablet away” (ANGELIQ web site: 
http://www.angeliq-us.com. Retrieved: July 13, 2009). The slogan suggesting that 
“relief may be once a-day tablet away,” introduced the idea that well-being is just 
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a pill away and depended on the assumption that potential consumers will desire 
the convenience of a daily tablet to treat their “symptoms” all day, every day. 
With the possibility that “relief may be once a-day tablet away,” the advertising 
slogan further suggested to consumers what can be expected from using their 
product. By pairing up the words “relief” and “once a-day tablet” in the same 
slogan, the message was clear. The slogan conveyed that medical intervention 
would lead to some type of “relief.”  
Another example was found on the Estrasorb web site which stated “Get 
Relief” (Estrasorb web site: http://www.estrasorb.com. Retrieved: July 15, 2009). 
Visitors to the PREMPRO web site were greeted by the slogan “Relief from Hot 
Flashes, Night Sweats, and Vaginal Symptoms” (PREMPRO web site: 
http://www.prempro.com. Retrieved: July 17, 2009). Thus, the most frequently 
observed word in the slogans aimed at consumers was the word “relief.” Here 
again, by pairing up the words “relief” alongside hot flashes, night sweats, and 
vaginal symptoms, the slogan conveyed that medical intervention would lead to 
“relief” from such symptoms. Moreover, the use of the specific word “relief” 
implied that something was unfavorable and was treatable with HT. By proposing 
to consumers that they could get “relief” from various symptoms, the language in 
the slogans helped to present symptoms as “problematic” and could be medically 
managed. 
As seen in Table 11, the use of the word “”relief” was followed by the use 
of the words “discover” and “treat” in the slogans which were observed two times 
each. For example, the ANGELIQ web site stated “Discover the Difference” 
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(ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009). By 
encouraging web site visitors to “Discover the Difference,” this slogan provided a 
structure for the pharmaceutical company to make a convincing case that there 
was a significant difference to be discovered when consumers learned more 
about their HT product. Similarly, web site visitors were presented with the 
slogan “Discover ENJUVIA” (ENJUVIA web site: http://www.enjuvia.com. 
Retrieved: July 14, 2009). 
As noted, the word “treat” was also found in several of the advertising 
slogans. The slogan on the Estrasorb web site tells consumers to “Treat 
Yourself” (Estrasorb web site: http://www.estrasorb.com. Retrieved: July 15, 
2009). Likewise, the slogan “Treat Your Menopausal Symptoms” was found on 
the PREMARIN web site (PREMARIN web site: http://www.premarin.com. 
Retrieved: July 17, 2009). 
Upon further analysis, the advertising slogans also demonstrated how the 
use of language could assist pharmaceutical companies in conveying messages 
about their products directly to consumers. In particular, the slogans “Treat 
yourself,” “Focus on you,” and “Find your comfort zone” caught my attention. In 
these instances, the three advertising slogans made a personal appeal by 
directly addressing the potential consumer by using the words “you,” “yourself” 
and “your” in the advertising slogans.  
To summarize, the use of the word “relief” was the most frequently used 
word in the advertising slogans aimed at consumers. By proposing to consumers 
that they could get “relief” by using HT, the slogans helped to introduce the idea 
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to consumers that menopause could be medically managed. Meanwhile, this was 
followed by the use of the words “discover” and “treat” in the slogans. All of these 
examples clearly illustrated the deliberate use of certain words to help set the 
stage for using HT products to get “relief” from problematic menopausal 
symptoms. Additionally, I observed the use of the words “you,” “yourself” and 
“your” in the advertising slogans which spoke directly to consumers. As made 
evident in the slogans across the web sites, the language employed articulated a 
biomedical perspective and treatment for menopause. For comparison, I then 
investigated the slogans employed on the web sites for HT aimed at health care 
providers.  
 
Advertising Slogans for Health Care Providers 
 
Four of the HT web sites (n=4) in the study sample utilized different 
advertising slogans when targeting health care providers. As such, each of these 
four advertising slogans is discussed in this section of the chapter. Table 12 lists 
the advertising slogans aimed at health care providers found on the HT web 
sites.  
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Table 12: Advertising Slogans for Health Care Providers 
on the HT Web Sites 
HT Web Site Advertising Slogans for Health Care 
Providers 
 
ANGELIQ N/A 
 
CombiPatch N/A 
 
ENJUVIA • Have You Discovered the 
ENJUVIA Effect? 
 
Estrasorb • A Novel, Effective Delivery 
System 
 
femhrt N/A 
 
Femring N/A 
 
PREMARIN • A Blend of Estrogens with 
Extensive Evidence to Support 
Your Recommendation 
 
PREMPRO • More Dosing Options than Any 
Other Single-Tablet 
Combination Hormone Therapy 
 
As seen in Table 12, the first advertising slogan aimed at health care 
providers was observed on the ENJUVIA web site. The slogan “Have You 
Discovered the ENJUVIA Effect?” posed a question to health care providers 
(ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009). Similar to 
the advertising slogan used for consumers on the same web site, which simply 
stated “Discover ENJUVIA,” this slogan utilized the word “discover” to encourage 
health care providers to also learn more about their product.  
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A second advertising slogan was found on the Estrasorb web site. The slogan 
“A Novel, Effective Delivery System” attempted to distinguish the HT product, 
which is a topical estrogen lotion, from other available HT products on the market 
(Estrasorb web site: http://www.estrasorb.com. Retrieved: July 15, 2009). In this 
case, the advertising slogan emphasized the “novel” delivery system of the 
product as being unique and different from its competitors. 
The third advertising slogan, “A Blend of Estrogens with Extensive 
Evidence to Support Your Recommendation,” was presented to health care 
professionals on the PREMARIN web site (PREMARIN web site: 
http://www.premarin.com. Retrieved: July 17, 2009). In this slogan, the reference 
to “evidence” was noticeable. Thus, the advertising slogan assured health care 
providers about the scientific merit of the HT product. 
Finally, a fourth advertising slogan was found on the PREMPRO web site. 
Health care providers were told that PREMPRO provided “More Dosing Options 
than Any Other Single-Tablet Combination Hormone Therapy” (PREMPRO web 
site: http://www.prempro.com. Retrieved: July 17, 2009). From this slogan it was 
evident that a range of dosage options was viewed as an attractive feature to 
advertise to health care professionals. Thus, my analysis indicates that the 
advertising slogans for health care professionals emphasized “discovering” a 
particular product, a “novel” delivery system, evidence of scientific merit, and a 
range of available dosage options. Clearly, the advertising slogans for health 
care providers relied on medical rhetoric that would be familiar to the target 
audience. Correspondingly, the language used in the slogans for health care 
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providers mentioned a “novel delivery system,” “more dosing options, and 
“scientific evidence to support your recommendation.” In this sense, the slogans 
for health care providers conveyed that menopause and symptoms could be 
medically managed with their HT products while also reinforcing the physician’s 
role in medically managing menopause.   
Overall, advertising slogans for consumers and health care providers 
appeared in larger font sizes on the HT web sites and attracted attention to 
messages about a product’s attributes. My analysis suggests that consumers 
were informed about what can be expected from using the HT products from the 
repeated use of the words “relief,” “discover,” and “treat” observed in the 
advertising slogans.  In addition, health care providers were informed about the 
range of available “treatment options” and dosage strengths. In other words, the 
advertising slogans differed depending on the potential market. Given this, the 
advertising slogans illustrated an important distinction between the information 
content being presented to health care providers and potential consumers. The 
slogans further demonstrated the role of language as an effective means of 
introducing the idea that menopause and menopausal symptoms could be 
medically managed with HT products. In the next section of the chapter, I take a 
closer look at the various color schemes and imagery found on the web sites for 
HT products. 
 
Color Schemes 
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As noted earlier, the use of color to help differentiate pharmaceutical 
products from other competitors is a fundamental DTCA marketing strategy 
(Kenagy and Stein, 2001). Importantly, color is an integral part of products, 
packaging, and logos and can be an effective means of “creating and sustaining 
brand and corporate images in customers’ minds” (Madden, Hewett, and Roth, 
1999, p. 90). Colors used on the various HT web sites ranged from purple, pink, 
green, blue, to yellow. Table 13 illustrates the colors found across the web sites 
for HT in the study sample. 
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Table 13: Colors used on the HT Web Sites 
HT Web Site Colors 
 
ANGELIQ Pink, purple, white 
 
CombiPatch Yellow, green, blue 
 
ENJUVIA Green, white, purple  
 
Estrasorb Purple, white, green 
 
femhrt Blue, purple, white 
 
Femring Pink, purple, white 
 
PREMARIN Blue, white 
 
PREMPRO Purple, white, green  
 
 
The most popular color scheme observed on the web sites for HT was the 
combination of purple, white, green. Three of the web sites utilized this color 
scheme (ENJUVIA, Estrasorb, and PREMPRO). This color combination was 
followed by the use of pink, purple, and white on two of the web sites (ANGELIQ 
and Femring). However, some differences across the HT web sites existed. One 
instance of the combination of yellow, green, and blue was observed 
(CombiPatch). Another color scheme was evident on the femhrt web site in which 
blue, purple, and white was present. Finally, one instance of the use of blue and 
white was found on the PREMARIN web site. Given this, the most popular color 
scheme observed on the HT web sites was the combination of purple, white, 
green and this was followed by the color combination of pink, purple, and white. 
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Notably, seven of the HT web sites utilized the color white. According to 
Kress and Van Leeuwen (2002), the color white has long been associated with 
the idea of “purity” (p. 348). Additionally, the color white mostly has positive 
connotations (Allan, 2009). On the pharmaceutical web sites, the color white was 
used heavily as a background color on seven of the web sites. In addition, white 
flowers were observed on the PREMPRO and PREMARIN web sites. Since color 
can symbolize ideas that help convey meaning, the white flowers assisted in 
making an association with purity, cleanliness, and serenity.  In these cases, the 
color white was tied to particular HT products and assisted consumers in the 
interpretation of product attributes. Here, the visual image of the white flowers 
made a connection with cleanliness and purity. As also seen in Table 13, six of 
the HT web sites used the color purple as a background color. Once again, the 
use of certain colors can express or reproduce ideas about femininity (Kress and 
Van Leeuwen, 2002). Given the prevalent use of white and purple on the HT web 
sites, I speculate that the pharmaceutical companies were making associations 
with femininity in order to appeal to potential female consumers.  
 
Organic and Nature Imagery 
 
In the online advertisements for HT, the use of arcs, circles, ribbons, and 
rounded edges were observed. Table 14 shows the use of this imagery across 
the web sites for HT. Next, I further examine these visual elements.   
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Table 14: Imagery used on the HT Web Sites 
HT Web Site Imagery 
 
ANGELIQ • Circles (pink and purple) 
• Swirly, scrolls that resemble 
flowers and stems (pink) 
• Ribbons (purple) 
 
CombiPatch • Ribbons (green and blue) 
• Circles (green and blue) 
 
ENJUVIA • Ribbons (green) 
 
Estrasorb • Leaves (green) 
• Ribbons (cream-colored) 
• Curves (purple) 
• Flowers (pink) 
 
femhrt • Circle (blue) 
 
Femring • Flowers (pink) 
 
PREMARIN* • Flowers (white) 
 
PREMPRO* • Flowers (white) 
 
 
(* HT web sites also used interactive web site banners) 
 
As Table 14 indicates, the use of ribbons was observed on four of the HT 
web sites (ANGELIQ, CombiPatch, ENJUVIA, and Estrasorb). An example of a 
curly or wavy green “ribbon” was observed on the ENJUVIA web site. This visual 
element was repeated whenever a woman was pictured wearing a green scarf 
closely resembling the green ribbon found in the web site banner. In fact, the 
green ribbon was reminiscent of a holiday ribbon or decoration on a package. 
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These repetitive elements, such as the soft “curves” of the green ribbon and 
green scarf, helped to create a visual coherence about the HT product. Hence, 
the use of such feminine imagery on the HT web sites, such as the curves and 
ribbons, were used as a way to make connections with femininity in order to 
appeal to and attract attention of potential female consumers.  
Soft “curves” or “ribbons” were also used to underline an advertising 
slogan. In particular, one example was observed on the Estrasorb web site, 
which is a topical estrogen lotion available by prescription. In this case, a cream-
colored “ribbon” (similar to the actual HT product in its white color and cream-like 
texture) was used to underscore the advertising slogan for the HT product. To 
this end, the curvy ribbon underscoring the Estrasorb advertising slogan “Feel 
Good Again” intentionally resembled the actual HT product which is an estrogen 
lotion.  
Circle shapes were also present on three of the web sites (ANGELIQ, 
CombiPatch, and femhrt). For example, CombiPatch web site had a blue circle in 
product logo which closely resembled the HT product (i.e. patch). Similarly, the 
femhrt and Femring web sites had blue circles incorporated into their logos which 
also resembled the shape of the HT product (tablets). In all three cases, the 
circles found in the HT product logos were blue in color. 
The presence of nature imagery was also observed on several of the HT 
web sites. As seen in Table 14, pictures of flowers and leaves were noted. 
Flowers were observed on five of the HT web sites. In three instances, the 
flowers were pink (ANGELIQ, Estrasorb, and Femring).  The use of green leaves 
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was noted on the Estrasorb web site. Hence, the use of ribbons was the most 
popular image found across the web sites and this was followed by the use of 
flowers and circles. Therefore, the ribbons, flowers, and circles in the online 
advertisements for HT drew upon traditional symbols of feminine imagery. 
Certainly, the use of a particular image in concert with a specific color, such as 
the pink flowers or green leaves, was a noticeable pattern in the online 
advertisements. As is evident, these were strategic marketing attempts to 
“package” information about the HT products in a way that would appeal or 
resonate with potential female consumers. 
 
Images of HT Products 
 
In addition, pictures of the various HT products were observed on seven of 
the HT web sites (n=7). Table 15 shows which of the web sites provided pictures 
of the various HT products. As seen in Table 15, pictures related to the HT 
products found on the web sites included images of the actual prescription 
tablets or pictures of the packaging for the HT product, such as lotion packets or 
the cardboard box.  
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Table 15: Web Sites with Pictures of HT Products 
HT Web Site Pictures of HT Product 
 
ANGELIQ • Tablets (pink) 
• Packaging (purple and pink box) 
 
CombiPatch • Patch 
• Packaging/Box 
 
ENJUVIA • Tablets (5 dosage strengths, 5 
different colored pills) 
 
Estrasorb • Lotion packets 
 
femhrt N/A 
 
Femring • Picture of product (ring) 
 
PREMARIN • Tablets (5 dosage strengths, 5 
different colored pills) 
 
PREMPRO • Tablets (3 dosage strengths, 3 
different colored pills) 
• Packaging/Box 
 
 
As noted, seven web sites had pictures of the actual HT products. Of these 
seven, the most popular images were pictures of the tablets. Four of the web 
sites for HT presented colorful pictures of the tablets (ANGELIQ, ENJUVIA, 
PREMARIN, and PREMPRO). One web site had a picture of the patch 
(CombiPatch). Another web site provided a picture of lotion packets (Estrasorb). 
In addition, one web site displayed a picture of the ring (Femring). Thus, seven of 
the web sites included pictures of the HT products.   
In addition, three of the web sites provided pictures of the packaging of the 
product (ANGELIQ, CombiPatch, and PREMPRO). Certainly, the product 
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packaging is an effective communication tool and the intention behind the 
inclusion of such product pictures can be viewed as two-fold. First, featuring 
pictures of the HT product may aid in easier consumer identification of the 
product. As I witnessed with the three instances from the study sample, the 
product packaging clearly displayed the product name and colorful logo. 
Secondly, product packaging also plays a crucial role in explaining to consumers 
how to use the HT product. With names such as the “EZ Dispenser,” the product 
packaging for PREMPRO enables the drug manufacturer to speak to the 
consumers directly with claims of how their product is easy to use by simply 
pushing the “tablets through the sealed foil to obtain your daily dose” (PREMPRO 
web site: http://www.prempro.com. Retrieved: July 17, 2009). Thus, pictures of 
various HT products and their packaging found on the web sites achieved 
several purposes. Pictures of the actual HT products or their packaging may 
assist with easier brand recognition, speak to consumers directly, and also help 
to differentiate among the various products on the markets with company logos. 
Accordingly, these are direct-to-consumer advertising strategies commonly used 
to ensure that a product is easy to remember (Kenagy and Stein, 2001). 
Yet, some marked differences across HT web sites were noted. In particular, 
only two of the pharmaceutical web sites for HT showed the product being used. 
The first instance was found on the Estrasrob web site in which a woman was 
shown applying the estrogen cream to her thigh. The second instance was 
observed on the Femring web site. In this case, a drawing depicted a woman 
demonstrating how to insert the feminine ring. Again, these were the only two 
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web sites in the sample that showed the HT products being used. None of the 
pharmaceutical web sites in the sample pictured women taking prescription pills.  
 
Portraits of Characters in the Online Advertisements 
 
This study also investigated the representation of female and male 
characters in the online advertisements, including depictions of health care 
professionals. Table 16 shows the range of the characters found across the web 
sites for HT.  As seen in Table 16, characters were observed on six of the HT 
web sites. Within these six web sites, a total of 25 images of characters were 
observed throughout the web sites. These twenty-five images depicted 28 
different characters. Therefore, in some instances, there were two characters 
present within one image.  
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Table 16: Portrayal of Characters on the HT Web Sites 
HT Web 
Site 
Primary 
Setting 
 
Primary 
Behavior 
 
Appearance (estimated age 
range, race, and attire) 
 
ANGELIQ 
(Three 
images) 
 
1. work 
2. recreational 
3. residential  
 
1. work 
2. walking  
3. talking 
 
1. Middle-aged Caucasian 
woman in business attire 
(jacket and scarf) 
2. Two Middle-aged Caucasian 
women in active wear (jogging 
suits) 
3. Picture of Middle-aged 
Caucasian woman in casual 
attire, Caucasian man, and a 
dog 
 
CombiPatch 
(Five 
images) 
 
1. not known 
2. recreational 
3. recreational 
4. recreational 
5. not known 
 
 
1. headshot, 
looking at 
audience 
2. walking/hiking 
3. yoga/stretches 
4. on exercise 
bike 
5. headshot, 
looking at 
audience 
 
1. Middle-aged Caucasian 
woman in casual attire 
(sweater) 
2. Middle-aged Caucasian 
woman in active wear (shirt, 
shorts, and hiking boots) 
3. Middle-aged Caucasian 
woman in active wear (sweat 
shirt and sweat pants) 
4. Middle-aged Caucasian 
woman in active wear (tank top, 
shorts, and sneakers) 
5. Middle-aged Caucasian 
woman in casual attire (shirt 
and vest) 
 
ENJUVIA 
(Three 
images) 
 
1. work 
2. not known 
3. health care 
environment 
 
1. work 
2. headshot, 
looking at 
audience 
3. sitting in exam 
room 
 
1. Middle-aged Caucasian 
woman in business attire (suit,  
scarf, and brief case) 
2. Middle-aged African 
American woman in casual 
attire (sweater) 
3. Middle-aged Caucasian 
woman sitting in exam room 
with female health care 
professional who is middle-
aged and Caucasian (wearing 
a white coat and stethoscope) 
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Estrasorb 
(Three 
images) 
 
1. not known 
2. not known 
3. not known 
 
 
1. headshot, 
looking at 
audience 
2. headshot, 
looking at 
audience 
3. headshot, 
looking at 
audience 
 
1. Middle-aged Caucasian 
woman in casual attire 
(sweater) 
2. Middle-aged Caucasian 
woman in casual attire 
(sweater) 
3. Middle-aged African 
American woman in casual 
attire (sweater) 
 
Femhrt 
(no images) 
 
N/A 
 
N/A 
 
N/A 
 
Femring 
(no images) 
 
N/A 
 
N/A 
 
N/A 
 
PREMARIN 
(Six 
images) 
 
1. residential 
2. residential 
3. residential 
4. residential 
5. residential 
6. residential 
 
1. talking to 
audience, 
“greeted” web site 
visitors 
2. headshot, 
looking at 
audience 
3. headshot, 
looking at 
audience 
4. headshot, 
looking at 
audience 
5. headshot, 
looking at 
audience 
6. headshot, 
looking at 
audience 
 
1. Middle-aged Caucasian 
woman in business attire 
(jacket and scarf) 
2. Middle-aged Caucasian 
woman in business attire 
(jacket and scarf) 
3. Middle-aged African 
American woman in business 
attire (jacket) 
4. Middle-aged Caucasian 
woman in casual attire 
(sweater) 
5. Middle-aged Caucasian 
woman in casual attire 
(sweater) 
6. Middle-aged Caucasian 
woman in casual attire 
(sweater) 
 
PREMPRO 
(Five 
images) 
 
1. residential 
2. residential 
3. residential 
4. residential 
5. residential 
 
1. talking to 
audience, 
“greeted” web site 
visitors 
2. headshot, 
looking at 
audience 
3. headshot, 
looking at 
audience 
1. Middle-aged Caucasian 
woman in casual attire 
(sweater) 
2. Middle-aged Caucasian 
woman in casual attire 
(sweater) 
3. Middle-aged Caucasian 
woman in casual attire 
(sweater) 
4. Middle-aged Caucasian 
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4. headshot, 
looking at 
audience 
5. headshot, 
looking at 
audience 
 
woman in casual attire 
(sweater) 
5. Middle-aged Caucasian 
woman in casual attire 
(sweater) 
 
 
 
Notably, all of the images depicted smiling people. Researchers have 
reported that direct-to-consumer advertisements are likely to be successful 
whenever they “establish positive identification with the depicted models” (Cline 
and Young, 2004, p. 137). Similarly, Kaufert and Lock (1997) found pictures of 
bright, healthy, and beautiful women appearing in pharmaceutical brochures. 
Here, the smiling people depicted in the images on the pharmaceutical web sites 
helped to develop a positive link between the HT products and happiness. 
Furthermore, the smiling people in the pictures could be conceived as adding 
their approval of the product.  
In my analysis, I also examined the primary setting of the images to help 
provide context. As such, I coded the primary setting depicted in the images as 
either “work,” “residential,” “recreational,” “health care environment,” or “not 
known.” Female characters appeared in a residential space more than any other 
setting. Therefore, a domestic or residential space was the most popular setting 
and served as the primary setting for 12 of the images. For example, five female 
characters were observed on the PREMARIN web site sitting on a couch, looking 
at photo albums, and having beverages in coffee mugs (PREMARIN web site: 
http://www.premarin.com. Retrieved: July 17, 2009). Although PREMARIN and 
PREMPRO are both products of Wyeth Pharmaceuticals, four different female 
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characters were observed on the PREMPRO web site sitting around a dining 
room table and having beverages in coffee mugs (PREMPRO web site: 
http://www.prempro.com. Retrieved: July 17, 2009). Here, the images depicted 
women in a social context in which they were shown smiling, interacting, and 
socializing. In this way, the images choreographed a “scene” that could be 
familiar to potential female consumers. As a result, such images may attract 
attention or identification with the people being depicted. 
I coded the primary setting as “not known” for six of the images. In these 
six cases, the images were headshots and the focus was on the woman’s face. 
With the characters’ faces being the focal point of the pictures, these images 
contained minimal or no surroundings. Interestingly, these character portraits 
showed the woman looking directly out at the web site audience, perhaps in 
order to engage with the viewer. In four other instances, the primary setting was 
recreational. By and large, a domestic setting the most popular setting for the 
images, followed by images grouped into the “not known” category, and then 
images in a recreational setting.  
As also seen in Table 16, I noted the primary behavior, or activity, of the 
characters being depicted in the advertisements. Instances of female characters 
looking directly at the web site audiences were observed 15 times in the images. 
As stated earlier, these images consisted of “headshots” which focused 
exclusively on the women’s faces as they looked directly at web site visitors. 
Therefore, the presence of female characters “looking at the web site audience” 
was clearly the most popular behavior (or activity) being performed in the 
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images. In effect, the female characters on the pharmaceutical web sites were 
looking back at our gaze. Goffman (1979) has also noted how magazine 
advertisements show women looking back at the viewer.  
In four other cases, examples of “physical activity” were observed. 
Specifically, two female characters were walking in an image found on the 
ANGELIQ web site (ANGELIQ web site: http://www.angeliq-us.com. Retrieved: 
July 13, 2009). In addition, a female character was shown performing yoga 
stretches on the CombiPatch web site (CombiPatch web site: 
http://www.combipatch.com. Retrieved: July 13, 2009). Another example was 
also present on the CombiPatch web site in which a female character was riding 
an exercise bike (CombiPatch web site: http://www.combipatch.com. Retrieved: 
July 13, 2009). 
My analysis suggests that these depictions are meaningful in terms of the 
degree of physical activity being portrayed. As discussed above, the majority of 
images showed female characters passively looking out at web site audiences. 
Also among the portrayal of female characters, some of the images depicted 
women as being active in a very limited fashion. While such lifestyle factors, such 
as exercising were depicted, the web sites did not state that these activities could 
help to reduce symptoms. Rather, the Femring web site stated “You do not want 
to take ‘time out’ to deal with symptoms of menopause… [and] Femring offers a 
convenient and discreet approach to estrogen therapy allowing you to get on with 
the things that are really important” (Femring web site: 
http://www.wcrx.com/products/femring. Retrieved: July 17, 2009). Here, women 
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were told that they would not have to spend their time worrying about the 
symptoms of menopause if they used HT. Another example was found on the 
ANGELIQ web site where a woman was shown jogging and yet the web site 
stated “HT is one of the most effective options to help manage menopausal 
symptoms such as hot flashes, night sweats, vaginal dryness, and potential bone 
loss” (ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009). 
One more example was found in which a woman was shown walking in hiking 
boots and the statement on the web site said: “CombiPatch is designed to stay 
on during activities… [and] you can get back to enjoying an active lifestyle while 
wearing the patch” (CombiPatch web site: http://www.combipatch.com. 
Retrieved: July 13, 2009). Therefore, as illustrated by these examples, the 
underlying premise was that hormones could help to achieve the activity that was 
being presented. To be sure, these visual images conveyed health, activity, and 
vitality that could be achieved through the use of HT. According to the online 
advertisements, the “treated” woman was healthy, active, and happy.  
Additionally, the appearance of the characters in the online 
advertisements, such as their estimated age, race, and attire (or dress), was 
included in my analysis. In the online advertisements for HT, 24 of the female 
characters were Caucasian, including one picture of a health care provider on the 
ENJUVIA web site.  As Coney (1994) states, hormone therapy has been 
“predominantly used by white, middle-class women” (p. 224). Therefore, the 
depictions of female characters on the pharmaceutical web sites reflected 
hormone use patterns reported in the literature. Cortese (2008) further notes that 
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target advertising assumes a particular group or groups have money to spend.  
Conversely, non-representation suggests the powerless status of groups that do 
not “possess significant material or political power” (Cortese, 2008, p. 15). In 
comparison, only three of the female characters in the images were African 
American (ENJUVIA, Estrasorb, and PREMARIN web sites).  
Since the majority of the female characters featured in the online 
advertisements were Caucasian women, this closely mirrored the demographic 
characteristics of the typical users of hormone therapies. This demographic 
pattern is also true of users of the Internet. Research reports that 79% of adult 
women use the Internet and 80% of Internet users are Caucasian, highlighting 
the fact that some groups lack access to the Internet (Pew Research Center 
Internet & American Life Project web site: http://www.pewinternet.org/Trend-
Data/Whos-Online.aspx. Retrieved: September 29, 2010). As a result, the 
pharmaceutical web sites were likely trying to appeal to this target audience for 
their products. 
With regards to the type of attire, 16 of the female characters wore causal 
attire such as sweaters. Unique among the sample, women were shown in 
business attire in only six of the images. Thus, women were portrayed in a 
professional role in limited manner. Images coded with the category of “business 
attire” were identified by various symbols such as business suits or brief cases. 
For example, one female character was observed on the ENJUVIA web site 
wearing a business suit (jacket and pants) and carrying a brief case (ENJUVIA 
web site: http://www.enjuvia.com. Retrieved: July 14, 2009). Finally, female 
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characters in active wear, such as jogging suits, were found in four of the 
images.  
Another unique finding was that only one image of a health care 
professional was depicted in the online advertisements for HT. As Table 16 
shows, a Caucasian female health care provider was depicted on the ENJUVIA 
web site (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009). 
To this end, the image portrayed the health care provider talking with a patient in 
what is presumably an exam room. Not surprisingly, I found that the use of such 
iconic imagery, such as the white coat and stethoscope, reflected symbols 
commonly associated with the health care environment making the health care 
provider easy to identify in the image.   
Furthermore, one Caucasian male character was present on the 
ANGELIQ web site.  In this image, the male character was shown talking with a 
female character. In addition, a dog was also present in the picture. This image 
was worth noting due to the fact that it was the only image of a male character 
observed in the online advertisements for HT.    
To briefly summarize, an analysis of the characters appearing in the online 
advertisements for HT was conducted. Among the online advertisements for HT, 
female characters were portrayed largely as passive and relegated to a 
residential space. This pattern persisted with the inclusion of “headshots” in the 
images where women were shown passively looking back at web site visitors. All 
of the images depicted people smiling. By also depicting women as participating 
in recreational activities, the images further presented “healthy” appearing 
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people.  Since the web sites did not say that lifestyle modifications, such as 
exercise, could help alleviate symptoms, the images implied that the activity 
being depicted could be achieved through the use of HT. Overall, the online 
advertisements for HT positioned women within the domestic or residential realm 
while also conveying that health, activity, and vitality could be achieved through 
the use of HT.    
 
Multimedia Elements   
 
 
As discussed above with the portraits of characters in the online 
advertisements, pharmaceutical companies may employ visual strategies to 
convey messages about their products. For instance, a web site banner allows a 
drug manufacturer to customize their web site for their intended audiences. A 
traditional web site banner, sometimes referred to as a web site header, is a 
graphic commonly found at the top of a web site and displays the company 
name, logo, and advertising slogan. Six of the HT web sites (n=6) in the study 
sample made use of a traditional web site banner. However, two instances in 
which web site banners were further enhanced by audio and animation were 
observed. In the online advertisements for HT, web site banners with multimedia 
were present on the PREMARIN and PREMPRO web sites (both are products 
from Wyeth Pharmaceuticals). With the use of audio and Macromedia flash 
animations, these audio-driven web site banner advertisements introduced their 
HT products to potential markets by basically functioning as mini-presentations.  
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The PREMARIN web site featured a presumably middle-aged Caucasian 
woman in a business suit welcoming visitors to the web site with an introduction 
that begins “Hi. I am Kathy. Menopause can be a very confusing time for many 
women” (PREMARIN web site: http://www.premarin.com. Retrieved: July 17, 
2009). The female character “Kathy” goes on to state “I am here to tell you that 
you are not alone. I will be your guide and together we will talk about some of the 
common symptoms of menopause” (PREMARIN web site: 
http://www.premarin.com. Retrieved: July 17, 2009). 
Likewise, the PREMPRO web site featured a middle-aged Caucasian 
woman named “Joanne” in casual attire greeting web site visitors. The character 
“Joanne” greeted web site visitors with the following: “Hi. I am Joanne. We all 
experience menopause differently, for some women it can be a confusing time… 
but you are not alone. Follow me and together we talk about some of the 
common symptoms of menopause” (PREMPRO web site: 
http://www.prempro.com. Retrieved: July 17, 2009). The female character 
“Joanne” continued with “we are in it together and we will find some of the 
answers you may be looking for” (PREMPRO web site: http://www.prempro.com. 
Retrieved: July 17, 2009). 
As previously noted, both PREMARIN and PREMPRO are products of 
Wyeth Pharmaceuticals. In both of these cases, the audio introductions are 
accompanied by captions which may be turned off or on at the discretion of the 
web site visitor. Nevertheless, both the PREMARIN and PREMPRO web sites 
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utilized web site banners enhanced with multimedia to welcome visitors to their 
web sites. 
In brief, the multimedia banners on the two HT web sites entice 
consumers to view much more information than can typically fit into a traditional 
banner (without audio or animation). These mini-commercials introduce the idea 
to consumers that menopause can be a “difficult time,” whereby reinforcing the 
notion that a physician can help navigate this difficult and confusing time. As 
such, the mini-commercials served as an introduction articulating a biomedical 
conceptualization of menopause as being “problematic.”  In doing so, the 
multimedia web site banners helped to advance the idea that menopause should 
be medically treated and managed. By harnessing such technologies, the 
manufacturer of these two HT products (Wyeth Pharmaceuticals) was further 
able to personalize an introduction to their web sites by having a female 
character speak directly to web site visitors. In light of this, the multimedia web 
site banners provided more information for potential consumers about the HT 
products in comparison to the text-only web sites in the sample. 
 
Summary 
 
In this chapter, I was particularly concerned with textual and visual 
elements observed on the web sites and how these elements helped to construct 
messages about the HT products for potential markets. To address this issue 
more fully, I investigated the advertising slogans presented to consumers. For 
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consumers, the advertising slogans included the repeated use of the words 
“”relief,” “discover,” and “treat” to inform consumers what can be expected from 
using the HT products. The ability of the slogans to conceptualize menopause as 
needing “relief” effectively introduced consumers to the idea that their HT 
products could provide some type of “relief.”   
For comparison, I then analyzed the advertising slogans aimed at health 
care providers. Slogans for health care providers were crafted with the busy 
practitioner in mind and utilized biomedical rhetoric familiar to the target 
audience. The promise of flexibility in HT treatment options, such as the range of 
available dosing options, and “evidence” of scientific data supporting the use of 
the HT product served as “selling points” in the advertising slogans aimed at 
health care professionals. Such an analysis contributes to our understanding of 
how the information content across the DTCA web sites for HT differed in its 
presentation depending on the target audience. Although the slogans differed 
depending on the target market for the HT products, the slogans demonstrated 
the importance of language used in the advertising slogans in articulating 
menopause as medically problematic.    
I also examined the color schemes and imagery utilized in the online 
advertisements for HT. The use of color was a fundamental advertising technique 
to help distinguish HT products from other competitors. Notably, the use of the 
colors white and purple on the HT web sites made associations with femininity. 
Further, feminine shapes were used on web sites, such as circles, curves, wavy 
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lines. Together, the gender specific nature of many of these strategies was an 
attempt to attract and appeal to potential female consumers for the HT products. 
Pictures of HT products and their packaging were also included on the 
web sites to aid in easier consumer identification of the product. Only two web 
sites actually pictured the HT product being used. Additionally, I analyzed the 
images of characters in the online advertisements. My findings suggest that 
female characters were mostly depicted as passive and shown in domestic 
settings. Given that the majority of the female characters in the online 
advertisements were Caucasian women this mirrored the demographic 
characteristics of both the common users of hormone therapies and typical users 
of the Internet. Moreover, only one image of a health care provider was 
presented as well as one image of a male character. 
Certainly, drug manufacturers of hormone therapies (HT) have capitalized 
on a range of advertising slogans, color schemes, and imagery to form the 
foundation for “selling” their products online directly to consumers and health 
care providers. In the next chapter, I take a closer look at how menopause was 
portrayed on the web sites for HT. In particular, the nature of the representation 
of menopause and the means used to construct this portrayal will be examined. 
Features found on web sites for HT, such as online tools for assessing 
menopausal symptoms, will also be investigated to help elucidate how 
menopause is constructed by drug manufacturers in online advertisements for 
HT.  
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CHAPTER 7 
THE PORTRAYAL OF MENOPAUSE 
 
Direct-to-consumer (DTC) web sites for hormone therapies allow for an 
examination of medicalization and pharmaceuticals by raising questions about 
the presentation of menopause. In particular, what are the web sites for hormone 
therapies representing about menopause? Likewise, how are messages about 
menopause constructed? To unravel these questions, this chapter examines how 
menopause is portrayed on the DTC web sites for hormone therapies (HT).  
First, textual descriptions of menopause found on the web sites for HT 
were examined. This examination included how menopause was defined on the 
HT web sites with particular attention to the language being used to describe 
menopause. Second, I explored the various explanations presented on the HT 
web sites for the “causes” of menopause. Next, the variety of menopausal 
“symptoms” identified on the HT web sites was analyzed. As I will demonstrate, 
when taken together these elements played an important role in how menopause 
was being portrayed in the online advertisements for HT. 
 
Description of Menopause  
 
In the online advertisements for HT, three main phrases were used to 
describe menopause. Table 17 illustrates how menopause was described on the 
various HT web sites. Firstly, menopause was described as a “change of life” on 
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four of the HT web sites (CombiPatch, femhrt, Femring, and PREMARIN). 
Secondly, menopause was described as “three phases.” These three phases 
were perimenopause, menopause, and postmenopause. The description of 
menopause as “three phases” was found on three of the HT web sites 
(ANGELIQ, PREMARIN, and PREMPRO). Meanwhile, the ENJUVIA web site 
referred to menopause as a “stage of life.”  
 
Table 17: Description of Menopause on HT Web Sites 
Name of HT Product Description of Menopause Key Phrases/Words 
ANGELIQ The end of regular 
menstruation, can be 
explained in three phases 
 
Three phases 
CombiPatch Change of life, reproductive 
system slowly shuts down 
 
Change of life 
ENJUVIA Stage of life, a change that all 
women eventually experience 
 
Stage of Life 
Estrasorb Period has stopped for one 
year 
 
Period has stopped 
femhrt Change of life, sooner or later 
all women go through it 
 
Change of life 
Femring Change of life, your body is 
adjusting to lower levels of 
hormones 
 
Change of life 
PREMARIN Change of life, a transition in 
three stages 
 
Change of life, three 
stages 
PREMPRO Transition in three stages 
 
Three stages 
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As noted, my analysis found that menopause was described on four of the 
HT web sites (CombiPatch, femhrt, Femring, and PREMARIN) as a “change of 
life.” However, the language used on the HT web sites clearly indicated that this 
“change of life” was not a welcomed or positive one. For example, the 
CombiPatch web site proclaimed to consumers that “you don't have to suffer 
through moderate to severe flashes and night sweats. You have options” 
(CombiPatch web site: http://www.combipatch.com. Retrieved: July 13, 2009). In 
this example, there were several important messages implied. First, women were 
introduced to the idea that they did not have to “suffer” from menopause. 
Second, women were told that they did not have to needlessly suffer because 
there were medical treatment options available. As evident in the language used 
in this example from the CombiPatch web site, menopause was introduced to 
consumers as problematic. According to the CombiPatch web site, women could 
learn to “adjust to this change” (CombiPatch web site: 
http://www.combipatch.com. Retrieved: July 13, 2009). Undeniably, this 
“adjustment” involved the use of hormone therapies. As Derry (2008) notes, 
postmenopausal women “do produce estrogen in their bodies [but] these lower 
levels of hormones were assumed to be negligible” (p. 722). Therefore, the 
language on the CombiPatch web site echoed this sentiment, namely that 
hormone levels were deficient and women could use HT products to adjust to this 
so-called decline.   
Moreover, the PREMARIN web site advocated that managing this “change 
of life” was best accomplished by conferring with a health care provider. 
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Specifically, consumers were told “it’s important to talk to your doctor or other 
health care professional about the best ways to keep healthy during this time of 
change” (PREMARIN web site: http://www.premarin.com. Retrieved: July 17, 
2009). From the description of menopause presented on the PREMARIN web 
site, women were informed that menopause should be medically managed. 
Previous research has also noted women are often told they should depend on a 
physician’s medical expertise rather than on their own judgment (Kaufert and 
Gilbert, 1986). Here, the PREMARIN web site also articulated the idea that 
physicians should be regarded as the main source for determining whether or not 
a woman is “menopausal.”  
Thus, not only was this “change of life” portrayed as unwelcomed 
specifically on the CombiPatch and PREMARIN web sites, it was also presented 
as being best managed by a health care expert for an optimal health outcome.  
Indeed, such representations of menopause as a medical event to be medically 
managed by an “expert” suggested that women should go to their physicians for 
information and advice. For these reasons, the language found on the 
CombiPatch and PREMARIN web sites reinforced the long-standing idea of 
physicians as experts over women’s experiences as “someone with power to 
define and categorize their experience” which are signs pointing towards a 
biomedical understanding of menopause (Kaufert and Gilbert, 1986, p. 14).  
Meanwhile, my analysis shows that three of the HT web sites (ANGELIQ, 
PREMARIN, and PREMPRO) portrayed menopause as “three stages.” The three 
phases that these web sites are referring to were perimenopause, menopause, 
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and postmenopause. Research has shown that menopause is not a universal 
experience and women experience menopause differently (Mansfield and Voda, 
1997). Coney also states that apart from menstruation stopping, there is nothing 
universal about menopause and there are as many “menopauses as there are 
cultures” (p. 95). Yet, the three stages listed on the HT web sites can be viewed 
as an attempt to medically “measure” when menopause begins and when it ends. 
Here again, the definitions of menopause found on the ANGELIQ, PREMARIN, 
and PREMPRO web sites suggested menopause was an event that could be 
defined and measured medically.  
Furthermore, the ENJUVIA web site referred to menopause as a “stage of 
life.” In fact, the ENJUVIA web site stated this stage was one that “all women 
eventually experience” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: 
July 14, 2009). As I have expressed, language and word choice were important 
to the overall context of the descriptions of menopause being used by the 
pharmaceutical companies in their online advertisements for HT. By suggesting 
that menopause was a stage that “all women eventually experience,” the 
ENJUVIA web site was associating menopause with something that was “natural” 
and “inevitable.”  
Ironically, this paradoxical definition presented menopause to female 
consumers as both normal and abnormal. The ENJUVIA web site stated “if you 
can't explain how you feel, often your healthcare professional can” (ENJUVIA 
web site: http://www.enjuvia.com. Retrieved: July 14, 2009). This description 
seems contradictory; although the online advertisement for ENJUVIA suggested 
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this was a natural and inevitable stage of life, women were told it may also be a 
time of confusion and best understood with the help of a health care provider. As 
seen in the above quote, the diagnostic role of the physician in distinguishing 
what is “normal” from “abnormal” was implied. Therefore, the ability of the 
ENJUVIA web site to simultaneously represent menopause as natural and 
disease-like through such language effectively placed menopause under the 
rubric of medical supervision.   
One more description of menopause was noted on the HT web sites. One 
instance of menopause being described as when a woman’s “reproductive 
system slowly shuts down” was observed on CombiPatch web site (CombiPatch 
web site: http://www.combipatch.com. Retrieved: July 13, 2009). By describing a 
woman’s reproductive system as “slowly shutting down,” the mechanical 
language in this example was reminiscent of the biomedical model in which the 
body is viewed as a machine breaking down.  An emphasis on how the “aging 
ovaries stop working” have resulted in menopause being regarded as a 
malfunction (Derry, 2002, p. 14). Here, the online advertisement likened the 
aging female body to a machine “breaking down,” which in turn, helps to illustrate 
how menopause was being articulated as a declining biological function.   
To summarize, menopause was described as either “three stages,” “a 
change of life,” or “a stage of life” on the HT web sites. From these examples, the 
language on the HT web sites introduced menopause as a medical event 
needing to be medically managed. Accordingly, statements found on several web 
sites (CombiPatch and PREMARIN) articulated a biomedical perspective by 
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presenting menopause as problematic thereby further solidifying the idea that 
menopause belongs under the domain of medicine.  The PREMARIN web site 
also told women that this “change of life” was best managed by a medical 
professional thus reinforcing the physician’s role and expertise in offering a 
diagnosis. Overall, my analysis indicated the descriptions of menopause on the 
HT web sites introduced menopause to consumers as a “problematic” biomedical 
event best managed by HT under the supervision of a health care provider. Next, 
I explored explanations for the “causes” of menopause provided on the HT web 
sites to further understand how menopause was portrayed in the online 
advertisements. 
 
Explanations for Menopause 
 
Explanations for menopause on the HT web sites further contributed to the 
overall portrayal of menopause. Table 18 illustrates how an explanation for 
menopause was represented on the various HT web sites. As noted in previous 
chapters, menopause was defined in this study as a natural part of the aging 
process, rather than an event that limits women’s psychological or physical 
capacities (McCrea, 1983). By contrast, my analysis showed that main 
explanations for menopause in the online advertisements were described 
through the prism of biological or physiological causes to account for these 
changes. The two main explanations, or “causes,” for menopause found on the 
HT web sites were the loss of hormones and the end of regular menstruation. 
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Table 18: Explanations for Menopause 
Name of HT Product Explanations for Menopause 
 
ANGELIQ End of regular menstruation, occurs when 
your body stops producing estrogen 
 
CombiPatch Ovaries taper off from producing estrogen 
and progesterone to the extent where 
menstruation stops 
 
ENJUVIA Decrease in the production of certain 
hormones 
 
Estrasorb Once your period has stopped for one year, 
loss of estrogen 
 
femhrt Your body is adjusting to lower levels of the 
hormones estrogen and progesterone 
 
Femring Loss of estradiol 
 
PREMARIN Once you have not had a period for 12 
consecutive months, ovaries stop producing 
estrogen and fertility ends 
 
PREMPRO Ovaries stop production of hormones and no 
menstrual periods for 12 consecutive months 
 
 
In the online advertisements, all of HT web sites (N=8) referred to menopause 
as the result of the loss of hormones. The ENJUVIA and PREMPRO web sites 
stated the decrease in production of hormones in general, while the other web 
sites for HT mentioned the loss of a specific hormone (i.e. estrogen, 
progesterone, and estradiol). Nevertheless, all of the HT web sites in the sample 
used the loss of hormones to explain menopause.  
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  Specifically, the femhrt web sites stated that the “body is adjusting to 
lower levels of the hormones estrogen and progesterone” (femhrt web site: 
http://www.wcrx.com/products/femhrt. Retrieved: July 25, 2009). The femhrt web 
site goes on to state “HT is a way of providing your body with the estrogen that 
you no longer produce naturally after menopause” (femhrt web site: 
http://www.wcrx.com/products/femhrt. Retrieved: July 25, 2009). Here, an 
emphasis was placed on the “loss” of estrogen.  
A focus on the loss of hormones was also evident on the CombiPatch  
web site which further explained that HT products work by “balancing the 
hormone levels in your body” (CombiPatch web site: http://www.combipatch.com. 
Retrieved: July 13, 2009). Here again, an emphasis on “balancing” hormone 
levels to make up for some loss of hormone production was clear. In addition, the 
ANGELIQ web site referred to menopause as a “balancing act” since a woman’s 
“reproductive cycle is based on a delicate balance of 2 hormones: estrogen and 
progesterone” (ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 
13, 2009). Further, the ANGELIQ web site stated “HT with ANGELIQ tablets can 
help bring back the balance” (ANGELIQ web site: http://www.angeliq-us.com. 
Retrieved: July 13, 2009). Once more, the importance of balancing hormones 
was emphasized in order to “restore” or “get back” to an adequate level. Given 
this, three of the HT web sites (ANGELIQ, CombiPatch, and femhrt) suggested 
that the loss of hormones should be supplemented with HT products to help 
restore this “balance.” From the above examples found on the HT web sites, it 
was assumed the lower estrogen levels were considered to be negligible. Such 
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explanations for menopause direct attention to the simple variable of estrogen 
(Derry, 2002). Another example was particularly evident on the PREMARIN web 
site which stated menopause begins when “estrogen production from your 
ovaries starts to decline” (PREMARIN web site: http://www.premarin.com. 
Retrieved: July 17, 2009). With such words as adjusting, balance, and decline 
found on the HT web sites, I found that “deficiency” and “loss” were common 
themes on the web sites. The implication was that women need to “balance” or 
“make up” for the loss of estrogen production. Importantly, these words set the 
stage for the idea of using prescription HT products to restore this balance.  
At the same time, five of the HT web sites cited the end of regular 
menstruation (ANGELIQ, CombiPatch, Estrasorb, PREMARIN, and PREMPRO). 
Here, a clinical definition (i.e. end of regular menstruation) was adopted to 
explain menopause. Even though changes in the menstrual cycle are a common 
condition of the menopausal transition, women may interpret these changes as 
“signs of disease and experience unnecessary fear” (Mansfield and Voda, 1997, 
p. 62). Thus, the explanations for menopause on the HT web sites were defined 
exclusively as the loss of estrogen production and the end of regular 
menstruation firmly grounded in a biomedical discourse of menopause.  
This analysis was instrumental for beginning to illustrate the ways in which 
biomedical rhetoric was being used to explain menopause on the HT web sites. 
By emphasizing menstrual cycle changes and declining estrogen production, the 
HT web sites drew on biomedical definitions of menopause. As such, menopause 
was portrayed on the pharmaceutical web sites for HT as some type of physical 
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problem related to biological functioning. In light of this, women were informed by 
the online advertisements that they could learn to adjust to these changes and 
restore the balance of hormone levels by using HT.   
As noted in earlier chapters, print advertisements found in popular magazines 
and medical journals have tended to also heavily draw on biomedical 
explanations of menopause as a hormone deficiency disease that can be easily 
“fixed” with drugs (Cimons, 2008; Richter, 2002; Whittaker, 1998). Similarly, my 
analysis also indicated that online advertisements continued to utilize biomedical 
rhetoric to emphasize a loss of hormones and implied that this transition was a 
state of biological decline. Indeed, all of the web sites in the sample emphasized 
the loss of hormones as a “reason” or explanation for menopause. While an 
emphasis on change was clear, only one web site (PREMARIN) actually used 
the word “decline.” Other web sites, such as ANGELIQ, CombiPatch, and femhrt, 
employed the terms “adjustment” and “balance.” When taken together, the 
language used on the web sites, helped to set the stage for using the HT 
products in order to restore or balance hormone levels. As a result, according to 
the web sites for HT, menopause could be viewed as a biomedical phenomenon 
and treated accordingly with HT. 
 
Variety of Menopausal Symptoms  
 
In addition to the definitions of menopause that accompanied the online 
advertisements, the HT web sites also prompted potential consumers to identify 
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with specific emotional or physical conditions. Table 19 indicates the type of 
menopausal symptoms that were found across the various HT web sites. 
Analysis of the data indicated that often these conditions were portrayed as 
problematic. In this way, by suggesting that these conditions were “symptoms” 
best addressed through medical avenues, potential consumers were prompted to 
identify with a particular HT product to alleviate the so-called symptoms. Hence, 
the variety of symptoms that were identified and the language used to describe 
these symptoms contributed to the representation of menopause in the online 
advertisements. As a consequence, the portrayal of symptoms and the language 
used to present these symptoms helped to constitute for female audiences what 
it means to be “menopausal.”  
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Table 19: Symptoms of Menopause on the HT Web Sites 
Name of HT Product Symptoms Listed on Web Site 
 
ANGELIQ Hot flashes, night sweats, vaginal dryness 
 
CombiPatch Hot flashes, night sweats, vaginal dryness, 
sleep disturbances, tiredness, 
postmenopausal osteoporosis, mood 
changes 
 
ENJUVIA Vasomotor symptoms, vaginal atrophy, hot 
flashes, night sweats, vaginal dryness, pain 
with sex, irregular periods, weight gain, 
problems sleeping, dry skin, mood swings, 
irritability 
 
Estrasorb Hot flashes, night sweats 
 
femhrt Hot flashes, night sweats, insomnia, vaginal 
changes, postmenopausal osteoporosis 
 
Femring Hot flashes, night sweats, vaginal dryness 
 
PREMARIN Hot flashes, night sweats, vaginal 
symptoms, postmenopausal symptoms such 
as increased risk of cardiovascular disease, 
weight gain, and bone loss 
 
PREMPRO Hot flashes, night sweats, vaginal symptoms 
 
 
Analysis of the data indicates that two “symptoms” of menopause in 
particular were common across all of the HT web sites (N=8). In the online 
advertisements, hot flashes and night sweats were mentioned as menopausal 
symptoms on all of the HT web sites. A further analysis of the online 
advertisements indicated that seven of the HT web sites (n=7) listed the same 
three symptoms (hot flashes, night sweats, and vaginal changes/dryness). 
Therefore, the symptoms that were identified largely as “common” symptoms of 
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menopause across the web sites included hot flashes, night sweats, and vaginal 
changes/dryness.  
Interestingly, the ENJUVIA web site was unique among the study sample 
for its use of biomedical rhetoric for describing symptoms. In this case, the terms 
“vasomotor symptoms” and “vaginal atrophy” were used on the ENJUVIA web 
site (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 2009). By 
using biomedical nomenclature, this particular advertisement in my data set 
placed these “symptoms” within a medical context thereby suggesting to 
consumers that menopause was “disease-like.”  
While the “common” three symptoms of hot flashes, night sweats, and 
vaginal changes were presented across all of the HT web sites, some important 
differences existed between the web sites. That is to say, instances of “other” 
menopausal symptoms were also observed. To provide some more context for 
this discussion, Coney (1994) says despite the claims of some health care 
providers that produce lengthy menu of menopausal symptoms, there are “only 
three signs [that] can be directly attributed to the physiological event of 
menopause” (p. 102). These are menstrual changes, vasomotor effects (hot 
flashes and night sweats), and loss of moisture and elasticity in the vagina 
(Coney, 1994).  Despite this, menopause continues to be defined by a long list of 
symptoms (Rostosky and Travis, 1996). Indeed, the HT web sites did not create 
the lists of symptoms rather they incorporated lists of symptoms already created 
by biomedical research (Mansfield and Voda, 1997). Therefore, further insight 
134 
 
 
into the portrayal of menopause was gained after examining these “other” 
menopausal symptoms presented on the HT web sites.  
One of the most telling differences across the various the HT web sites 
were the additional symptoms listed on the CombiPatch and ENJUVIA web sites. 
In particular, mood changes, mood swings, and irritability were also observed on 
the CombiPatch and ENJUVIA web sites. Moreover, the ENJUVIA web site 
further listed irregular periods, weight gain, and dry skin as “other” symptoms of 
menopause (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 
2009). These changes are not necessarily related to menopause and just 
because a woman may experience mood changes or irritability during the 
menopausal transition “does not mean that menopause caused the condition” 
(Mansfield and Voda, 1997, p. 60, italics in the original). Yet, by having these 
listed as so-called symptoms of menopause on the CombiPatch and ENJUVIA 
web sites suggested a possible link or association.  
Additionally, the CombiPatch and femhrt web sites listed “postmenopausal 
osteoporosis” as a symptom of menopause (CombiPatch web site: 
http://www.combipatch.com. Retrieved: July 13, 2009). The PERMARIN web site 
also identified an increased risk of cardiovascular disease, weight gain, and bone 
loss as “postmenopausal” symptoms (PREMARIN web site: 
http://www.premarin.com. Retrieved: July 17, 2009).  Therefore, these three web 
sites in the sample (CombiPatch, femhrt, and PREMARIN) illustrated a technique 
described in previous research of linking osteoporosis with menopause in such a 
way that “osteoporosis practically becomes identified as a symptom of 
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menopause” (Worcester and Whatley, 1992). Again, such a technique has been 
seen as a way to expand the list of symptoms to include conditions that have not 
been traditionally associated with menopause. The U.S. Department of Health 
and Human Services has noted that estrogen should not be used as a first-line of 
treatment for osteoporosis (U.S. Department of Health and Human Services web 
site: http://www.womenshealth.gov/faq/menopause-treatment.cfm. Retrieved: 
January 24, 2010). 
In all of this an especially crucial area was illuminated. One of the key 
ways in which these “other” symptoms have been instrumental is in their ability to 
encompass emotional or physical conditions that may not be related to 
menopause. For example, weight gain, dry skin, and mood changes may be 
explained by a host of other reasons than menopause and could be easily 
viewed as unrelated. Yet, having such symptoms listed on the web sites implied 
to consumers that they were important and implied they could be treated with HT. 
The pharmaceutical web sites were incorporating lists of so-called menopausal 
symptoms that already existed in the biomedical literature; however, the online 
advertisements for HT were effectively able to imply a connection by listing them 
as possible symptoms and linking them with menopause. At the present, 
menopausal hormone therapy is recommended only as a short-term treatment of 
moderate to severe symptoms such as hot flashes or night sweats (U.S. 
Department of Health and Human Services web site: 
http://www.womenshealth.gov/menopause/treatment. Retrieved: January 24, 
2010). Through the alignment of such emotional and physical issues and 
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presenting them to consumers as so-called symptoms of menopause, drug 
manufacturers were able to further promote the widespread use of HT for an 
extended range of menopausal “symptoms.”    
In brief, groups of “common” and “other” symptoms emerged. A 
comparison of “common” and “other symptoms” brought into focus a technique to 
incorporate an expansive list of so-called menopausal “symptoms” into the HT 
web sites. Hence, my analysis demonstrated an array of menopausal 
“symptoms” was presented to consumers on the web sites as treatable with HT. 
By suggesting to potential consumers that their physical and emotional issues 
might fit medical models of menopause, the online advertisements capitalized on 
already existing lists of symptoms found in the biomedical literature and linked 
these symptoms with menopause to include emotional changes and the 
prevention of osteoporosis. Consequently, such sweeping claims of menopausal-
related symptoms could be used to further propose the use of HT products for 
emotional and physical conditions beyond the “commonly” regarded symptoms of 
hot flashes, night sweats, and vaginal changes. Next, I take a closer look at the 
language used to describe the symptoms of menopause. 
 
Portrayal of Symptoms 
 
This section of the chapter analyzes the language used to describe the 
various menopausal symptoms listed on the HT web sites. Table 20 illustrates 
the language used to describe symptoms of menopause presented across the 
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HT web sites in the study sample. Here, I was most interested in the way 
language was used by the pharmaceutical companies to describe symptoms in 
either a positive or negative light.  
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Table 20: Portrayal of Symptoms 
Name of HT Product Portrayal of Symptoms Key Phrases/Words 
 
ANGELIQ Disruptive and inconvenient 
hot flashes, night sweat can 
lead to poor sleep quality 
and a reduced sense of self   
 
Disruptive 
Inconvenience 
Poor sleep quality 
Reduce sense of self 
CombiPatch Hot flashes may interrupt 
your sleep, causing 
tiredness and possibly 
mood changes 
 
Interrupt sleep 
Tired 
Mood Changes 
 
ENJUVIA Hot flashes may be easily 
tolerated or range from 
embarrassing to debilitating 
 
Easily Tolerated 
Embarrassing  
Debilitating 
Estrasorb Moderate to severe hot 
flashes, can be severe 
enough to interrupt your 
sleep and make you feel 
miserable 
 
Severe 
Interrupt sleep 
Miserable 
femhrt Night sweats are often 
severe enough to wake 
you, many women going 
through menopause 
experience insomnia  
 
Severe 
Insomnia  
Femring Hot flashes intruding on 
your day, night sweats 
interrupting your sleep, 
unpredictable hot flashes 
throughout the day 
 
Intruding on day 
Interrupting sleep 
Unpredictable hot 
flashes  
PREMARIN Unpredictable hot flashes, 
may also feel irritated, 
annoyed, or frustrated 
during a hot flash 
 
Unpredictable hot 
flashes 
Irritated 
Annoyed 
Frustrated 
 
PREMPRO Unpredictable hot flashes, 
may also feel irritated, 
annoyed, or frustrated 
during a hot flash, 
Unpredictable hot 
flashes 
Irritated 
Annoyed 
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uncomfortable or painful 
intimacy, hampered sex 
lives 
 
Frustrated 
Uncomfortable 
Painful intimacy 
Hampered sexual 
relations 
 
 
As Table 20 indicates, menopausal symptoms were represented by a 
number of recurring key phrases or words. In the online advertisements, 
menopausal symptoms were described as unpredictable, inconvenient, 
embarrassing, and portrayed as an interruption or intrusion. For example, the 
ANGELIQ web site described hot flashes as “disruptive and inconvenient” 
(ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009). 
Furthermore, unpredictable hot flashes may also leave one feeling “irritated, 
annoyed, or frustrated” (PREMARIN web site: http://www.premarin.com. 
Retrieved: July 17, 2009). 
Another example was found on the ENJUVIA web site which stated hot 
flashes may range from “embarrassing to debilitating” (ENJUVIA web site: 
http://www.enjuvia.com. Retrieved: July 14, 2009). In addition, night sweats could 
“lead to poor sleep quality and a reduced sense of self” (ANGELIQ web site: 
http://www.angeliq-us.com. Retrieved: July 13, 2009). On one hand, the 
ANGELIQ web site claimed night sweats and poor sleep could lead to a reduced 
sense of self, and yet, one might argue, how do we know that an individual has 
no sense of self? Unfortunately, neither an explanation nor description was 
offered to provide further context. Moreover, the negative impact that 
menopausal symptoms could have on sexual relations was implied on the 
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PREMPRO web site which stated vaginal changes can result in uncomfortable or 
painful intimacy leading to “hampered sex lives” (PREMARIN web site: 
http://www.premarin.com. Retrieved: July 17, 2009). 
One of the most sweeping aspects of the HT web sites was the overall 
portrayal of symptoms in a negative light. This was accomplished by presenting 
symptoms in terms of physical symptoms, such as night sweats and vaginal 
dryness. The physical symptoms were then associated with having a negative 
impact on social and personal relations. Notably, the PREMPRO associated 
vaginal changes with hampered sex lives. Similarly, the ENJUVIA web site 
proclaimed that poor sleep quality resulting from night sweats could lead to a 
“reduced sense of self.”  Furthermore, instances of “disruptive hot flashes” found 
on the ANGELIQ, PREMARIN, and PREMPRO web sites portrayed menopausal 
symptoms as unpredictable, a disruption to daily life, and even something that 
was out-of-control.  
By portraying such symptoms as “disruptive,” symptoms were presented 
as problematic to consumers thereby positioning them within a disease-like 
model requiring medical treatment. Certainly, the language used to portray the 
symptoms in these instances helped to set the stage for using the HT products. If 
left untreated, extremes were presented to consumers, namely that symptoms 
could become debilitating, lead to a reduced sense of sense, and result in 
hampered sex lives. It is also noteworthy that the use of positive language, such 
as describing menopause as a “beginning” or “freedom,” was not observed on 
any of the web sites for HT.  
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Under further scrutiny, I observed a technique in which the web sites 
attempted to convey that other women were also “suffering” similar menopausal 
symptoms. For example, the Estrasorb web site asked consumers the question 
“Hot Flashes? You’re In Good Company!” (Estrasorb web site: 
http://www.estrasorb.com. Retrieved: July 15, 2009).  Such advertisements 
favorably shape consumers’ impressions about a particular product because 
“consumers are led to believe that the use of such a product is done en masse” 
(Arney and Rafalovich, 2007, p. 54).  The use of the specific phrase “You are not 
alone” can help create what Arney and Rafalovich (2007) refer to as a 
“Community of Sufferers” in which potential consumers are encouraged to join 
the bandwagon to use a particular product (p. 54).  
The notion that menopausal symptoms were common to a large number 
of women was also promoted through the use of numbers and statistics on the 
HT web sites. For instance, the CombiPatch web site asserted that hot flashes 
were common during menopause and “eighty-five percent of women experience 
this undesirable symptom” (CombiPatch web site: http://www.combipatch.com. 
Retrieved: July 13, 2009).  Unfortunately, no reference or citation was provided to 
put this claim into context for the web site user. This finding is in agreement with 
previous research also reporting that claims were not supported in magazine 
advertisements for HT (Carlson, Li, and Holm, 1997).  
A similar example was found on the ENJUVIA web site which stated 
“nearly three out of four women have hot flashes during menopause” (ENJUVIA 
web site: http://www.enjuvia.com. Retrieved: July 14, 2009). Here again, a 
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reference to this claim was not provided; however, we were assured by this 
statement that large numbers of women experience hot flashes. Therefore, 
assuming that web users may identify with the symptoms described on the HT 
web sites, a potential consumer may feel that she belongs to the group of 
“sufferers” because the symptoms in the advertisements were portrayed as 
common to a large group of women (Arney and Rafalovich, 2007).   
In sum, lists of symptoms taken from the biomedical literature were 
capitalized and incorporated on the HT web sites. Indeed, the term “symptoms” is 
commonly associated with problems and illness (Rostosky and Travis, 1996). 
The web sites linked menopause with a long list of “symptoms” and treatments 
for these symptoms, as if it were a disease. Perhaps most striking about the 
portrayal of symptoms on the pharmaceutical web sites for HT was the way in 
which a connection was implied between the physical symptoms and the impact 
on social and personal relations. Symptoms such as hot flashes and vaginal 
changes were presented to consumers as “problematic” using such language as 
debilitating, reduced sense of self, and hampered sex lives. In short, symptoms 
presented across the HT web sites were grounded in a biomedical perspective 
which further articulated a disease-like model of menopause necessitating 
medical intervention. 
 
Prescription of Action 
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Conrad and Leiter (2008) expressed concerns over the ability of DTCA to 
encourage consumers to self-diagnosis and influence requests for prescription 
medications. Statements on the HT web sites that encouraged women to seek 
medical treatment and advice were also evident. To investigate this phenomenon 
further, I analyzed the language used on the HT web sites that encouraged 
consumers to perform some kind of behavior or activity. To illustrate this 
argument, Table 21 describes the various statements found across the HT web 
sites.  
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Table 21: Prescription of Action 
Name of HT Product Prescription of Action  
 
ANGELIQ Ask to your health care professional if 
ANGELIQ is right for you  
 
CombiPatch Talk to your doctor or pharmacist for 
more information 
 
ENJUVIA Ask your healthcare professional if 
ENJUVIA is right for you 
 
Estrasorb Talk to your healthcare provider about 
Estrasorb for the relief of hot flashes 
and night sweats 
 
femhrt Talk to your doctor about what 
treatment option is right for you 
 
Femring Talk to your doctor about what 
treatment option is right for you 
PREMARIN Discuss the level of relief you can 
expect with PREMARIN with your 
health care professional 
 
PREMPRO Discuss the level of relief you can 
expect with PREMPRO with your 
health care professional 
 
As seen in Table 21, all of the HT web sites in the sample (N=8) exhibited 
statements encouraging prospective consumers to inquire about medical 
treatment with a health care professional. In fact, all of the statements started 
with action verbs, such as “talk,” “ask,” and “discuss.” In this way, all of the HT 
web sites clearly suggested that consumers should do something. To further 
understand the action or behavior that was being advocated, I examined the 
actual language presented to consumers on the web sites. 
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Out of the eight web sites, four of the HT web sites used the word “talk” in 
their statements (CombiPatch, Estrasorb, femhrt, and Femring). For example, the 
CombiPatch web site stated “talk to your doctor or pharmacist for more 
information” (CombiPatch web site: http://www.combipatch.com. Retrieved: July 
13, 2009). Another example was found on the Estrasorb site which stated “talk to 
your healthcare provider about Estrasorb for the relief of hot flashes and night 
sweats” (Estrasorb web site: http://www.estrasorb.com. Retrieved: July 15, 
2009). In addition, both the femhrt and Femring web sites encouraged 
consumers to “talk to your doctor about what treatment option is right for you” 
(femhrt web site: http://www.wcrx.com/products/femhrt. Retrieved: July 25, 
2009). 
Two of the HT web sites (ANGELIQ and ENJUVIA) used the word “ask” in 
their statements. For example, visitors to the ANGELIQ web site were prompted 
to “ask to your health care professional if ANGELIQ is right for you” (ANGELIQ 
web site: http://www.angeliq-us.com. Retrieved: July 13, 2009). Similarly, the 
ENJUVIA web site promoted “ask your healthcare professional if ENJUVIA is 
right for you” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 
2009). By encouraging consumers to “ask” a health care provider about HT, the 
statements in question on ANGELIQ and ENJUVIA web sites were prescriptive. 
In this sense, these two web sites recommended a particular behavior or action 
for consumers (i.e. ask about HT) while also reinforcing that notion that a health 
care provider could determine “what is right for you.” Not only was a consumer 
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behavior being advocated, but the expert role of medical authority was 
reinforced.    
 In comparison, the word “discuss” was observed on two other HT web 
sites (PREMARIN and PREMPRO). The PREMARIN web site urged consumers 
to “discuss the level of relief you can expect with PREMARIN with your health 
care professional” (PREMARIN web site: http://www.premarin.com. Retrieved: 
July 17, 2009).  Likewise, the PREMPRO web site suggested consumers should 
“discuss the level of relief you can expect with PREMPRO with your health care 
professional” (PREMPRO web site: http://www.prempro.com. Retrieved: July 17, 
2009).  Here, the pairing of the words “discuss” and “relief” in both of the 
statements associated discussing HT options with a health care provider and 
some form of relief that could be expected from the HT products. Therefore, 
when you “discuss” HT options, you will learn about the “relief” you can expect.  
Although all of the web sites encouraged women to follow-up with health 
care providers, some differences across the web sites were detected. 
Interestingly, five of the HT web sites (n=5) encouraged consumers to inquire 
about a specific HT product. These five web sites were ANGELIQ, ENJUVIA, 
Estrasorb, PREMARIN, and PREMPRO. To illustrate this point, the ANGELIQ 
web site stated “ask to your health care professional if ANGELIQ is right for you” 
(ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009). 
On the other hand, three of the HT web sites (CombiPatch, femhrt, and 
Femring) encouraged consumers to inquire about general treatment options but 
they did not explicitly mention the name of an HT product. For instance, the 
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Estrasorb web site encouraged consumers to “talk to your doctor about what 
treatment option is right for you” (Estrasorb web site: http://www.estrasorb.com. 
Retrieved: July 15, 2009). Thus, more of the HT web sites in the study sample 
encouraged consumers to inquire about a particular HT product than asking 
about general treatment options. Nevertheless, all of the HT web sites 
encouraged women to follow-up with a health care professional regarding HT 
treatment options. As witnessed from the language used on the HT web sites, 
consumers were encouraged to contact a health care professional and inquire 
about medical treatment options. Overall, statements found across all of the 
pharmaceutical web sites prescribed a behavior or course of action for 
consumers.  
 
Self-Diagnostic Symptom Tools  
 
Up to this point, I have considered the textual representation of menopause 
on the HT web sites by examining the descriptions for menopause and how the 
various “symptoms” were portrayed through the use of language. In addition, half 
of the HT web sites in the sample (n=4) provided online self-diagnosing symptom 
tools for web site consumers. Table 22 indicates which of the HT web sites had 
symptom tools.  
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Table 22: HT Web Sites with Symptom Tools 
Name of HT Product Symptom Tools 
 
 
ANGELIQ 
 
Yes 
 
CombiPatch No 
 
ENJUVIA Yes 
 
Estrasorb No 
 
femhrt No 
 
Femring No 
 
PREMARIN Yes 
 
PREMPRO Yes 
 
 
Concerning self-diagnosis, Conrad and Potter (2000) contend that adults who 
self-diagnose disorders might have become familiar with the condition through 
the media. Indeed, this concern illustrates the public’s reliance on the media for 
information and poses interesting questions about media portrayals of 
menopause and the role of media in shaping the public’s perception of health 
and illness. Since media outlets, including online advertisements, are an effective 
means of disseminating information about drugs and medical “conditions,” an 
examination of how menopause was portrayed through the online self-diagnosing 
symptom tools was warranted.  
Specifically, the ANGELIQ, ENJUVIA, PREMARIN, and PREMPRO web sites 
(n=4) provided symptom tools for web site users to assess the type and degree 
of severity of their menopausal symptoms. The self-diagnosing symptom tools 
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were an example of an interactive component found on the HT web sites. With 
these online symptom tools, consumers were presented with a series of 
questions and response categories to select from. The web site user then 
proceeded through the series of questions by clicking (or advancing) to the next 
question in the series until the web site visitor reached the end of the questions. 
At this point, a customized “report” of menopausal symptoms was provided to the 
web site user. I posit that these interactive self-diagnosing tools were yet another 
vehicle through which the pharmaceutical companies could construct and convey 
messages about menopause, symptoms, and their HT products. As such, they 
are an interesting subject for sociological analysis. Next, I examined the self-
diagnosing symptom tools found on the HT web sites.  
Out of curiosity, I performed an experiment with the PREMARIN symptom 
tool. In this experiment, I completed the PREMARIN symptom tool three different 
times. For each of my attempts, I indicated a different degree of “severity,” for my 
so-called menopausal symptoms. At first, I selected that my symptoms “rarely” 
affected my life. Then, I indicated that my (hypothetical) symptoms “moderately” 
affected my life. Finally, I checked the response options expressing that my 
symptoms were “severely” affecting my life.  With all three attempts at answering 
the PREMARIN symptom tool questions, the recommendation on my customized 
symptom “reports” was the same. In essence, all three reports recommended 
printing and sharing the “results” about my symptoms with a health care provider. 
Additionally, all three reports linked back to the PREMARIN web site to learn 
more about treatment options. From this experiment, I can reasonably conclude 
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that this online symptom tool in particular was not sophisticated enough to 
discern my responses, especially given the fact that I clearly indicated various 
degrees of “severity.” Thus, the tool primarily functioned to encourage contact 
with a health care provider while also referring me back to the HT web site for 
more information about HT treatment options. 
The symptom tool located on the ANGELIQ web site was labeled “Assess 
Your Symptoms.” The front page of the symptom tool declared that the “first step 
to help you manage your menopausal symptoms is to be aware of what your 
body is telling you” (ANGELIQ web site: http://www.angeliq-us.com. Retrieved: 
January 18, 2010). As seen in this statement, web site users were informed from 
the beginning that this tool could help them gain new knowledge about their 
bodies so that they can become more aware of what their bodies were telling 
them. Furthermore, a disclaimer in smaller font was also provided stating that the 
symptom tool could not offer a diagnosis; therefore, one should “schedule an 
appointment with a health care provider” (ANGELIQ web site: http://www.angeliq-
us.com. Retrieved: January 29, 2010). Not only did the legal disclaimer function 
to protect the pharmaceutical companies so they would not appear to be giving a 
diagnosis, but it also deferred to medical authority for a diagnosis thereby further 
encouraging potential consumers to contact a health care provider.  
In general, symptom tools are designed as a quick and easy way for 
consumers to assess their experiences and determine when to seek medical 
attention. Once an ANGELIQ web site user clicked on the symptom tool they 
were greeted by the message “Menopause. It’s a natural part of life, but these 
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symptoms don’t have to be” (ANGELIQ web site: http://www.angeliq-us.com. 
Retrieved: January 18, 2010). From this statement, consumers were told that 
menopause was natural. However, the statement further implied that symptoms 
were “unnatural.” Here, the tension between “natural” (in this case, menopause) 
and “unnatural” (menopausal symptoms) was conveyed and created a context for 
consumers to learn how to “treat” such undesirable symptoms with HT products. 
In this sense, it encouraged women to regard any changes as unacceptable 
symptoms.  
Next, the web site user would proceed through a series of eleven questions 
designed to provide “new insight” into how the consumer feels (ANGELIQ web 
site: http://www.angeliq-us.com. Retrieved: January 18, 2010). Presumably, 
consumers would learn more about their symptoms, which were framed as 
unnatural and unhealthy from the very beginning of their interaction with the 
online tool. Table 23 indicates the types of questions and response options that 
were presented to web site users on the ANGELIQ “Assess Your Symptoms” 
Tool. 
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Table 23: Questions from the ANGELIQ “Assess Your Symptoms” Tool 
Symptoms Questions Response Categories 
 
How old are you? 
 
Consumer types in response 
How long has it been since your last 
period? 
Two response options:  
1. Less than one year 
2. More than one year 
 
Are you experiencing menopausal 
symptoms, such as hot flashes, night 
sweats, and vaginal dryness?  
 
Three response options:  
1. Yes 
2. No 
3. Not sure 
 
Have you had your ovaries surgically 
removed? 
 
Two response options:  
1. Yes 
2. No  
 
How often do you experience hot 
flashes?  
 
Three response options:  
1. Rarely (very little or not at all) 
2. Frequently (often enough that I 
find it to be irritating and 
embarrassing) 
3. Severely (so often that it 
severely interferes with my daily 
activities) 
 
On average, how many hot flashes do 
you experience each day? 
 
Consumer types in response  
How often do you experience night 
sweats? 
 
Three response options:  
1. Rarely (very little or not at all) 
2. Frequently (often enough that I 
find it to be annoying and 
uncomfortable) 
3. Severely (so often that it 
severely interferes with my sleep 
patterns) 
 
On average, how many times do night 
sweats disrupt your sleep per night? 
 
Consumer types in response 
 
Are vaginal symptoms causing you 
discomfort?  
• Dryness 
On a scale of 1 to 5 ( 1 being not at all, 
5 being most severe)  
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• Itching 
• Burning 
• Discomfort during sex 
 
Are you considering using or currently 
using a combination (estrogen and 
progestin) therapy? 
Two response options:  
1. Yes 
2. No  
 
(If yes, what are you current using? 
Consumer types in response) 
 
Would you consider using a once-a-
day combination pill to help manage 
your symptoms? 
Two response options:  
1. Yes 
2. No  
 
 
The ANGELIQ “Assess Your Symptoms” Tool entailed eleven questions 
about hot flashes, night sweats, and vaginal dryness. In this online symptom tool, 
symptoms were also presented in terms of physical symptoms. Specifically, two 
questions asked about hot flashes. As seen in Table 23, a web site visitor was 
asked “how often do you experience hot flashes?” The physical symptoms were 
then associated with having a negative affect on social and personal situations. 
For instance, consumers were asked to indicate how often they experienced hot 
flashes and they could select a response from three options (rarely, frequently, 
and severely). Interestingly, the response option “severely” was defined as “so 
often that it severely interferes with my daily activities” (ANGELIQ web site: 
http://www.angeliq-us.com. Retrieved: January 29, 2010). Unfortunately, such 
“daily activities” referred to in the response option were not further defined for 
consumers. Moreover, since the mention of “daily activities” was undefined, there 
was no way for women working outside of the home to indicate if they 
experienced different “daily” concerns. Another two questions centered on 
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physical symptoms, including night sweats and one more question about vaginal 
symptoms. The remaining six questions that comprised the ANGELIQ “Assess 
Your Symptoms” Tool asked about age, how long it had been since 
menstruation, if the woman’s ovaries had been surgically removed, and if the 
consumer was currently using any combination of hormone therapies.  
At the completion of the ANGELIQ “Assess Your Symptoms” Tool, the web 
site user would be presented with a customized report entitled “My Symptom 
Report” which could be printed out and shared with their health care provider. 
Consumers were told to “use what you learn to talk to your healthcare 
professional and explore what treatment options may be right for you” (ANGELIQ 
web site: http://www.angeliq-us.com. Retrieved: January 27, 2010). Based on 
this statement, I speculate one function of the symptom tools was to facilitate 
communication between the potential consumer and a health care provider.  In 
brief, the pattern of presenting symptoms to consumers as “unnatural” was clear 
in this online tool. Through the response options, the online tool then implied that 
these physical symptoms could have a negative impact on social and personal 
dimensions. As a result, consumers were encouraged to print out and share their 
customized “symptom report” with their health care provider to learn more about 
HT options.     
The pattern of presenting symptoms as “problematic” continued in the next 
online symptom tool. Secondly, the ENJUVIA web site provided the “Menopause 
Impact Tool” for web site users. Just as the name suggests, this tool could be 
used by consumers to assess the “impact” menopausal symptoms were having 
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on their lives. Clearly, the name of the online tool implied that symptoms would 
have an impact, it was just a matter of using their tool in order to assess how 
much of an impact. Obviously, there was a built-in assumption about the nature 
of menopausal symptoms and in this case symptoms were conceptualized and 
articulated as capable of having an “impact.” Therefore, the question becomes, 
how can women lessen this impact? Table 24 shows the types of questions and 
response options from the ENJUVIA “The Menopause Impact Tool.” 
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Table 24: Questions from the ENJUVIA “The Menopause Impact Tool” 
 
Symptoms Questions Response Categories 
 
In the last month, to what extent have 
you been bothered by the following 
symptoms?  
• Hot flashes 
• Night sweats or chills 
• Sleep disturbance 
• Joint pain or stiffness 
• Fatigue  
 
Three response options:  
1. Not at all or rarely 
2. A little or moderately 
3. Regularly or frequently 
To what extent have these symptoms 
negatively impacted the following? 
• Feelings about yourself 
• Relationships 
• Work 
 
Three response options:  
1. Not at all or rarely 
2. A little or moderately 
3. Regularly or frequently 
 
In the last month, to what extent have 
you been bothered by the following 
symptoms?  
• Genital dryness, pain, and/or 
burning 
• Pain during sexual activity 
• Decreased sexual desire 
• Decreased sexual frequency 
 
Three response options:  
1. Not at all or rarely 
2. A little or moderately 
3. Regularly or frequently 
 
To what extent have these symptoms 
negatively impacted the following? 
• Feelings about yourself 
• Relationships 
• Work 
 
Three response options:  
1. Not at all or rarely 
2. A little or moderately 
3. Regularly or frequently 
 
In the last month, to what extent have 
you been bothered by the following 
symptoms?  
• Anxiety 
• Irritability 
• Sadness 
• Difficulty concentrating 
 
Three response options:  
1. Not at all or rarely 
2. A little or moderately 
3. Regularly or frequently 
 
To what extent have these symptoms 
negatively impacted the following? 
Three response options:  
1. Not at all or rarely 
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• Feelings about yourself 
• Relationships 
• Work 
 
2. A little or moderately 
3. Regularly or frequently 
 
 
The ENJUVIA web site stated the symptom tool “provides information that 
your health care professional can use to determine which treatment might be 
right for you” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: January 18, 
2010). In this statement, the reoccurring theme of the role of health care 
providers in providing a diagnosis and medically managing menopause was 
conveyed. Similar to the ANGELIQ symptom tool, the importance of sharing the 
“results” of the ENJUVIA symptom assessment was emphasized. Once again, 
the importance of reporting symptoms to a health care professional was 
stressed. As Kaufert and Gilbert (1986) noted, one indication that medicalization 
is occurring is whenever women are told that they should depend on a physician 
rather than their own judgment. Here, the ANGELIQ and ENJUVIA web sites 
perpetuated the idea that menopause was a medical event to be medically 
managed. Since only health care professionals “can determine which treatment 
is right,” this statement reinforced the “expert” role of physicians in their ability to 
define and categorize women’s experiences. 
Likewise, consumers navigated through a series of six questions on the 
ENJUVIA web site designed to assess how menopause symptoms impacted 
their lives in four key areas. These areas were hot flashes, night sweats, sexual 
health, and psychological symptoms. To help assess the impact of menopausal 
symptoms, web site users were asked to indicate to what extent they were 
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“bothered” by symptoms, such as hot flashes, night sweats or chills, sleep 
disturbance, joint pain or stiffness, and fatigue (ENJUVIA web site: 
http://www.enjuvia.com. Retrieved: January 29, 2010). The use of negative 
language, such as being “bothered,” consistently conveyed the message that 
symptoms were bothersome and problematic for which HT was a viable 
treatment.  
As seen in Table 24, consumers were asked in five of the questions to 
speculate the extent to which these symptoms had “negatively impacted” various 
aspects of their lives, such feelings about their own selves, relationships, and 
work. The three response options that were provided for these five questions 
included “not at all or rarely,” “a little or moderately,” and “regularly or frequently.”  
Although the pattern of response options for these five questions was consistent, 
it was not very helpful to consumers because definitions for the varying response 
categories were not provided. Meanwhile, the repeated use of the words 
“bothered” and “negatively impacted” in the questions observed on the ENJUVIA 
“The Menopause Impact Tool” played an important role in portraying such 
symptoms as bothersome while suggesting these had an undesirable or negative 
effect on personal, relationships, and work aspects. Here again, symptoms were 
linked to affecting social and personal situations. In doing this, the 
pharmaceutical companies were able to directly propose to consumers a need 
for their HT products to alleviate “bothersome” symptoms. 
In comparison to the other online symptom tools in the sample, the ENJUVIA 
symptom tool was the only one to include psychological symptoms among the list 
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of possible menopausal symptoms. As Table 24 illustrates, the ENJUVIA 
“Menopause Impact Tool” included psychological symptoms such as anxiety, 
irritability, sadness, and difficulty concentrating. As I discussed earlier in this 
chapter, these psychological “symptoms” may be explained by a host of other 
reasons other than menopause. They could also be easily viewed as unrelated. 
Yet, the inclusion of such psychological symptoms in the ENJUVIA online tool 
implied to consumers that they were important and associated with menopause. 
Finally, upon completion of the ENJUVIA symptom tool consumers received a 
“Menopause Impact Analysis” report. Consumers were told they could “print the 
results and share them with your healthcare professional” (ENJUVIA web site: 
http://www.enjuvia.com. Retrieved: January 27, 2010).  
Two more web sites (PREMARIN and PREMPRO) provided online self-
diagnosing symptom tools. Both symptom tools asked the same eleven 
questions and also provided the same response categories to consumers. This 
similarity is not surprising considering the fact that both PREMARIN and 
PREMPRO are products of Wyeth Pharmaceuticals. Although both tools had the 
same content, two differences were noted amongst the PREMARIN and 
PREMPRO online symptom tools. First, the PREMARIN and PREMPRO online 
symptom tools utilized different background colors. For instance, the PREMARIN 
symptom tool was blue. In contrast, the PREMPRO symptom tool was purple. In 
fact, these color choices were consistent with the color schemes found on each 
corresponding HT web site. In addition, a different woman was pictured on each 
of the symptom tools. On the left side of each symptom tool, a different picture of 
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a woman was present. Again, different pictures of women on the PREMARIN and 
PREMPRO online symptom tools helped to visually tie the specific symptom tool 
to a particular HT web site. Essentially, I found that the content of the 
PREMARIN and PREMPRO online symptom tools was the same but some visual 
differences, such as the background color and images of two different women, 
were employed to help tie the symptom tool to the particular HT web site. Given 
this, next I analyzed the questions from the PREMARIN and PREMPRO 
“Menopausal Symptoms Assessor” Tools. 
Upon arriving at the PREMARIN and PREMPRO “Menopausal Symptoms 
Assessor” tools, web site users were told that “tracking and assessing your 
menopausal symptoms are important first steps in managing them” (PREMARIN 
web site: http://www.premarin.com. Retrieved: January 18, 2010). This statement 
reinforced the connection between assessing your symptoms and the ability to 
“manage” them. The terms “tracking,” “assessing,” and “managing” are symbolic 
medical terms that stem from the dominant biomedical view of menopause where 
any changes are regarded as pathological. The PREMARIN and PREMPRO 
symptom tools consisted of eleven questions for the consumer to answer. Table 
25 shows the types of questions and response options from the PREMARIN and 
PREMPRO “Menopausal Symptoms Assessor” Tools. 
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Table 25: Questions from the PREMARIN and PREMPRO “Menopausal 
Symptoms Assessor” Tool 
Symptoms Questions Response Categories 
 
How old are you? 
 
Consumer types in response 
How would you describe your 
menstrual status? 
Four response options:  
1. No change in frequency or flow 
of my menstrual period 
2. There seem to be some 
changes in the flow, frequency, 
or length of my period 
3. I stopped having my menstrual 
periods 
4. I stopped having menstrual 
periods because of surgery 
 
How long has it been since your last 
menstrual period? 
 
Two response options:  
1. Less than a year 
2. More than a year 
 
Please indicate the severity of your hot 
flashes. 
 
Four response options:  
1. None 
2. Mild 
3. Moderate 
4. Severe 
 
Next, please indicate the frequency of 
your hot flashes over the course of one 
day. 
 
Four response options:  
1. None 
2. 1 to 2 
3. 3 to 4 
4. 5 or more 
 
Are hot flashes affecting your life? 
(Please check all appropriate 
responses) 
 
Seven response options:  
1. Hot flashes are not affecting my 
life at all 
2. I am constantly embarrassed 
3. I feel anxious all the time 
4. I am constantly sweating 
5. Sometimes I feel a little 
uncomfortable 
6. It’s disruptive when I’m working 
7. Hot flashes affect my personal 
life 
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Please indicate the severity of your 
night sweats. 
 
Four response options:  
1. None 
2. Mild 
3. Moderate 
4. Severe 
 
I experience night sweats over the 
course of one night: 
 
Four response options:  
1. Not at all 
2. Once  
3. Twice 
4. Three times or more 
 
Indicate all that describe how night 
sweats affect your life.  
(Check all that apply) 
 
Six response options:  
1. No effect 
2. Lack of energy 
3. Constantly tired 
4. Have trouble sleeping through 
the night 
5. Sleep is frequently interrupted 
6. Irritable  
 
Describe any vaginal symptoms you 
might be experiencing: 
• Dryness 
• Itching 
• Irritation 
• Pain with sexual activity  
 
Four response options:  
1. None 
2. Mild 
3. Moderate 
4. Severe 
 
Check all that accurately describe how 
vaginal symptoms affect your life. 
(Check all that apply) 
 
Four response options:  
1. No effect 
2. The symptoms make me 
uncomfortable sometimes 
3. Sexual activity often leads to 
bleeding 
4. Sexual activity is limited due to 
frequent discomfort 
 
 
From the eleven total questions that comprised the PREMARIN and 
PREMPRO “Menopausal Symptoms Assessor” tools, one question asked about 
the consumer’s age, two questions were related to menstrual status, three 
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questions inquired about hot flashes, three more questions asked about night 
sweats, and two final questions asked about vaginal symptoms.  As witnessed 
with the other symptom tools, the web site user was asked to indicate the 
severity of symptoms and how hot flashes, night sweats, and vaginal symptoms 
were “affecting” their life (PREMARIN web site: http://www.premarin.com. 
Retrieved: January 18, 2010). Once again, the prevalence of negative language, 
such as being asked to indicate the “severity of symptoms,” served to 
characterize symptoms as problematic.    
As seen in Table 25, the consumer was presented with seven response 
options to indicate how hot flashes were “affecting” their life. The consumer was 
also instructed to “check all appropriate responses” to the question, meaning that 
they could select several response categories. In fact, the use of the words 
“anxious,” “embarrassed,” “disruptive,” and “uncomfortable” in the majority of the 
response options helped to provide a context in which symptoms were portrayed 
in a negative light.  In other words, the presentation of the choices was not 
balanced. As such, the pharmaceutical companies effectively portrayed the 
symptoms as “problematic” and “bothersome” on these online symptom tools 
through the use of negative language thereby setting the stage for use of their 
HT products. 
In particular, the construction of response categories was interesting because 
they were not mutually exclusive categories. The response options that a 
consumer could select included: “hot flashes are not affecting my life at all,” “I am 
constantly embarrassed,” “I feel anxious all the time,” “sometimes I feel a little 
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uncomfortable,” “it’s disruptive when I’m working,” and “hot flashes affect my 
personal life” (PREMARIN web site: http://www.premarin.com. Retrieved: 
January 29, 2010). Specifically, these categories were not mutually exclusive 
because overlap in the response options was present. For example, a web site 
visitor could indicate both that “hot flashes are not affecting my life at all” and “I 
feel anxious all the time.”  Hence, whenever response options are not mutually 
exclusive, respondents have more than one legitimate way to answer the 
question. Furthermore, the response options helped make a connection between 
hot flashes and their ability to “disrupt” work and “affect” one’s personal life. As a 
result, the eleven questions that overall constitute the PREMARIN and 
PREMPRO symptom tools helped to illustrate how language could be 
instrumental in creating a context for the web site user to assess their 
menopausal symptoms and the degree of severity. 
One unique difference of the PREMARIN and PREMPRO symptom tools was 
an online glossary feature built into the symptom tools. For example, web site 
users could “roll over” words with their computer mouse to learn definitions of 
certain words. For instance, definitions for hot flashes and night sweats could be 
obtained. After completing the questions, consumers were once again presented 
with a report and were encouraged to “print it out and take it with you to your next 
doctor’s appointment” (PREMARIN web site: http://www.premarin.com. 
Retrieved: January 27, 2010). In fact, the PREMARIN and PREMPRO symptom 
tools tell consumers to share “the results with your health care professional to 
help have an effective discussion” (PREMARIN web site: 
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http://www.premarin.com. Retrieved: January 27, 2010). By suggesting that 
sharing the results of the online symptom tool could help achieve an “effective 
discussion” with a health care professional, the implication of this statement was 
that the self-diagnosing tool could lead to enhanced or improved communication 
among consumers and health care providers.   
At this point, I will review the ways in which my analysis suggests the self-
diagnosing symptom tools functioned as another type of presentation form to 
convey messages about menopause in the online advertisements for HT. Their 
use of language was amplified on the web sites for HT where consumers were 
asked to indicate the severity and frequency of their symptoms. First, the use of 
language in the online self-diagnosing symptom tools provided a particular 
context for web site users as they interacted with the tools to assess their 
symptoms and the degree of severity of these symptoms. Specifically, 
symptoms, such as sweats and vaginal dryness, were presented to consumers in 
terms of physical symptoms and then these symptoms were linked negatively to 
having an impact on personal and social relations. The language observed in the 
question wording about menopausal symptoms, as well as certain words used in 
the response categories, conveyed the message that symptoms were unnatural, 
bothersome, and problematic. After all, we were reminded, menopause is a 
“natural part of life, but these symptoms don’t have to be” (ANGELIQ web site: 
http://www.angeliq-us.com. Retrieved: January 18, 2010). The use of such words 
as “anxious,” “embarrassed,” “disruptive,” and “uncomfortable” further helped to 
illustrate this point (PREMARIN web site: http://www.premarin.com. Retrieved: 
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January 29, 2010). Certainly, the portrayal of menopausal symptoms as 
“impacting” and “affecting” daily activities, work, and relationships as stated 
across the four symptoms tools may also give impetus for seeking medical 
attention and set the stage for hormone use.   
Second, the categories of questions found on the self-diagnosing symptom 
tools ranged from vasomotor symptoms (commonly known as hot flashes and 
night sweats), vaginal symptoms, sexual health, and psychological symptoms. As 
I have highlighted, the inclusion of psychological “symptoms,” such as anxiety, 
irritability, sadness, and difficulty concentrating, was one technique that I 
observed on the HT web sites. While the online symptom tools capitalized on 
lists of menopausal symptoms generated in the biomedical literature, this 
technique functioned to further expand the list of possible “menopausal 
symptoms” that could be treated with HT. Indeed, the very fact that the list of 
symptoms incorporated into the online symptom tools were gleaned from 
biomedical research further demonstrated how the pharmaceutical companies 
drew upon the dominant medical discourse (Mansfield and Voda, 1997; Rostosky 
and Travis, 1996). Such negative descriptions of symptoms characterized any 
changes as “problematic” and helped to set the stage for the use of their HT 
products.  
Upon closer examination, I also found a significant dimension of the online 
self-diagnostic symptom tools was their attempt to encourage contact with a 
health care provider. All four of the online self-diagnosing symptom tools 
encouraged consumers to share the “results” of the symptom tools with a health 
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care professional. Therefore, following-up with a health care provider to inquire 
about which HT treatment might be appropriate was consistently emphasized to 
consumers. Moreover, printer-friendly versions of the “symptom reports” were 
also provided as an option for consumers at the completion of the four online 
self-diagnostic symptom tools. Since the symptom “reports” could be printed out 
and shared with a health care provider, the HT web sites further helped to draw 
the connection that communicating with a health care provider was a logical next 
step. Ultimately, these instances where contact with a health care provider was 
encouraged further deferred to medical authority which, in turn, helps the 
pharmaceutical companies in their efforts to promote the use of their HT products 
which are only available by prescription.  
While examining the online symptom tools, concerns about the reliability and 
validity of the symptoms tools also emerged.  According to Creswell (2003), 
reliability is concerned with the accuracy of the actual survey instrument and 
validity is concerned with the instrument’s success at measuring what the 
researcher originally set out to measure (i.e. menopause symptoms).  
Nevertheless, the four HT web sites did not state if the online symptom tools 
were tested for reliability and validity.  
I also assessed the reading level of the four online symptom tools. To 
accomplish this, I utilized an online tool called “TxReadability,” a free application 
developed by the Accessibility Institute at the University of Texas at Austin. Using 
the Flesch-Kincaid Grade level, this tool indicates the grade a person will have to 
reach to be able to understand the text (Accessibility Institute at the University of 
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Texas web site: http://webapps.lib.utexas.edu/TxReadability/app. Retrieved: 
March 9, 2010). The Flesch-Kincaid Grade level is one of the common formulas 
used to assess reading levels (Kars, Baker, and Wilson, 2008). For example, a 
score indicating the grade level of seven means that a seventh grader should be 
able to understand the text. An analysis of the text of the four online self-
diagnosing symptom tools in this study sample (found on the ANGELIQ, 
ENJUVIA, PREMARIN, and PREMPRO web sites) yielded a combined score of 
7.74. This score falls between a 7–8th grade reading level in the United States. 
Considering it is estimated that one in four adults in the United States read at or 
below the 3rd grade reading level, this grade level far surpasses the estimated 
reading level of the average adult in the U.S. (National Adult Literacy Survey, 
1992).  
Individually, the online symptom tools also exceeded the estimated national 
reading level. The readability score of ANGELIQ symptom tool was 7.9 which is 
close to a 8th grade reading level. Next, the ENJUVIA symptom tool received a 
score of 9.78 which is equivalent to a 9-10th grade reading level. Finally, the 
PREMARIN and PREMPRO online symptom tools yielded a score of 6.95 
requiring a 6-7th grade reading level to understand the information. Both 
PREMARIN and PREMPRO online symptom tools received the same score 
because they were the same tool produced by the same pharmaceutical 
manufacturer (Wyeth Pharmaceuticals). Notwithstanding, the reading levels were 
too high on all four of the online symptom tools in the study sample. This analysis 
was fruitful because I identified another technique that may encourage 
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consumers to follow-up with health care providers. In this case, consumers may 
seek assistance in “making sense” of the information which I have shown was 
written at a high reading level on the web sites. In sum, the online self-diagnosing 
symptom tools were presented as a way for consumers to learn “what their 
bodies are telling them,” functioned to expand the range of menopausal 
symptoms to include psychological symptoms, and encouraged contact with a 
health care provider.  
 
Tests for Medicalization 
 
Kaufert and Gilbert (1986) describe several “tests for medicalization” that 
can be applied to the pharmaceutical web sites to help determine if the process 
of medicalization was occurring. One sign is when the decline of estrogen 
production has become a central theme (Kaufert and Gilbert, 1986).  As noted 
above, the loss of hormones was used across all of the pharmaceutical web sites 
in the sample to explain a “reason” for menopause. Thus, menopause was 
defined exclusively as a biological event on the pharmaceutical web sites for HT.  
Another sign of medicalization is if proposed treatment options for 
menopause involve the use of hormone therapies to supplement or balance this 
loss of hormones (Kaufert and Gilbert, 1986). Since menopause was presented 
as disease-like requiring medical management, the online advertisements helped 
to introduce the idea of using HT to restore or balance hormone levels. 
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Moreover, symptoms were portrayed as unnatural, problematic, and bothersome 
further setting the stage for use of HT. 
One more indication that medicalization is occurring is when women are 
told that they should depend on a physician to have their menopausal status 
recognized and defined, rather than relying on their own judgment (Kaufert and 
Gilbert, 1986). This sentiment was also articulated on the pharmaceutical web 
sites. For example, consumers were informed on the ENJUVIA web site that 
health care professionals “can determine which treatment is right.” Further, the 
ANGELIQ web site told women it was “important for you to pay attention to how 
you are feeling and talk to your healthcare professional about it” (ANGELIQ web 
site: http://www.angeliq-us.com. Retrieved: July 13, 2009). Once again, a health 
care provider’s knowledge was privileged. As the above quotes demonstrated, 
the “expert” role of physicians in their ability to define and categorize women’s 
experiences was reinforced.  
In general, the web sites in the study sample conformed to these “tests for 
medicalization.” The web sites explained menopause in biomedical terms 
implying it was a medical event to be medically managed, focused on the loss of 
hormones, introduced HT to restore or balance hormone levels, and reinforced 
medical authority in providing a medical diagnosis. My analysis also revealed 
another medicalizing technique. Since the reading level of the four online 
symptom tools far surpassed the estimated reading level of the average adult in 
the United States, this created a context for which medicalization can occur. 
Since the reading level of information found on the pharmaceutical web sites in 
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the sample was too high, it suggested consumers may need to consult with a 
health care to make sense of the information. In this way, it also reinforced the 
role of physician as an “expert.”  As a result of this finding, I propose this is one 
more sign of medicalization and can be used to further demonstrate how the 
process of medicalization was operating on the pharmaceutical web sites for HT. 
When we take these “signs” together as a whole, we gain a sense of how the 
process of medicalization was occurring on the pharmaceutical web sites for HT.   
However, there were some marked differences across the HT web sites. 
As stated, all of the web sites in the sample drew heavily on the “menopause as 
disease” discourse and emphasized the loss of hormones as a “reason” or 
explanation for menopause. While an emphasis on change was clear on the web 
sites, only one web site (PREMARIN) actually used the word “decline.” Other 
web sites, such as ANGELIQ, CombiPatch, and femhrt, employed the terms 
“adjustment” and “balance.” However, together the language used on the web 
sites helped to set the stage for using the HT products in order to restore 
hormone levels.  
The ENJUVIA web site was unique among the study sample for its use of 
biomedical rhetoric for describing symptoms. I noted that the terms “vasomotor 
symptoms” and “vaginal atrophy” were used on the ENJUVIA web site. This 
biomedical nomenclature suggested a disease-like nature of menopause and 
placed these “symptoms” within a medical context.   
I also noted how symptoms were presented in terms of physical 
symptoms, such as night sweats and vaginal dryness. The physical symptoms 
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were then associated with having a negative impact on social and personal 
relations. This technique was particularly evident on the ENJUVIA web site which 
proclaimed that poor sleep quality resulting from night sweats could lead to a 
“reduced sense of self.”  By characterizing symptoms as “disruptive,” the 
negative language further set the stage for using the HT products. 
In comparison to the other online symptom tools, the ENJUVIA symptom 
tool was the only one to include psychological symptoms among the list of 
possible menopausal symptoms. Specifically, the ENJUVIA “Menopause Impact 
Tool” included psychological symptoms such as anxiety, irritability, sadness, and 
difficulty concentrating. The inclusion of such psychological symptoms in the 
ENJUVIA online tool implied to consumers that they were both important and 
also linked to menopause. 
Moreover, the ENJUVIA web site further listed irregular periods, weight 
gain, and dry skin as “other” symptoms of menopause (ENJUVIA web site: 
http://www.enjuvia.com. Retrieved: July 14, 2009). Additional menopausal 
“symptoms” were listed on the CombiPatch web site, including mood changes, 
mood swings, and irritability. These changes are not necessarily related to 
menopause and by having these listed as so-called symptoms of menopause on 
the CombiPatch and ENJUVIA web sites suggested a possible link or association 
with menopause.  
Moreover, the CombiPatch web site described menopause as when a 
woman’s “reproductive system slowly shuts down” (CombiPatch web site: 
http://www.combipatch.com. Retrieved: July 13, 2009).  The mechanical 
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language in this example was reminiscent of the biomedical model in which the 
body is viewed as a machine breaking down.  On the CombiPatch web site, the 
aging female body was compared to a machine “breaking down,” which in turn, 
illustrated how menopause was being articulated as a declining biological 
function.   
The above examples illustrate the differences among the HT web sites. In 
comparison to other web sites the sample, CombiPatch and ENJUVIA 
represented menopause as a highly medicalized process with their use of 
biomedical rhetoric (i.e. “atrophy” and “ovaries shutting down”). Furthermore, the 
CombiPatch and ENJUVIA web sites included psychological symptoms and 
linked them with menopause. For these reasons, I concluded that the degree of 
medicalization across the web sites varied with the CombiPatch and ENJUVIA 
web sites being more explicit in their adoption of a biomedical perspective.  
 
Summary 
 
From my analysis, several things became clear. First, descriptions of 
menopause found on the pharmaceutical web sites for HT articulated and 
advanced a biomedical perspective of menopause. In adopting a medical 
perspective, menopause was described as a “change of life” or a “stage” 
requiring medical management. Second, the biomedical rhetoric used to explain 
the “reasons” for menopause emphasized the loss of hormones and end of 
regular menstruation thereby setting the stage for using HT products to adjust or 
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restore this balance. Third, the web sites employed the terminology of illness, 
including the term “symptoms” which is a medically symbolic term. In the online 
advertisements for HT, women were told that their symptoms were to be 
assessed, tracked, and managed which clearly relates to a disease-like model of 
menopause. Likewise, symptoms were presented to consumers as problematic 
and bothersome. If left untreated, the web sites implied that symptoms could lead 
to hampered sex lives and a reduced sense of self. Fourth, the web sites were 
prescriptive and advocated certain consumer behaviors or actions. Specifically, 
women were told to “discuss” or “ask” their health care provider about HT. By 
following-up with a physician to inquire about HT, consumers would learn more 
about the “relief” they could expect from using HT. Hence, the biomedical 
definitions and explanations of menopause, list of symptoms needing to be 
medically managed, and the consumer actions being advocated on the web sites 
worked together in unison to set the stage for using HT to balance hormone 
levels and alleviate symptoms. 
Throughout my analysis, attention to language and word choice was vital 
for gaining an understanding of how the pharmaceutical companies portrayed 
menopause in the online advertisements. During my analysis, I found that the 
online advertisements for HT continued to reflect a biomedical understanding of 
menopause by presenting menopause as a loss of hormones accompanied by 
problematic and bothersome symptoms for which HT may help to balance 
hormone levels. Thus, my analysis adds to our understanding of how menopause 
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was being portrayed on web sites for HT and elucidated several mechanisms 
through which the process of medicalization can occur.   
Having considered the representation of menopause in online 
advertisements for HT, I would now like to expand my analysis in two ways. First, 
I examined the presentation of benefits of HT to consumers on the web sites. 
Second, I explored how the possible side effects of HT were portrayed in the 
online advertisements for HT. Therefore, at center stage of my analysis in the 
next chapter was how the benefits, side effects, and risks of HT were portrayed 
by drug manufacturers in online advertisements for HT.  
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CHAPTER 8 
PRESENTATION OF BENEFITS AND SIDE EFFECTS  
OF HORMONE THERAPIES 
 
In this chapter, my analysis of the presentation of benefits and side effects 
of hormone therapies (HT) in the online advertisements is offered. To help 
contextualize the discussion, it is important to briefly review direct-to-consumer 
(DTC) advertising and its regulation. In 1999, the U.S. Food and Drug 
Administration (FDA) provided recommendations for the mass media promotion 
of direct-to-consumer promotion of prescription drugs (FDA Web site: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation
/Guidances/ucm070065.pdf. Retrieved: May 23, 2010). The FDA further issued 
an update for print advertisements in 2004 which focused on conveying risk 
information for consumers (FDA Web site: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation
/Guidances/ucm069984.pdf. Retrieved: May 23, 2010). As such, existing FDA 
rules require all DTC prescription drug advertisements that mention the brand 
name and treated disease to present a “fair balance of the benefits and risks 
associated with the drug” (Huh and Cude, 2004, p. 530).  Unfortunately, the FDA 
itself has not provided an explicit definition for their “fair balance” disclosure 
(Holtz, 1998).   
To complicate matters, the FDA “has not written any regulations specific to 
DTC prescription drug websites” (Huh and Cude, 2004, p. 530). Thus, 
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pharmaceutical web sites are viewed largely as an “extension of traditional print 
advertising” (Davis, Cross, and Crowley, 2007, p. 35). Therefore, if a web site 
mentions a drug by name, it must meet the standard applied to print advertising 
(Moore and Newton, 1998).  
Despite the “growing importance of prescription drug websites,” few 
empirical studies have examined consumer-targeted prescription drug 
advertising in the online environment (Huh and Cude, 2004, p. 529).   
In light of this situation, I first examined the portrayal of benefits of HT to 
consumers on the web sites. In addition, I also explored how benefits of HT were 
presented to health care professionals. Next, I investigated how side effects were 
presented in the online advertisements for HT. As researchers have noted, risk 
information, such as side effects and contraindications, may be critical 
information that consumers seek from a web site (Holtz, 1998; Huh and Cude, 
2004). As such, also of particular interest to my analysis was how the Women’s 
Health Initiative (WHI) was framed in discussions for consumers and health care 
providers. Finally, the chapter concludes with a discussion of issues that 
emerged from my analysis pertaining to how benefits, side effects, and the WHI 
were portrayed by drug manufacturers in online advertisements for HT. 
 
Location of Benefits 
 
To examine the portrayal of benefits of HT on the web sites, I started by 
assessing the location of benefits information on the HT web sites. According to 
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the FDA, a benefit is “help provided by a drug for the person who is taking it” 
(FDA Web site: 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdverti
sing/ucm072025.htm. Retrieved: February 13, 2010). In this study, I employed 
this definition provided by the FDA in order to identify where the web sites 
discussed the positive outcomes that could be expected as a result of using the 
various HT products.  
All of the HT web sites (N=8) discussed the benefits of HT on a specific web 
page devoted to benefits information. In every instance, benefits information for 
consumers was located on a web page titled “About” followed by name of the 
particular HT product (N=8). For example, the proclaimed benefits of using 
ANGELIQ were observed on a web page entitled “About ANGELIQ” on the HT 
web site. Likewise, the advertised benefits of using PREMARIN were presented 
on a web page labeled “About PREMARIN.” As such, this was a recurring pattern 
across all of the HT web sites.  
Furthermore, two HT web sites highlighted benefits information in two 
separate places. The PREMARIN and PREMPRO web sites, both products from 
Wyeth Pharmaceuticals, provided two web pages for consumers to learn about 
the benefits of the HT products. In these cases, the benefits of PREMARIN and 
PREMRO were found on a web page titled “About PREMARIN/PREMPRO” as 
well as another web page with identical information labeled “Benefits of 
PREMARIN/PREMPRO.” By having the benefits information listed on the 
pharmaceutical web sites in multiple places, web site users would be more likely 
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to find this information in case they did not know to look for this information under 
the “About” menu option. The significance of the placement of benefits 
information of HT on specific web pages illustrated that the proclaimed benefits 
of each HT product were prominently featured on each of the web sites. 
Moreover, two HT web sites in particular (PREMARIN and PREMPRO) used the 
repetition of this information in two distinct places to announce beneficial aspects 
of their HT products to web site users. Next, I take a closer look at the description 
of the “benefits” of HT in the online advertisements. 
 
Presentation of Benefits to Consumers 
 
Table 26 shows the advertised benefits of HT to consumers were 
represented by a number of key phrases or words. In the online advertisements, 
key phrases used to describe the benefits of HT included “effectively control,” 
“significantly reduce,” and “rapid relief” from menopausal symptoms. According to 
the ENJUVIA web site, ENJUVIA was “demonstrated to effectively control hot 
flashes, night sweats, vaginal dryness, and pain with sex” (ENJUVIA web site: 
http://www.enjuvia.com. Retrieved: July 14, 2009).  Furthermore, Estrasorb 
“significantly reduces daily hot flashes” (Estrasorb web site: 
http://www.estrasorb.com. Retrieved: July 15, 2009).  Another example was 
found on the ANGELIQ web site which stated the ANGELIQ pill provided “rapid 
relief of hot flashes, night sweats, and vaginal dryness” (ANGELIQ web site: 
http://www.angeliq-us.com. Retrieved: July 13, 2009). 
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Other descriptions of benefits observed included that CombiPatch was 
“easy to apply, discreet, and small” (CombiPatch web site: 
http://www.combipatch.com. Retrieved: July 13, 2009).  CombiPatch was also 
“designed to stay on during various activities including swimming, showering and 
bathing. So you can enjoy an active lifestyle while wearing the patch” 
(CombiPatch web site: http://www.combipatch.com. Retrieved: July 13, 2009).  In 
addition, using Estrasorb “fits easily into your beauty routine… [and] leaves your 
legs soft, smooth, and moisturized” (Estrasorb web site: 
http://www.estrasorb.com. Retrieved: July 15, 2009). 
As seen in Table 26, six of the HT web sites stated benefits for hot 
flashes, night sweats, and vaginal symptoms (ANGELIQ, CombiPatch, ENJUVIA, 
Femring, PREMARIN, and PREMPRO). The femhrt web site highlighted benefits 
for hot flashes and night sweats. Finally, the Estrasorb web site mentioned 
benefits for night sweats. None of the pharmaceutical web sites in the study 
sample (N=8) linked back the U.S. Food and Drug Administration (FDA) web site.   
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Table 26: Description of Benefits of HT for Consumers 
Name of HT 
Product 
 
Description of Benefits for Consumers 
ANGELIQ • Rapid relief of hot flashes, night sweats, and vaginal 
dryness 
• Reduction of hot flashes and night sweats 
 
CombiPatch • Reduce hot flashes 
• Treat hot flashes, and vaginal dryness, itching and 
burning 
• Easy to apply, discreet and small 
• Ultra Convenience: The patch is designed to stay 
on during various activities including swimming, 
showering and bathing. So you can enjoy an active 
lifestyle while wearing the patch. 
 
ENJUVIA • Demonstrated to effectively control hot flashes, 
night sweats, vaginal dryness, and pain with sex 
• Shown to lower the number and severity of hot 
flashes and night sweats 
• Significantly reduced the severity of vaginal dryness 
and pain with sex 
 
Estrasorb • Significantly reduces daily hot flashes: 
• Easy to use 
• Fits easily into your beauty routine. Just apply 
Estrasorb lotion once a day to each leg. 
• Leaves your legs soft, smooth, and moisturized 
• Effective: in a clinical study, hot flashes were 
reduced by 85% 
• Well-tolerated: very few skin reactions have been 
reported 
 
femhrt • Treatment of menopause symptoms such as hot 
flashes/night sweats 
• Help reduce your chances of developing 
osteoporosis 
 
 
Femring • Effective way to treat menopause symptoms 
• Convenient and discreet delivery option 
• Aids in the relief of hot flashes, night sweats, and 
vaginal dryness 
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• Help reduce menopausal symptoms 
 
 
PREMARIN • You can expect relief from your menopausal 
symptoms to begin quickly with PREMARIN. (You 
may begin to feel relief from hot flashes in 1 to 3 
weeks.) 
• Hot flashes and night sweats are likely to become 
less frequent and intense. 
• Relief from vaginal symptoms 
• Help reduce your chances of developing 
osteoporosis 
• Proven to increase bone mineral density at the hip 
and the spine and help prevent postmenopausal 
osteoporosis 
 
PREMPRO • Proven to effectively relieve hot flashes, night 
sweats, and vaginal symptoms 
• Hot flashes and night sweats are likely to become 
less frequent and less intense 
• Help reduce your chances of developing 
osteoporosis 
• proven to increase bone mineral density at the hip 
and spine and help prevent postmenopausal 
osteoporosis 
 
 
 
 
 
Further analysis revealed that the “benefits” of HT advertised to 
consumers could be grouped into two main themes. One of the primary benefits 
of HT presented on the HT web sites was symptom reduction. Specifically, 
mention of this benefit was observed on all of the HT web sites (N=8). According 
to one web site, ANGELIQ provided a “reduction of hot flashes and night sweats” 
(ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009).  
ENJUVIA was also “shown to lower the number and severity of hot flashes and 
night sweats” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 
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2009).  Furthermore, ENJUVIA “significantly reduced the severity of vaginal 
dryness and pain with sex” (ENJUVIA web site: http://www.enjuvia.com. 
Retrieved: July 14, 2009).  Similarly, “hot flashes and night sweats are likely to 
become less frequent and intense” with PREMARIN (PREMARIN web site: 
http://www.premarin.com. Retrieved: July 17, 2009).  Thus, the reduction in the 
number and severity of menopausal symptoms, such as hot flashes, night 
sweats, and vaginal dryness, was highlighted as a benefit on all of the HT web 
sites. As Table 26 illustrates, the terms “reduce” or “reduction” were observed 
across all of the HT web sites in the study sample. 
It is worth noting that the Estrasorb web site asserted “the number of hot 
flashes per day were reduced by 85%” in a clinical study (Estrasorb web site: 
http://www.estrasorb.com. Retrieved: July 15, 2009).  Interestingly, a citation to 
the actual research study was not provided for consumers on the Estrasorb web 
site to support this claim. With regards to this omission, perhaps there was an 
assumption that women did not want to know this scientific information, or maybe 
they did not need to know, or possibly women would not be able to track down 
the medical study. Nevertheless, claims of a scientific basis raise important 
questions around the use of such declarations whenever there is insufficient 
evidence provided to consumers. In fact, this claim may also be seen as an 
attempt to differentiate this particular HT product from other hormone products 
that do not make such claims. 
The prevention of osteoporosis was another principal “benefit” of HT 
presented to consumers in the online advertisements. This preventative benefit 
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was observed on three HT web sites (femhrt, PREMARIN, and PREMPRO). 
According to one web site, femhrt could “help reduce your chances of developing 
osteoporosis by increasing bone mass” (femhrt web site: 
http://www.wcrx.com/products/femhrt. Retrieved: July 25, 2009). Likewise, 
PREMARIN informed consumers the HT product reduced “your chances of 
developing osteoporosis” (PREMARIN web site: http://www.premarin.com. 
Retrieved: July 17, 2009). In addition, PREMPRO could also “help prevent 
postmenopausal osteoporosis” (PREMPRO web site: http://www.prempro.com. 
Retrieved: July 17, 2009).  While the FDA acknowledges that hormones “may 
reduce your chances of getting thin, weak bones,” the FDA informs consumers 
there are “other medicines and things you can do to help your bones” (FDA web 
site: http://www.fda.gov/ForConsumers/ByAudience/ForWomen/ucm118624.htm. 
Retrieved: February 14, 2010). Unfortunately, the FDA does not provide further 
details about these other medicines or “things” that one can do to slow bone loss. 
Nonetheless, this particular comment about bone health from the FDA 
was also echoed in another statement for health care providers which 
recommended “when these drugs are being prescribed only to prevent 
osteoporosis, health care providers are encouraged to consider other treatments 
before prescribing estrogen or estrogen with progestin” (FDA web site: 
http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135339.htm. 
Retrieved: February 22, 2010). As mentioned in an earlier chapter, previous 
research found that drug advertisements in women’s magazines encouraged all 
women over thirty-five years to consider taking hormones for osteoporosis as a 
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“preventive measure” (Worcester and Whatley, 1992, p. 9). The technique of 
casting menopause as a “risk” for osteoporosis and therefore promoting HT for 
the prevention of bone loss and fractures has also been reported in the literature 
as a way of expanding the list of possible symptoms treatable with HT (Dukes, 
1997; Palmlund, 1997; Worcester, 2004; Worcester and Whatley, 1992).  Here, 
my analysis suggests there was also a trend in the online drug advertisements of 
promoting HT for osteoporosis as a preventive measure.  
To summarize, symptom reduction and the prevention of osteoporosis 
were two main benefits of HT promoted to consumers in the online drug 
advertisements. Another feature that I observed on the HT web sites was the use 
of “patient stories” or testimonials to support claims of a product’s benefits. To 
illustrate the “benefits” of HT, three of the web sites (Estrasorb, PREMARIN, and 
PREMPRO) turned to “real life” stories. In these three online HT advertisements, 
women’s stories were portrayed as first-person accounts of using HT. In all three 
instances, the women depicted in these stories made reference to seeking 
further medical advice as a means of alleviating menopausal symptoms. Under 
the “Personal Experiences” menu option found on the Estrasorb web site, 
consumers were introduced to a Caucasian woman named “Alice.” Consumers 
were told that Alice was a 58 year old executive suffering from severe hot flashes 
and night sweats which were “disrupting sleep patterns and getting in the way of 
daily activities and relationships” (Estrasorb web site: http://www.estrasorb.com. 
Retrieved: July 15, 2009).  Alice was quoted as saying that her situation was 
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“intolerable… [and] I’m going to talk with my doctor about Estrasorb” (Estrasorb 
web site: http://www.estrasorb.com. Retrieved: July 15, 2009).   
The “Women’s Stories” found on PREMARIN and PREMPRO web sites 
provided further examples of personal stories attesting to the benefits of HT and 
encouraging medical intervention for menopausal symptoms. On the PREMARIN 
web site, consumers were introduced to a Caucasian woman named “Maureen.” 
Unlike what was witnessed with the Estrasorb character “Alice,” Maureen’s age 
and occupation were not provided on the PREMARIN web site. Nevertheless, 
Maureen informed web site users that she went to see her doctor to inquire about 
PREMARIN. Maureen recounted that “one of the best things she said to me was 
that she uses it and she thinks it’s great. And that really helped me feel 
comfortable about utilizing PREMARIN” (PREMARIN web site: 
http://www.premarin.com. Retrieved: July 17, 2009).  By suggesting that a health 
care provider also used PREMARIN, this story further reassured consumers 
about the appropriateness of HT for menopausal symptoms while also adding 
legitimacy to the claim. One more example was found on the PREMPRO web 
site in which a different Caucasian woman named “Debbie” stated “when I first 
started experiencing symptoms, I didn’t know what was happening, so I asked 
my doctor about it” (PREMPRO web site: http://www.prempro.com. Retrieved: 
July 17, 2009). After taking PREMPRO, Debbie further noted that her hot flashes 
“got significantly better” after about two weeks (PREMPRO web site: 
http://www.prempro.com. Retrieved: July 17, 2009). 
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In fact, I realized that these women’s stories adhered to a biomedical model 
of illness by discussing topics such as signs of symptoms of menopause, 
diagnosis, and treatment. Even more troubling was a disclaimer found on the 
Estrasorb web site that stated that the “patient profiles are hypothetical [and] 
models are used for illustrative purposes only” (Estrasorb web site: 
http://www.estrasorb.com. Retrieved: July 15, 2009).  I should also note that it 
was not known if the “Women’s Stories” found on the PREMARIN and 
PREMPRO web sites were actual patients or hypothetical scenarios. 
Nonetheless, the women’s stories attested to the proclaimed benefits of HT 
thereby encouraging consumers to seek medical treatment. Consequently, the 
use of “women’s stories” were constructed as first-person testimonials about 
experiences with HT and functioned to support a product’s claims about benefits.  
 
Presentation of Benefits to Health Care Professionals 
 
My analysis also revealed that benefits of HT were presented differently to 
health care providers than consumers in the online advertisements. In this 
section of the chapter, I further inspect how the benefits of HT were portrayed on 
portions of the HT web sites designated specifically for health care professionals. 
Table 27 illustrates the various “selling points” of HT presented to health care 
professionals on the HT web sites. 
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Table 27: Selling Points of HT Emphasized to Health Care Professionals 
Name of HT 
Product 
Description of Selling Points for Health Care 
Professionals 
 
ANGELIQ None 
 
CombiPatch • It’s a convenient alternative for patients seeking 
relief for menopausal symptoms 
• Two strengths of CombiPatch are available 
• It’s comfortable: has a low incidence of skin 
irritation and side effects 
• It’s discreet: CombiPatch is small and transparent 
 
ENJUVIA • Delivers effective relief of vasomotor symptoms, 
and vaginal dryness and pain with sex to your 
symptomatic menopausal patients 
• Significantly reduces the frequency and severity of 
vasomotor symptoms and vaginal dryness and 
pain with sex, symptoms of vulvar and vaginal 
atrophy, associated with menopause 
• ENJUVIA is something you—and your patients—
will be glad to discover 
• ENJUVIA dosing is flexible, too. 
 
 
Estrasorb • Fast, effective symptom relief 
• Proven in a well-controlled clinical trial 
• 85% reduction in daily hot flashes 
• Demonstrated safety and tolerability 
• Demonstrated patient satisfaction: 91% of patients 
liked the way their skin felt after applying 
Estrasorb 
 
femhrt None 
 
Femring None 
 
PREMARIN • A blend of estrogens with extensive evidence to 
support your recommendation 
• Significant relief of vasomotor symptoms as early 
as 3 weeks 
• Significant increase in spine and hip bone mineral 
density 
• Range of dosing options 
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PREMPRO • More dosing options than any other single-tablet 
combination hormone therapy 
• Individualize her therapy with a range of dosing 
options 
• Significant reduction in moderate to severe hot 
flashes, even at low dose 
• Significant increase in spine and hip bone mineral 
density, even at low dose 
 
 
 
 
As Table 27 demonstrates, six of the HT web sites (n=6) presented selling 
points of HT to health care professionals. Notably, four HT web sites (n=4) 
highlighted a range of dosage options. The CombiPatch web site informed health 
care professionals that two strengths of CombiPatch were available (CombiPatch 
web site: http://www.combipatch.com. Retrieved: July 13, 2009).  Another 
example was found on the PREMARIN web site which highlighted a “range of 
dosing options” on the section of the web site aimed to health care professionals 
(PREMARIN web site: http://www.premarin.com. Retrieved: July 17, 2009). 
Furthermore, PREMPRO claimed to offer “more dosing options than any other 
single-tablet combination hormone therapy” (PREMPRO web site: 
http://www.prempro.com. Retrieved: July 17, 2009). Finally, health care 
professionals were reminded that “ENJUVIA dosing is flexible, too” (ENJUVIA 
web site: http://www.enjuvia.com. Retrieved: July 14, 2009).  Clearly, a range of 
dosage options was viewed as an attractive feature that would appeal to health 
care professionals. 
Also visible on sections of the HT web sites for health care providers were 
references to “evidence” to support claims about the products’ benefits. 
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Specifically, two of the HT web sites (n=2) referenced “evidence” for health care 
providers. According to the Estrasorb web site, the HT product had been “proven 
in a well-controlled clinical trial” (Estrasorb web site: http://www.estrasorb.com. 
Retrieved: July 15, 2009).  PREMARIN was also described to health care 
professionals as a “blend of estrogens with extensive evidence to support your 
recommendation” (PREMARIN web site: http://www.premarin.com. Retrieved: 
July 17, 2009).  On the Estrasorb and PREMARIN web sites, citations to studies 
supporting these beneficial claims were provided for health care professionals. 
Therefore, my analysis revealed that references to actual studies were provided 
only on portions of the HT web sites aimed at health care providers. In fact, five 
of the HT web sites (CombiPatch, ENJUVIA, Estrasorb, PREMARIN, and 
PREMPRO) provided references to actual studies for health care professionals. 
In contrast, consumers were not provided with clinical evidence to support 
pharmaceutical companies’ claims about the benefits of HT. 
Other selling points emphasized to health care providers that were 
observed included the mention of “convenience” and “patient satisfaction.” 
CombiPatch was described as a “convenient alternative for patients seeking 
relief for menopausal symptoms” (CombiPatch web site: 
http://www.combipatch.com. Retrieved: July 13, 2009). In addition, the Estrasorb 
web site referred to “demonstrated patient satisfaction” which is further explained 
by the statement “91% of patients liked the way their skin felt after applying 
Estrasorb” (Estrasorb web site: http://www.estrasorb.com. Retrieved: July 15, 
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2009). Thus, “convenience” and “patient satisfaction” were additional selling 
points promoted to health care professionals in the online advertisements for HT. 
To summarize, the presentation of benefits of HT in the online drug 
advertisements varied depending on the intended audience. Consumers were 
informed about the possibility of symptom reduction and the prevention of 
osteoporosis. On the other hand, health care professionals were told about the 
range of dosage options, evidence to support claims of efficacy, and patient 
satisfaction with HT products. Similar to my earlier findings in which I found that 
the pharmaceutical companies employed different product slogans for different 
web site audiences, here I also observed variations in the types of “benefits” or 
“selling points” emphasized for consumers and health care professionals. 
Another distinguishing characteristic was the lack of scientific evidence provided 
for consumers. Moreover, patient testimonials, such as the hypothetical stories 
presented on the Estrasorb web site, were used to support product claims on 
several of the HT web sites. Next, I examined how the side effects of HT were 
presented across the HT web sites. 
 
Location of Side Effects  
 
This section of the chapter analyzes the location of information about the 
possible side effects of HT on the web sites. Table 28 shows where the side 
effects of HT were discussed in the online advertisements. Specifically, I was 
interested in the location in which these side effects were disclosed.  
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Table 28: Location of Side Effects Information on the HT Web Sites 
Name of HT 
Product 
Separate Web 
Page for Side 
Effects 
 
Name of Web Page with 
Side Effects Information 
 
ANGELIQ 
 
Yes 
 
 
“Safety Information”  
 
 
CombiPatch 
 
Yes 
 
 
“Risks and Benefits of 
Hormone Therapy” 
 
 
ENJUVIA 
 
Yes 
 
 
“Safety and Tolerability” 
 
 
Estrasorb 
 
No  
 
 
N/A 
 
femhrt 
 
Yes 
 
 
“Important Safety Information” 
 
 
Femring 
 
Yes 
 
 
“Important Safety Information” 
 
 
PREMARIN 
 
Yes 
 
 
“Side Effects and Safety” 
 
 
PREMPRO 
 
Yes 
 
 
“Side Effects and Safety” 
 
 
As Table 28 indicates, seven of the HT web sites (n=7) had specific web 
pages discussing possible side effects. Six of the HT web sites (n=6) used the 
word “safety” in the title of the web page where the side effects of HT were 
discussed. For example, the names of the web pages on the PREMARIN and 
PREMPRO sites where side effects were mentioned were called “Side Effects 
and Safety.” The Femring and femhrt web sites had a page called “Important 
Safety Information” which outlined the possible side effects associated with HT. 
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Additionally, the ANGELIQ web site had a page entitled “Safety Information” and 
ENJUVIA highlighted side effects on a page called “Safety and Tolerability.”  
In particular, one HT web site did not have a specific web page where side 
effects were discussed. On the Estrasorb web site, possible side effects were 
found in a footer at the bottom of the web site. Although this footer appeared 
throughout the web site, the text in this footer was notably a smaller font size 
compared to the main content found on the Estrasorb web site. Therefore, this 
online advertisement did not present a balance of information about the drug's 
possible side effects compared to the advertised benefits because the location 
and smaller font size minimized the importance of side effects. As a result, the 
side effects could potentially be overlooked by web site users due to the fact that 
this information appeared in a smaller font size than the benefits information and 
was placed at the bottom of the advertisement far from the benefits. Thus, both 
the location and font size of the possible side effects on the Estrasorb web site 
was a cause for concern. This example illustrated the need for better and 
consistent risk communication in online drug advertisements. Next, I examined 
how the side effects of HT were portrayed in the online drug advertisements. 
 
Presentation of Side Effects  
 
According to the FDA, a side effect of a drug refers to “what can go wrong 
when the drug is used” (FDA Web site: 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdverti
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sing/ucm072025.htm. Retrieved: February 20, 2010). Table 29 illustrates the 
language used to describe possible side effects of HT on the web sites. Here, I 
was most interested in the way language was used by the pharmaceutical 
companies to describe these side effects. My analysis shows that the side effects 
were presented as either “common” side effects or “less common but serious” 
side effects. 
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Table 29: Description of “Common” Side Effects and 
“Less Common but Serious” Side Effects  
Name of HT Product “Common” Side Effects “Less Common but 
Serious” Side Effects  
 
ANGELIQ • Headache 
• Breast pain 
• Irregular vaginal 
bleeding or spotting 
• Stomach/abdominal 
cramps, bloating 
• Nausea and vomiting 
• Hair loss 
 
 
 
• Breast lumps 
• Unusual vaginal 
bleeding  
• Dizziness and 
faintness  
• Changes in speech 
• Severe headaches 
• Chest pain 
• Shortness of breath 
• Pains in your legs  
• Changes in vision 
• Vomiting 
 
CombiPatch • Breast pain 
• Vaginal bleeding 
• Headache 
 
 
N/A 
ENJUVIA • Headache 
• Breast pain 
• Irregular vaginal 
bleeding or spotting 
• Stomach/abdominal 
cramps, bloating 
• Nausea and vomiting 
• Hair loss 
 
 
N/A 
Estrasorb • Headache 
• Breast pain 
• Irregular vaginal 
bleeding or spotting 
• Stomach/abdominal 
cramps, bloating 
• Nausea and vomiting 
• Skin irritation, redness or 
rash at application site 
• Hair loss 
N/A 
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femhrt • Headache 
• Breast pain 
• Irregular vaginal 
bleeding or spotting 
• Stomach/abdominal 
cramps, bloating 
• Nausea and vomiting 
• Hair loss 
 
 
• Breast lumps 
• Unusual vaginal 
bleeding  
• Dizziness and 
faintness  
• Changes in speech 
• Severe headaches 
• Chest pain 
• Shortness of breath 
• Pains in your legs  
• Changes in vision 
• Vomiting 
 
Femring • Headache 
• Vaginal infection 
• Breast tenderness 
• Vaginal bleeding or 
spotting 
• Back ache 
• Abdominal bloating 
 
 
• Breast cancer 
• Cancer of the uterus 
• Stroke 
• Heart attack 
• Blood clots 
• Dementia 
• Gallbladder disease 
• Ovarian cancer  
PREMARIN • Vaginitis due to yeast or 
other causes 
• Vaginal bleeding 
• Painful menstruation 
• Leg cramps 
 
 
N/A 
PREMPRO • Breast pain/enlargement  
• Vaginitis due to yeast or 
other causes  
• Leg cramps  
• Vaginal 
spotting/bleeding  
• Painful menstruation  
 
N/A 
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As demonstrated in Table 29, breast pain and vaginal bleeding were two 
common side effects observed across all of the HT web sites (N=8). In fact, six of 
the HT web sites (n=6) listed the same “common” side effects of HT. These six 
possible side effects were headaches, breast pain, irregular vaginal bleeding or 
spotting, stomach/abdominal cramps or bloating, nausea and vomiting, and hair 
loss. Such statements of possible side effects coincided with the FDA which has 
also noted these six side effects as common with estrogen and estrogen with 
progestin drug products (FDA Web site: 
http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135339.htm. 
Retrieved: February 22, 2010).  
In the previous chapter, I discussed my findings from analyzing the reading 
levels of the information presented on the four online symptom tools in the study 
sample. My analysis revealed the information was written at grade levels that 
exceeded the estimated reading level of the average adult in the U.S. (National 
Adult Literacy Survey, 1992).  I further assessed the reading level of these six 
common side effects of HT. To accomplish this, I again utilized an online tool 
called “TxReadability,” a free application developed by the Accessibility Institute 
at the University of Texas at Austin. To summarize briefly, the Flesch-Kincaid 
Grade level indicates the grade a person will have to reach to be able to 
understand the text (Accessibility Institute at the University of Texas web site: 
http://webapps.lib.utexas.edu/TxReadability/app. Retrieved: March 9, 2010). For 
instance, a score indicating the grade level of seven means that a seventh grader 
should be able to understand the text. An analysis of the text describing the six 
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common side effects of HT across the eight web sites in this study sample 
yielded a score of 12.94. This score is equivalent to a 12th grade reading level in 
the United States or some college education. As I previously noted, considering it 
is estimated that one in four adults in the United States read at or below the 3rd 
grade reading level, this grade level far surpasses the estimated reading level of 
the average adult in the U.S. (National Adult Literacy Survey, 1992). Moreover, 
the Wayne State University Institutional Review Boards (IRB) also provides 
guidelines for documents used in the informed consent process in participant 
research studies. Generally, the IRB requires consent forms to be written at 6th-
8th grade reading level (Wayne State University Human Investigation Committee 
web site: http://www.hic.wayne.edu/policies/9-1_informed_consent_options.pdf. 
Retrieved: May 14, 2010). In this context, it is plausible to conclude that the 
information presented across all of the HT web sites about “common” side effects 
was too difficult for many of the intended web sites users, thus it should be 
rewritten to take into consideration lower literacy levels.  
Further, when compared to the reading level of the online symptoms tools, 
which was a combined score of 7.74 falling between a 7–8th grade reading level, 
the information about common side effects was even higher. This finding 
demonstrated a range in reading levels and accessibility of information on the 
pharmaceutical web sites. Interestingly, I found that information on the 
pharmaceutical web sites was not consistently written at the same reading level. 
Rather, the reading level varied making some information less accessible, such 
as the side effects information which I reported was written at an even higher 
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reading level than information from the online symptom tools.  Once again, since 
important information about possible side effects was not as readily accessible 
for consumers, I speculate that consumers may need to consult with health care 
professionals in order to make sense of the information about side effects 
provided on the pharmaceutical web sites. In light of this, consumers would have 
to rely on the “expertise” and medical knowledge of a health care professional to 
acquire relevant information about possible side effects.   
Other side effects associated with HT were also mentioned in the online drug 
advertisements. Three of the HT web sites (Femring, PREMARIN, and 
PREMPRO) listed “vaginal infection” or “vaginitis” as a common side effect. In 
addition, two of the HT web sites (PREMARIN and PREMPRO) listed “leg 
cramps” as a common side effect. As Table 29 shows, two of the HT web sites 
(PREMARIN and PREMPRO) also listed “painful menstruation” as a common 
side effect. Another example of a “common” side effect observed was skin 
irritation (Estrasorb cream). 
In addition to “common” side effects, three web sites (ANGELIQ, femhrt, 
and Femring) listed “less common but serious” side effects. As Table 29 
illustrates, ANGELIQ listed “unusual vaginal bleeding” as a “less common but 
serious” side effect (ANGELIQ web site: http://www.angeliq-us.com. Retrieved: 
July 13, 2009).  However, ANGELIQ also stated “irregular vaginal bleeding or 
spotting” was a common side effect (ANGELIQ web site: http://www.angeliq-
us.com. Retrieved: July 13, 2009).  Consequently, I noticed some overlap 
between the “common” and “less common but serious” side effects presented on 
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the HT web sites. This trend continued on the femhrt web site which listed 
“vaginal bleeding” and “vomiting” as both common and “less common but 
serious” side effects (femhrt web site: http://www.wcrx.com/products/femhrt. 
Retrieved: July 25, 2009).  As witnessed on the ANGELIQ and femhrt web sites, 
the pattern of presenting side effects to consumers as both “common” and “less 
common but serious” could be a potential source of confusion for consumers. 
In summary, both the location of the side effects information and the language 
used to describe possible side effects of HT illuminated several issues. First, 
seven of the HT web sites (n=7) had specific web pages discussing the possible 
side effects. However, possible side effects were found only in a footer at the 
bottom of the Estrasorb web site thereby underscoring the need for better risk 
communication. Regarding the description of side effects, possible side effects of 
HT were presented as either “common” and “less common but serious” in the 
online drug advertisements. Indeed, breast pain and vaginal bleeding were two 
common side effects observed across all of the HT web sites. However, one 
noticeable trend was the presentation of the same side effects to consumers as 
both “common” and “less common but serious” which could lead to confusion 
amongst consumers and warrants further clarification.   
In light of the Women’s Health Initiative (WHI), concerns about hormones 
being linked to an increased risk for cancer, heart attacks, and dementia were 
also addressed on the web sites. In the online drug advertisements, information 
about risks associated with HT were observed in the footer across all of the HT 
web sites in the study sample (N=8). Specifically, three main statements about 
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risks of HT were repeated consistently across all of the HT web sites. First, it was 
noted that estrogens increase the chance of getting cancer of the uterus. 
Second, it was mentioned that using estrogens (with or without progestins) may 
increase the chance of getting heart attacks, strokes, breast cancer, and blood 
clots. Finally, all of the HT web sites (N=8) stated that using estrogens (with or 
without progestins) may increase the chance of getting dementia. These three 
statements found across all of the HT web sites were consistent with FDA 
statements that also noted these as possible risks associated with HT (FDA Web 
site: 
http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135339.htm. 
Retrieved: February 24, 2010). Given the ongoing concerns about risks 
associated with using HT, which were raised by the WHI clinical trial, next I 
examined how and where the WHI was mentioned on the HT web sites. 
 
References to Women’s Health Initiative (WHI) 
 
In examining the portrayal of the WHI on the web sites, the location of where 
WHI was discussed was an important consideration. Table 30 indicates where 
information about the WHI was found across the eight HT web sites. As Table 30 
indicates, all of the HT web sites (N=8) directly referred to the WHI. However, the 
location of the information about the WHI is deserving of attention.  
Five of the HT web sites (n=5) referred to the WHI in sections of the web 
site aimed at health care providers. Out of these five HT web sites, four of them 
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(ENJUVIA, Estrasorb, PREMARIN, and PREMPRO) mentioned the WHI in the 
footer of web pages intended for health care providers. Unique among the study 
sample, CombiPatch was the only HT web site that discussed the WHI for health 
care providers on a specific web page appropriately entitled the “Women’s Health 
Initiative” (CombiPatch web site: http://www.combipatch.com. Retrieved: July 13, 
2009). In addition, the CombiPatch web site also provided health care 
professionals with a link to the official WHI web site (http://www.whi.org/findings) 
for more information about the WHI study’s findings.  
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Table 30: Web Sites that Mention WHI and Location of WHI Information 
Name of HT 
Product 
Mention of WHI Location of Where WHI 
is Mentioned 
 
Intended for 
Consumer or 
Health Care 
Provider 
 
ANGELIQ 
 
Yes 
 
“Recent News about 
Hormone Therapy”  
 
 
Consumer 
CombiPatch Yes “Women’s Health 
Initiative” 
 
Health Care 
Provider 
ENJUVIA Yes Mentioned in footer on 
web page for health care 
providers 
 
Health Care 
Provider 
Estrasorb Yes Mentioned in footer on 
web page for health care 
providers 
 
Health Care 
Provider 
femhrt Yes “Recent Concerns 
Regarding HT” 
 
Consumer 
Femring Yes “Hormone Therapy 
News” 
 
Consumer 
PREMARIN Yes Mentioned in footer on 
web page “Health Care 
Professionals’ Info” 
 
Health Care 
Provider 
PREMPRO Yes Mentioned in footer on 
web page “Health Care 
Professionals’ Info” 
 
Health Care 
Provider 
 
The pharmaceutical web sites differed in how they presented and framed 
the WHI. By way of contrast, only three web sites in the sample discussed the 
WHI on specific sections of the web site intended for consumers (ANGELIQ, 
femhrt, and Femring). On these three HT web sites, the titles of the web page 
where the WHI was referenced placed an emphasis on “recent concerns” or 
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“news” about HT.  For instance, the ANGELIQ web page discussing the WHI was 
entitled “Recent News about Hormone Therapy” (ANGELIQ web site: 
http://www.angeliq-us.com. Retrieved: July 13, 2009).  On the femhrt web site, 
the WHI was mentioned on the web page “Recent Concerns Regarding HT” 
(femhrt web site: http://www.wcrx.com/products/femhrt. Retrieved: July 25, 
2009).  In addition, the “Hormone Therapy News” web page on the Femring site 
provided consumers with information about the WHI (Femring web site: 
http://www.wcrx.com/products/femring. Retrieved: July 17, 2009). Since only 
three of the HT web sites offered discussions about the WHI for consumers, the 
lack of proper attention to the WHI and any discussion regarding the implications 
for consumers was noticeably deficient on the HT web sites. 
I also noted other distinguishable differences across the pharmaceutical 
web sites. The Femring and femhrt web sites, both products from Warner 
Chilcott, highlighted benefits reported from the WHI. These two web sites cited 
fewer hip fractures and fewer cases of colorectal cancer among users of HT in 
the WHI clinical trial. Indeed, putting a positive “spin” on the WHI was an 
interesting way to frame the WHI results that effectively minimized commonly 
held concerns about hormone use. Further, the ANGELIQ web site stated that 
HT “still may be appropriate for many” and encouraged consumers to ask their 
health care providers if the “possible benefits of HT outweigh the risks” 
(ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009).  
Clearly, these three web sites painted a positive picture of the WHI study results 
by emphasizing potential benefits of HT. Again, these three web sites were the 
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only pharmaceutical web sites for HT in the study sample that specifically 
discussed the WHI with consumers. As evident, the framing of the WHI on these 
three web sites minimized the risks and concerns associated with the WHI for 
consumers by highlighting positive findings of the WHI. It was further suggested 
that possible benefits may outweigh potential risks. 
On the three consumer-oriented portions of the HT web sites where the 
WHI was referenced (ANGELIQ, femhrt, and Femring), consumers were further 
encouraged to ask a health care provider for more information about the WHI 
findings. According to ANGELIQ web site “many aspects of the findings were not 
clear. However, hormone therapy still may be appropriate for many. This is 
something each individual woman should discuss with her healthcare provider” 
(ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009).  In 
another example, consumers were informed their “health care provider can 
discuss what [the WHI] results mean to you” (femhrt web site: 
http://www.wcrx.com/products/femhrt. Retrieved: July 25, 2009).  The Femring 
web site also encouraged consumers to also discuss the WHI results with their 
health care provider and to “review your hormone therapy options with your 
health care provider” (Femring web site: http://www.wcrx.com/products/femring. 
Retrieved: July 17, 2009). As a consequence, the WHI was referenced in a 
limited manner on consumer-oriented sections of the HT web sites. Given the 
limited information about the WHI study provided to consumers, scant discussion 
about any implications, and inadequate educational information, consumers were 
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encouraged to follow-up with their health care providers for further explanations 
about the WHI findings and to discuss HT options.  
My analysis revealed that the manner in which the WHI was framed 
depended on the intended audience. In contrast, the WHI was referenced in a 
different manner to health care providers. In the online drug advertisements for 
HT, discussions of the WHI for health care providers centered on warnings about 
cardiovascular and other risks brought to light by the WHI study. Mention of 
these cardiovascular and other risks were observed on the five HT web sites 
which referenced the WHI for health care providers. For example, the ENJUVIA 
web site stated “the estrogen alone substudy of the Women's Health Initiative 
(WHI) reported increased risks of stroke and deep vein thrombosis (DVT) in 
postmenopausal women (50 to 79 years of age)” (ENJUVIA web site: 
http://www.enjuvia.com. Retrieved: July 14, 2009). Furthermore, the ENJUVIA 
web site went on to state “the estrogen-plus-progestin substudy of the WHI 
reported increased risks of myocardial infarction, stroke, invasive breast cancer, 
pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 
79 years of age)” (ENJUVIA web site: http://www.enjuvia.com. Retrieved: July 14, 
2009). 
Thus, how the WHI was discussed on the HT web sites depended on the 
intended audience. Interestingly, the CombiPatch also stated the FDA “now 
recommends smaller doses over a shorter time for temporary symptom relief” 
(CombiPatch web site: http://www.combipatch.com. Retrieved: July 13, 2009).  A 
final point to note in this discussion was that all of the HT web sites mentioned 
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smaller doses of HT or “low-dose” HT options. Table 31 shows that “low-dose” 
HT options were emphasized to both consumers and health care providers on 
the HT web sites. As Table 31 indicates, four the HT web sites (CombiPatch, 
ENJUVIA, PREMARIN, and PREMPRO) repeated the availability of “low-dose” 
HT options in several places. I argue that this was an important reflection of post-
WHI concerns being acknowledged by the pharmaceutical companies. Indeed, 
mention of “low-dose” HT options was in alignment with the current FDA 
recommendation regarding HT which states “hormones should be used at the 
lowest dose that helps and for the shortest time” (FDA Web site: 
http://www.fda.gov/ForConsumers/ByAudience/ForWomen/ucm118624.htm. 
Retrieved: February 22, 2010). 
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Table 31: Web Sites that Mention “Low-Dose” HT 
Name of HT Product Mention “Low-Dose” HT Wording/Phrase Used 
 
 
ANGELIQ 
 
Yes 
 
 
ANGELIQ should be taken 
for the shortest duration of 
time at the lowest dose. 
 
CombiPatch Yes 
 
Two places: 
1. For Consumers: You 
and your health care 
professional should talk 
regularly about whether 
you are taking the 
lowest dose that works 
for you. (in footer) 
2. For Health Care 
Professionals: The FDA 
and the North American 
Menopause Society 
(NAMS) now 
recommend smaller 
doses over a shorter 
time for temporary 
symptom relief.  
 
ENJUVIA Yes 
 
Two places: 
1. For Consumers: 
estrogens should be 
used at the lowest dose 
for the shortest period 
of time. (in footer) 
2. For Health Care 
Professionals: Low-
Dose Efficacy With the 
ENJUVIA 
 
Estrasorb Yes 
 
Estrogens with or without 
progestins should be 
prescribed at the lowest 
effective doses and for the 
shortest duration consistent 
with treatment goals and 
risks for the individual 
woman. 
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(in footer for health care 
professionals) 
 
femhrt Yes 
 
Low-Dose femhrt 0.5/2.5 is 
the lowest effective dose 
approved by the FDA to 
treat menopausal 
symptoms with this 
combination of hormones. 
 
Femring Yes 
 
For treatment of 
menopausal symptoms, 
recent guidelines 
recommend the lowest 
effective dose for 
menopause for the shortest 
time.  
 
PREMARIN Yes 
 
Four places: 
1. For Consumers: flexible 
low-dose options 
2. For consumers: 
PREMARIN has been 
proven to relieve 
menopausal symptoms 
even at the lowest dose 
3. For Consumers: The 
lowest effective dose of 
PREMARIN should be 
used. 
4. For Health Care 
Professionals: 
estrogens with or 
without progestins 
should be prescribed at 
the lowest effective 
doses and for the 
shortest duration 
consistent with 
treatment goals and 
risks for the individual 
woman. (in footer) 
 
PREMPRO Yes 
 
Four places: 
1. For Consumers: 
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PREMPRO offers 
effective hormone 
therapy with low-dose 
options to treat your 
menopausal symptoms 
2. For consumers: 
PREMPRO should be 
used at the lowest 
effective dose and for 
the shortest duration 
consistent with your 
treatment goals and 
risks. 
3. For Consumers: 
PREMPRO comes in 
several dosage 
strengths—including 
two low-dose 
formulations. These 
options allow your 
health care professional 
to choose the one that 
is right for you. 
4. For Health Care 
Professionals: 
estrogens with or 
without progestins 
should be prescribed at 
the lowest effective 
doses and for the 
shortest duration 
consistent with 
treatment goals and 
risks for the individual 
woman. (in footer) 
 
 
Summary 
 
In summary, this chapter expanded my analysis in two ways. First, I 
examined the presentation of benefits of HT to consumers and health care 
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professionals on the web sites. My analysis indicated different benefits were 
emphasized for these two potential markets. Benefits promoted to consumers 
included symptom reduction and the prevention of osteoporosis. I also observed 
an expanded list of “benefits” were being promoted to consumers beyond what 
the HT products were originally FDA-approved for, such as smooth skin and the 
convenience of HT fitting “easily into a daily beauty routine.”  Interestingly, claims 
of benefits for consumers were not supported by actual scientific sources and the 
use of hypothetical stories on several of the HT web sites to support product 
claims of benefits were perplexing patterns that I witnessed. On the other hand, 
health care professionals were presented with several “selling points,” were 
informed about the range of available dosing options, provided with evidence to 
support claims of efficacy, and told about patient satisfaction with HT products.  
Second, I explored how the side effects of HT were portrayed in the online 
advertisements for HT. Notably, the side effects were presented as either 
“common” or “less common but serious” side effects across the HT web sites. 
Indeed, I found some overlap between these two categories of side effects. Thus, 
the pattern of presenting side effects to consumers as both “common” as well as 
“less common but serious” may be a source of potential confusion for 
consumers. Equally noticeable was the location of the side effects information. In 
particular, the Estrasorb web site only discussed possible side effects in the 
footer of the web site and in a smaller font size which could easily be overlooked. 
Therefore, the location and font size of the possible side effects on the Estrasorb 
web site, as well as the high reading level across all of the HT web sites, were 
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causes for concern and highlighted the need for better risk communication in 
online drug advertisements.  
Finally, I found that the discussion of the WHI was presented in a positive 
light to consumers and repetition of the availability of “low-dose” HT options 
reflected post-WHI concerns. Up to this point, I have examined how the location 
of information and actual descriptions were contributing factors to how the 
proclaimed benefits, possible side effects, and potential risks of HT were 
portrayed by drug manufacturers in online advertisements for HT. In the next 
chapter, I move on to summarize and discuss my key findings. 
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CHAPTER 9 
DISCUSSION 
 
Direct-to-consumer advertising (DTCA) appears to be flourishing (Conrad and 
Leiter, 2008). Since the Internet has become another direct avenue for 
pharmaceutical companies to reach consumers, it is important to determine how 
online advertisements are portraying menopause. This portrayal is relevant for 
understanding society’s views of menopause and it also “sheds light on how 
women are informed about this life-changing experience” (Hust and Andsager, 
2003, p. 114). My study of pharmaceutical web sites for hormone therapies (HT) 
indicated that a medicalized view of menopause remained consistent in the 
online advertisements. In particular, a number of conclusions can be drawn from 
my findings.  
 
Biomedical Perspective of Menopause 
 
First, the pharmaceutical web sites for HT consistently articulated a 
biomedical perspective of menopause. An underlying assumption of the 
biomedical model is that menopause is “best understood in terms of the biology 
of disease mechanisms” (Derry, 2002, p. 20). In adopting a medical perspective, 
descriptions on the pharmaceutical web sites for HT described menopause as a 
“change of life” or a “stage” requiring medical management.  The web sites 
consistently advocated that this “change” was best managed by a medical 
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professional. Thus, the physician’s role and expertise in offering a diagnosis was 
reinforced. This finding is consistent with previous research that has also noted 
women are often told they should depend on a physician’s medical expertise 
rather than on their own judgment (Kaufert and Gilbert, 1986). 
Previous studies have also shown that menopause has been framed in 
popular magazines as a “deficiency disease” easily fixed with drugs (Cimons, 
2008; Lupton, 1996; Meyer, 2001; Shoebridge and Steed, 1999). In this study, I 
found that explanations for menopause on the web sites focused exclusively on 
the loss of hormones and the end of regular menstruation. By emphasizing 
menstrual cycle changes and declining estrogen production, the HT web sites 
drew on biomedical definitions of menopause. With such words as adjusting, 
balance, and decline found on the HT web sites, the implication was that women 
need to “balance” or “make up” for the loss of estrogen production. Therefore, 
“deficiency” and “loss” were common themes on the pharmaceutical web sites. 
This finding is similar to other researchers that found the terms “deficiency” and 
“atrophy” were used in self-help texts about menopause (Lyons and Griffin, 
2003). Clearly, this language reflected a biomedical model that views menopause 
as an “estrogen deficiency disease for which estrogen replacement is the therapy 
of choice” (Kaufert and Gilbert, 1986, p. 8). Importantly, these words on the web 
sites also set the stage for the idea of using prescription HT products to restore 
this balance. As Derry (2008) notes, postmenopausal women “do produce 
estrogen in their bodies [but] these lower levels of hormones were assumed to be 
negligible” (p. 722).  
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To further illustrate this point, menopause was described on the 
CombiPatch web site as when a woman’s “reproductive system slowly shuts 
down.” By describing a woman’s reproductive system as “slowly shutting down,” 
the mechanical language was reminiscent of the biomedical model in which the 
body is viewed as a machine breaking down. Here, this particular online 
advertisement likened the aging female body to a machine “breaking down.” 
Again, this comparison contributed to the portrayal of menopause as a declining 
biological process or function. My finding reinforces previous research also 
showing menopause has been socially constructed by clinical communities and 
pharmaceutical companies as a pathological and an abnormal condition in need 
of medical intervention (Dillaway, 2005; McCrea, 1983; Posner, 1979; Riessman 
1983; Whittaker, 1998). 
Further analysis revealed that the pharmaceutical web sites were 
prescriptive and advocated certain consumer behaviors or actions. Specifically, 
women were told to “discuss” or “ask” their health care provider about HT. The 
web sites implied by following-up with a physician to inquire about HT, women 
would learn more about the “relief” they could expect from using HT. Hence, the 
biomedical definitions of menopause, explanations of menopause focusing on 
estrogen loss, and the consumer actions being advocated on the pharmaceutical 
web sites worked together to portray menopause as a medical event to be 
medically managed. 
 
Presentation of “Problematic” Symptoms  
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As Rostosky and Travis (1996) noted, menopause continues to be defined 
by a long list of symptoms derived from the biomedical research. This pattern 
persisted on the pharmaceutical web sites for HT in which a range of 
menopausal “symptoms” were listed. One of the most sweeping aspects of the 
HT web sites was the overall portrayal of symptoms in a negative light. This was 
accomplished by presenting symptoms in terms of physical symptoms, such as 
hot flashes, night sweats, and vaginal dryness. The physical symptoms were 
then associated with having a negative impact on social and personal relations. 
Symptoms such as hot flashes and vaginal changes were presented to 
consumers as “problematic” using such language as debilitating, reduced sense 
of self, and hampered sex lives.  
The term “symptom” itself is commonly associated with problems and 
illness (Rostosky and Travis, 1996). By portraying symptoms as “disruptive,” 
such symptoms were presented as problematic to consumers thereby further 
positioning them within a disease-like model requiring medical treatment. Women 
were also told on the web sites that their symptoms were to be tracked and 
managed which related to a disease-like model of menopause. The terms 
“tracking,” “assessing,” and “managing” are also symbolic medical terms that 
stem from a dominant biomedical view of menopause.  Certainly, the use of 
negative language in the portrayal of symptoms helped to set the stage for using 
the HT products. Such negative language consistently conveyed the message 
that symptoms were bothersome and problematic for which HT was a viable 
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treatment. As noted, extremes were presented to consumers, namely that 
symptoms could become debilitating, lead to a reduced sense of self, and result 
in hampered sex lives if left untreated. It is also noteworthy that the use of 
positive language was not observed on any of the web sites in the sample, such 
as describing menopause as a “beginning” or “freedom.”  
Further, consumers visiting the ANGELIQ web site were greeted by the 
message: “Menopause. It’s a natural part of life, but these symptoms don’t have 
to be” (ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 2009). 
From this statement, consumers were told that menopause was natural. 
However, the statement further implied that symptoms were “unnatural.” Here, 
the tension between “natural” (in this case, menopause) and “unnatural” 
(menopausal symptoms) was conveyed and created a context for consumers to 
learn how to “treat” such undesirable symptoms with HT products. In this sense, 
it encouraged women to regard any changes as unacceptable symptoms.  
One of the most discernable differences across the various the HT web 
sites were the additional symptoms listed on the CombiPatch and ENJUVIA web 
sites. In particular, mood changes, mood swings, and irritability were also 
observed on the CombiPatch and ENJUVIA web sites. Moreover, the ENJUVIA 
web site further listed irregular periods, weight gain, and dry skin as “other” 
symptoms of menopause. These changes are not necessarily related to 
menopause and just because a woman may experience mood changes or 
irritability during the menopausal transition “does not mean that menopause 
caused the condition” (Mansfield and Voda, 1997, p. 60, italics in the original). 
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The web sites incorporated lists of menopausal symptoms from the existing 
biomedical literature and were able to imply a connection by listing these as 
possible symptoms and linking them with menopause in the online 
advertisements for HT. 
Additionally, three web sites in the sample (CombiPatch, femhrt, and 
PREMARIN) linked osteoporosis with menopause in such a way that 
“osteoporosis practically becomes identified as a symptom of menopause” 
implying HT could be taken to stop this process (Worcester and Whatley, 1992). 
The technique of promoting HT for the prevention of osteoporosis has been 
reported in the literature as a way to expand the list of symptoms to include 
conditions that have not been traditionally associated with menopause (Dukes, 
1997; Palmlund, 1997; Worcester, 2004; Worcester and Whatley, 1992).  By 
suggesting to potential consumers that their physical and emotional issues might 
fit medical models of menopause, the online advertisements capitalized on 
already existing lists of symptoms found in the biomedical literature and linked 
these symptoms with menopause to include emotional changes and the 
prevention of osteoporosis. While this finding is consistent with previous 
research, my analysis contributes to the existing body of literature to include 
analyses of pharmaceutical advertisements in an online environment. Here 
again, the dominant biomedical discourse of menopause was prominent on the 
pharmaceutical web sites for HT. 
 
Online Self-Diagnosing Symptom Tools 
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Likewise, the negative portrayal of menopause persisted in the online 
symptom tools found on four of the HT web sites in the study sample. In these 
instances, information was provided to consumers by means of a set of 
diagnostic questions, such as an online symptom tool that women could use to 
assess their menopausal symptoms. The use of language in the online self-
diagnosing symptom tools provided a particular context for web site users as 
they interacted with the tools to assess their symptoms and the degree of 
severity of these symptoms. The prevalence of negative language observed in 
the question wording about menopausal symptoms and the response categories 
contributed to the negative portrayal of menopause. Words such as “anxious,” 
“embarrassed,” “disruptive,” and “uncomfortable” characterized symptoms as 
problematic. Certainly, presenting symptoms as “impacting” and “affecting” daily 
activities, work, and relationships may also give motivation for seeking medical 
advice. As such, symptoms were portrayed as “problematic.” Through the use of 
such negative language observed across the online symptom tools, this also 
helped to set the stage for use of prescription HT products.  
Moreover, the categories of questions found on the self-diagnosing symptom 
tools ranged from vasomotor symptoms (commonly known as hot flashes and 
night sweats), vaginal symptoms, sexual health, and psychological symptoms. 
Once again, the inclusion of psychological “symptoms,” such as anxiety, 
irritability, sadness, and difficulty concentrating, was a technique that I have 
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noted on the HT web sites. Here again, this technique further expand the list of 
possible “menopausal symptoms” that could be treated with HT.  
Upon closer examination, I also found a significant dimension of the online 
self-diagnostic symptom tools was their attempt to encourage contact with a 
health care provider. All four of the online self-diagnosing symptom tools 
encouraged consumers to share the “results” of the symptom tools with a health 
care professional. By encouraging women to regard any “discomforts as 
unacceptable symptoms” that should be reported to a health care provider, this 
further provided evidence of the adoption of the biomedical model of menopause 
on the web sites (Derry, 2002, p. 22). A similar finding was found by Lyons and 
Griffin (2003) in which menopause was discussed in self-help books as requiring 
ongoing management by a medical professional. While previous research has 
reported that traditional print advertisements found in magazines and self-help 
books have framed menopause as necessitating medical supervision, my 
research extends the existing literature by adding an analysis of online self-
diagnosing symptoms tools that is absent from current discussions on the 
portrayal of menopause and menopausal symptoms. Thus, we saw how the 
online symptom tools provided female consumers with a context for interacting 
with the tools to assess the “impact” and severity of their symptoms.  
In addition, I also assessed the reading level of the four online symptom tools 
and found that the information presented to consumers far surpassed the 
estimated reading level of the average adult in the U.S. (National Adult Literacy 
Survey, 1992).  Indeed, since the reading level of pharmaceutical advertisements 
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for hormone therapies has not been addressed in previous studies, this is 
another dimension of my research that extends the existing body of literature. In 
sum, the online self-diagnosing symptom tools functioned to expand the range of 
menopausal symptoms to include psychological symptoms, encouraged 
consumers to report their symptoms to a health care provider, and presented 
information written at a reading level that was too high for many of the intended 
web site users.  
 
Portrayal of Characters 
 
In addition, I analyzed the images of characters in the online 
advertisements. My findings indicated that female characters were mostly 
middle-aged Caucasian women depicted as passive and shown in domestic 
settings. As Coney (1994) states, hormone therapy has been “predominantly 
used by white, middle-class women” (p. 224). Thus, the majority of the female 
characters in the online advertisements were Caucasian women which closely 
mirrored the demographic characteristics of the typical users of hormone 
therapies. 
Only one image of a health care provider was presented. In this case, the 
image portrayed the Caucasian female health care provider talking with a female 
patient in what was presumably an exam room. Not surprisingly, I found that the 
use of such iconic imagery, such as the white coat and stethoscope, reflected 
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symbols commonly associated with the health care environment making the 
health care provider easy to identify in the image.   
All of the images on the pharmaceutical web sites in the sample depicted 
people smiling. Some images showed women participating in recreational 
activities, further depicting “healthy” appearing people. While such lifestyle 
factors, such as exercising were depicted, the web sites did not state that these 
non-medical options and activities could help to reduce symptoms as previous 
research has shown (Mansfield and Voda, 1997). Rather, a woman was shown 
jogging and yet this web site stated HT was one of the most effective options to 
help manage menopausal symptoms such as hot flashes, night sweats, vaginal 
dryness, and potential bone loss. Another web site showed a woman walking in 
hiking boots and consumers were told that the HT product (a patch) would allow 
women to “get back” to an active lifestyle. Therefore, the underlying premise was 
that hormones could help to achieve the activity that was being presented. To 
this end, the visual images helped to convey health, activity, and vitality that 
could be achieved through the use of HT. According to the online 
advertisements, the “treated” woman was healthy, active, and happy. Similarly, 
Kaufert and Lock (1997) found pictures of bright, healthy, and beautiful women 
appearing in pharmaceutical brochures. Thus once again, according to the online 
advertisements for HT, the “treated” woman was portrayed as healthy, active, 
and happy.  
As noted in an earlier chapter, I also found that menopause was described 
as “natural” on one of the web sites, but consumers were then told that their 
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symptoms were unnatural. The ANGELIQ web site stated “Menopause. It’s a 
natural part of life, but these symptoms don’t have to be” (ANGELIQ web site: 
http://www.angeliq-us.com. Retrieved: July 13, 2009). From this statement, 
consumers were told that menopause was natural. However, the statement 
further implied that symptoms were “unnatural.” Here, the tension between 
“natural” (in this case, menopause) and “unnatural” (menopausal symptoms) was 
conveyed and created a context for consumers to learn how to “treat” such 
undesirable symptoms with HT products. Another example was evident in the 
statement “while there’s no way to avoid menopause” HT can reduce the impact 
of symptoms (ANGELIQ web site: http://www.angeliq-us.com. Retrieved: July 13, 
2009). On the surface these statements might appear to be the “menopause as 
natural” discourse as described by Lyons and Griffin (2003) found in self-help 
books; however, a closer examination showed these statements were not 
resisting the biomedical discourse of “menopause as a disease” as one would 
expect to see if a feminist or socio-cultural perspective of menopause was being 
articulated. In these cases, menopausal symptoms were still being portrayed as 
problematic thereby warranting treatment with HT.  
Thus, symptoms and proposed medical treatments were presented within 
a biomedical realm which reflected the traditional medical paradigm. For these 
reasons, I concluded that the web sites were not offering an alternative to the 
biomedical discourse. Rather, the images and portrayal of problematic symptoms 
requiring medical treatment helped to further articulate a biomedical model of 
menopause on the pharmaceutical web sites.    
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Information Content 
 
My analysis showed how the online information content was presented 
differently for two potential markets, female consumers and health care providers 
because specific sections of the web sites were clearly labeled for each intended 
audience. Additionally, the use of feminine imagery on the HT web sites, such as 
curves and ribbons, and the use of the colors white and purple were strategically 
used as a way to make connections with femininity in order to appeal to potential 
female consumers.  
With regards to the pharmaceutical web sites, I was concerned with what 
information was given to women and health care providers about menopause 
and HT, how information was presented to these two audiences, and what 
information was suspiciously lacking or absent. My analysis demonstrated that 
the menu options presented to consumers differed from the content for health 
care providers. First and foremost, consumers were introduced to the HT 
products and HT treatment options.  
The advertising slogans further illustrated an important distinction between 
the content being presented to consumers and health care providers. Consumers 
were informed about what can be expected from using the HT products from the 
repeated use of the words “relief,” “discover,” and “treat” observed in the 
advertising slogans. Notably, pictures of HT products and their packaging were 
included on the web sites for consumers to aid in easier consumer identification 
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of the product. In comparison, health care providers were informed about the 
range of available “treatment options” and dosage strengths. In other words, the 
information content on the pharmaceutical web sites differed depending on the 
potential market. Indeed, consumers were presented with different menu 
choices, different advertising slogans, and pictures of the actual HT products 
compared to health providers. 
The proclaimed benefits of HT were also strikingly different in their 
presentation to consumers in comparison to the content provided to health care 
professionals. As Conrad (2007) pointed out, early medical articles reported that 
estrogen could “reduce menopausal symptoms” (p. 121). Primary benefits 
promoted to consumers on the pharmaceutical web sites for HT could be 
grouped into two themes: symptom reduction and the prevention of osteoporosis. 
Clearly, this reflected a current trend of focusing on symptom management in the 
promotion of hormone therapies (Voda and Ashton, 2006). Interestingly, claims 
of benefits for consumers were not supported by actual scientific sources and the 
use of hypothetical stories on several of the HT web sites to support claims of 
benefits were patterns that I also witnessed. Similarly, Carlson, Li, and Holm 
(1997) found that authors of articles in popular magazines did not provide 
references for claims of efficacy about HT. This is troubling given that women 
have cited the popular media as a main source of information on menopause 
(Clinkingbeard et al., 1999). 
In comparison, health care professionals were presented with several 
“selling points” and were informed about the range of available dosing options, 
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provided with evidence to support claims of efficacy, and told about patient 
satisfaction with HT products. The major finding here was that the creation of 
distinct web portals for consumers and health care professionals enabled the 
drug manufacturers to organize and present information to potential markets for 
their products.  As such, this analysis contributes to our understanding of how the 
web site content differed in its presentation depending on the target audience.  
The presentation of the side effects of HT underscored the need for better 
risk communication to patients in the online drug advertisements. Notably, the 
side effects were presented as either “common” or “less common but serious” 
side effects across the HT web sites. Under further scrutiny, I found some 
overlap between these two categories of side effects. Thus, the pattern of 
presenting side effects to consumers as both “common” as well as “less common 
but serious” may be a source of potential confusion. Equally noticeable was the 
location of the side effects information. In particular, one web site only discussed 
possible side effects in the footer of the web site and in a smaller font size which 
could easily be overlooked. Therefore, both the location and font size of the 
possible side effects on the web site in the study sample was a cause for 
concern.  
Furthermore, an analysis of the reading level of the text describing the six 
common side effects of HT across the web sites in this study exceeded the 
estimated reading level of the average adult in the U.S. (National Adult Literacy 
Survey, 1992). In light of this, I concluded that the information presented across 
all of the HT web sites about “common” side effects was too difficult for many of 
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the intended web sites users. As a result, this important drug information should 
be rewritten for consumers to make informed drug-related decisions.  
 
Framing of the Women’s Health Initiative 
 
Further, I found that the discussion of the Women’s Health Initiative (WHI) for 
consumers minimized potential risks and framed the WHI in a positive light. 
Among the study sample, there were only three pharmaceutical web sites that 
provided discussions about the WHI to consumers (ANGELIQ, Femring, and 
femhrt). In particular, the Femring and femhrt web sites highlighted benefits 
reported from the WHI. These two web sites cited fewer hip fractures and fewer 
cases of colorectal cancer among users of HT in the WHI clinical trial. Clearly, 
putting a positive “spin” on the WHI results minimized concerns expressed by 
women about possible side effects associated with hormone use as reported in 
the literature (Mansfield and Voda, 1994). Further, the ANGELIQ web site stated 
that possible benefits of HT may outweigh the risks. Indeed, these three web 
sites painted a positive picture of the WHI study results by emphasizing potential 
benefits of using HT. Unfortunately, these three web sites were the only 
pharmaceutical web sites for HT in the study sample that furnished information 
about the WHI to consumers. As evident on these three web sites, concerns 
about the WHI findings were minimized by highlighting positive findings of the 
WHI and the web sites suggested that possible benefits may outweigh the 
potential risks of using HT.  
228 
 
 
As a consequence, the WHI was discussed in a limited manner on 
consumer-oriented sections of the HT web sites. Given the limited information 
about the WHI study provided to consumers, scant discussion about any 
implications, and inadequate educational information, consumers were 
encouraged to follow-up with their health care providers for explanations about 
the WHI findings and to discuss HT treatment options. Further analysis also 
revealed an emphasis on the availability of “low-dose” HT options repeated 
across the HT web sites. Thus, I posit that the pharmaceutical manufacturers 
were attempting to re-position HT as a viable treatment by highlighting positive 
results from the WHI study and emphasizing the availability of “low-dose options” 
while effectively minimizing any WHI-related concerns. As stated by Voda and 
Ashton (2006), “post-WHI risks to women’s health persist” (p. 410). 
 
Medicalization of Menopause  
 
 One of the stronger points of this study was its ability to demonstrate how 
the pharmaceutical web sites adopted a biomedical model of menopause, which 
in turn, helped to create a context for the process of medicalization to occur. 
Conrad (2007) explained the process of medicalization as defining a problem in 
medical terms, adopting a medical framework, and proposing to treat a problem 
with medical interventions. In fact, Conrad (2007) identified the pharmaceutical 
industry as one of the emerging forces providing momentum for further 
medicalization.  
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Kaufert and Gilbert (1986) further outlined several “tests for 
medicalization” that I applied to the pharmaceutical web sites to help determine if 
the process of medicalization could be occurring. One important sign is when the 
decline of estrogen production has become a central theme (Kaufert and Gilbert, 
1986).  As evident in my findings, the loss of hormones was used across all of 
the web sites in the sample to explain a “reason” for menopause. As a result, 
menopause was defined exclusively as a biological event.  
Another sign of medicalization is when proposed treatment options for 
menopause involve the use of hormone therapies to supplement or balance the 
loss of hormones (Kaufert and Gilbert, 1986). Here again, since menopause was 
presented as disease-like requiring medical management, the online 
advertisements helped to introduce the idea of using HT to restore or balance 
hormone levels. Furthermore, symptoms were portrayed as unnatural, 
problematic, and bothersome further setting the stage for use of HT. 
Another indication that medicalization can be occurring is when women 
are told that they should depend on a physician to have their menopausal status 
recognized and defined, rather than relying on their own judgment (Kaufert and 
Gilbert, 1986). On the ENJUVIA web site, consumers were informed that health 
care professionals “can determine which treatment is right.” As the above quote 
demonstrated, the “expert” role of physicians was reinforced as well as their 
authority to define and categorize women’s experiences.  
In this context, the web sites in the study sample exhibited the “signs” 
 that medicalization could be occurring. Primarily, the web sites explained 
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menopause in biomedical terms implying it was a medical event to be medical 
managed. Further, the loss of hormones was a common theme on the web sites 
which introduced HT as a way to restore or balance hormone levels. The web 
sites also reinforced medical authority in providing a medical diagnosis over 
women’s experiences.  
My analysis also revealed another important technique missing from 
previous discussions about medicalization in the literature. The reading level of 
the online symptom tools and side effects information far surpassed the 
estimated reading level of the average adult in the United States, thus creating a 
context for which medicalization could also occur. Since the reading level of 
information found on the pharmaceutical web sites in the sample was too high, it 
suggested consumers may need to consult with a health care to make sense of 
the information. In this way, it also reinforced the role of physician as an “expert.”   
This finding pushes and extends the existing literature to include a new 
“test” for medicalization. As a result of this finding, I propose the reading level of 
information is one more sign further demonstrating how the process of 
medicalization was operating on the pharmaceutical web sites for HT. Hence, 
this finding adds and contributes new dimensions to the analyses of the 
medicalization of menopause in direct-to-consumer advertisements. When taken 
together as a whole, we gain a sense of how the web sites provided a context for 
the process of medicalization to occur on the pharmaceutical web sites for HT.   
 
Comparison of Pharmaceutical Web Sites  
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Although my findings revealed some unifying themes across the HT web 
sites, there were some marked differences across the pharmaceutical web sites. 
All of the web sites in the sample drew heavily on the “menopause as disease” 
discourse and emphasized the loss of hormones as a “reason” or explanation for 
menopause. While an emphasis on change was clear on the web sites, only one 
web site (PREMARIN) actually used the word “decline.” Other web sites, such as 
ANGELIQ, CombiPatch, and femhrt, employed the terms “adjustment” and 
“balance.” Yet, when taken together the language on the web sites helped to set 
the stage for using the HT products in order to balance or restore hormone 
levels.  
Unique among the study sample was the ENJUVIA web site for its use of 
biomedical rhetoric for describing symptoms. Specifically, the terms “vasomotor 
symptoms” and “vaginal atrophy” were used on the ENJUVIA web site. This 
biomedical nomenclature suggested a disease-like nature of menopause and 
placed these “symptoms” within a medical context.   
In comparison to the other online symptom tools, the ENJUVIA symptom 
tool was the only one to include psychological symptoms among the list of 
possible menopausal symptoms. Specifically, the ENJUVIA “Menopause Impact 
Tool” included psychological symptoms such as anxiety, irritability, sadness, and 
difficulty concentrating. The inclusion of such psychological symptoms in the 
ENJUVIA online tool implied to consumers that they were both important and 
also linked to menopause. 
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Additional menopausal “symptoms” were listed on the CombiPatch and 
ENJUVIA web sites, including mood changes, mood swings, and irritability. 
Moreover, the ENJUVIA web site further listed irregular periods, weight gain, and 
dry skin as “other” symptoms of menopause.  These changes are not necessarily 
related to menopause and by having these listed as so-called symptoms of 
menopause on the CombiPatch and ENJUVIA web sites suggested a possible 
link or association.  
Moreover, the CombiPatch web site described menopause as when a 
woman’s “reproductive system slowly shuts down.” The mechanical language 
was reminiscent of the biomedical model in which the body is viewed as a 
machine breaking down.  Here, the aging female body was compared to a 
machine “breaking down” illustrating how menopause was being articulated as a 
declining biological function.   
The above examples help to illustrate the differences among the HT web 
sites. In comparison to other web sites the sample, CombiPatch and ENJUVIA 
presented menopause as a highly medicalized process with their use of 
biomedical rhetoric (i.e. “atrophy” and “ovaries shutting down”). Furthermore, the 
CombiPatch and ENJUVIA web sites included psychological symptoms and 
linked them with menopause. For these reasons, I concluded that the degree of 
medicalization across the web sites varied with the CombiPatch and ENJUVIA 
web sites being more explicit in their adoption of a biomedical perspective and 
perpetuating that menopause was a medical event requiring medical 
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management. In the final chapter, I discuss several policy implications of my 
findings and ideas for future research. 
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CHAPTER 10 
CONCLUSIONS 
 
Advertisements are one of the most important cultural factors molding and 
reflecting our lives (Williamson, 2002). In fact, 30% of adults surveyed in the 
United States claim that they have talked with a physician about a specific 
medication as a result of some form of direct-to-consumer advertising (Kaiser 
Family Foundation, 2001). Meanwhile, Conrad and Leiter (2008) note how the 
Internet has become “another direct avenue from pharmaceutical companies to 
consumers” (p. 834). Hence, the proliferation of online health information 
provided to consumers on pharmaceutical web sites provides momentum for 
investigations of media representations of health, disease, and illness. In 
particular, consumer-targeted prescription drug advertising serves as an 
interesting lens through which we can begin to examine the portrayal of 
menopause in online drug advertisements. Therefore, the aim of this study was 
to explore the portrayal of menopause on web sites sponsored by 
pharmaceutical companies for hormone therapies (HT). 
In this study, menopause was defined as a natural part of the aging process, 
rather than an event that limits women’s psychological or physical capacities 
(McCrea, 1983). Previous research has illuminated aspects of the 
pharmaceutical industry’s involvement in the promotion of hormone therapies 
(HT) for the treatment of menopausal symptoms, such as hot flashes, night 
sweats and vaginal changes, to physicians and consumers through 
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advertisements in medical journals, newspapers, and popular magazines. Yet, 
little is known about the convergence of women and menopause in 
advertisements for HT in the online environment.  
In this study, I was particularly concerned with the representation of 
menopause in online advertisements for HT. Therefore, the main purpose of this 
study was to explore the portrayal of menopause on web sites sponsored by 
pharmaceutical companies for FDA-approved HT. To address this issue more 
fully, I investigated the descriptions of menopause, portrayal of menopausal 
“symptoms,” and the use of online self-diagnosing symptom tools. Additionally, I 
analyzed the presentation of proclaimed benefits and possible side effects as 
well as the portrayal of various characters depicted in the online drug 
advertisements. I also sought to examine if the online information was presented 
differently for various web site audiences, such as consumers and health care 
professionals.  
To unravel these questions, a qualitative content analysis of web sites for 
FDA-approved hormone therapies (HT) was undertaken to gain an 
understanding of how menopause was being portrayed in online drug 
advertisements. Using this qualitative method allowed the researcher to perform 
some exploratory research that suggests additional qualitative research in this 
area would be productive. A total number of 608 printed pages of web site 
content from eight web sites (N=8) for HT were analyzed in this study. The full-
text of the web pages was analyzed with a focus on the content and contextual 
meaning of the text and visual elements. In order to make the study as 
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reproducible and systematic as possible, I developed a coding instrument to help 
characterize the online drug advertisements. 
Four research questions guided data collection and analysis. The four 
research questions again were:  
 
1. What was the prominent discourse about menopause on the 
pharmaceutical web sites? Did it vary across the web sites? If 
the biomedical perspective was used in the portrayal of 
menopause, then menopause would be presented as a medical 
event to be medically managed. Furthermore, “deficiency” would 
be a common theme if the biomedical perspective was 
accepted. If a feminist perspective was used in the portrayal of 
menopause, I would expect to see an alternative discourse that 
rejected the medical construction of menopause as requiring 
medical treatment and supervision by a health care 
professional.  In addition, I explored how symptoms were 
presented and if the symptoms were the same across the web 
sites.  
2. How was the Women’s Health Initiative (WHI) framed on the 
pharmaceutical web sites? Likewise, I also examined if 
evidence of actual clinical studies, such as the WHI or others, 
were referenced on the pharmaceutical web sites. 
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3. Who were the intended target audience or audiences of the web 
sites? To help determine if the web sites were geared towards a 
specific audience, I examined the language and/or visual cues 
employed on the pharmaceutical web sites. 
4. Was the information presented differently for various audiences, 
and if so, how? (i.e. health professionals, consumers, etc.). For 
example, I investigated if the advertising slogans differed 
depending on the target audience. In addition, I examined what 
(if anything) was absent or lacking on the web sites. 
 
These questions also set the stage for my analysis which was divided into 
five chapters spanning an overview of the web site characteristics, textual and 
visual elements of the web sites, the portrayal of menopause, and the 
presentation of benefits and side effects of HT. In particular, Chapters 5 and 6 
focused on the characteristics of the direct-to-consumer web sites for HT. In 
these chapters, I examined the menu options, slogans, color schemes, and 
imagery employed on the web sites for both consumers and health care 
professionals. Two questions were explored in these chapters. In particular, I 
identified two main audiences for the HT web sites, consumers and health care 
providers, and I also investigated how the online information was presented 
differently for these two potential markets.  
Chapter 7 explored the portrayal of menopause on the web sites for HT. 
One key question was examined in this chapter. Specifically, this chapter 
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revealed how menopause was being portrayed in the online advertisements by 
analyzing the definitions of menopause, descriptions of menopausal “symptoms,” 
and self-diagnosing symptom tools found across the HT web sites in the study 
sample. Chapter 8 analyzed the presentation of benefits and side effects of HT. 
This chapter helped to illuminate what was deficient or missing in the online drug 
advertisements for HT, such as references to actual clinical studies to support 
proclaimed benefits and scant discussion of the Women’s Health Initiative for 
consumers. Chapter 9 offered a discussion of my key findings and drew on 
similar studies from the literature. 
 
Key Findings  
 
My study of pharmaceutical web sites for hormone therapies (HT) indicated 
that a medicalized view of menopause was consistent in the online 
advertisements. In general, menopause was portrayed on the pharmaceutical 
web sites as a medical event caused by a loss of hormones often accompanied 
by “problematic” symptoms that could be alleviated by hormone therapies. Other 
authors have reached similar conclusions about the biomedical framing of 
menopause in traditional print magazine advertisements (Gannon and Stevens, 
1998; Hust and Andsager, 2003; Lyons and Griffin, 2003; Shoebridge and Steed, 
1999). My analysis contributed to the existing literature by adding an analysis of 
pharmaceutical advertisements in the online environment. Hence, my findings 
reinforced the overall dominance of the biomedical perspective of menopause in 
239 
 
 
advertisements. One of the stronger points of this study was its ability to 
demonstrate how a biomedical model of menopause was adopted and advanced 
on the pharmaceutical web sites which, in turn, created a context for which the 
process of medicalization could occur. To this end, several important findings 
emerged from my analyses.  
First and foremost, the web sites drew heavily on terms that were negative 
and focused overwhelmingly on hormone loss thereby contributing to the 
disease-like conceptualization of menopause. In particular, “deficiency” and 
“loss” were common themes. In doing so, the pharmaceutical companies were 
able to effectively set the stage for using their HT products to adjust or balance 
hormone levels. My findings also showed that potential female consumers were 
exposed to an array of models and visual cues associated with positive 
characteristics (i.e. healthy, active, and smiling) that consumers might identify 
with. Moreover, the images of women found on the pharmaceutical web sites 
frequently depicted women within the domestic realm. Given that the majority of 
the female characters in the online advertisements were Caucasian women this 
also mirrored the demographic characteristics of both the common users of 
hormone therapies and typical users of the Internet. To be sure, this is important 
because if consumers identify with the models in the online advertisements for 
HT, then they “may also be more likely to engage in health care behaviors 
needed to gain access to the advertised products” (Cline and Young, 2004, p. 
151).  
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Further analysis revealed that drug manufacturers promoted the 
widespread use of HT for an extended range of menopausal “symptoms” 
treatable with HT, such as weight gain and dry skin. To this end, I also found that 
claims of benefits for consumers were not supported by actual scientific sources 
on the web sites and the use of hypothetical “women’s stories” to support product 
claims was also observed. One web site discussed possible side effects in the 
footer of the web site and in a smaller font size which could easily be overlooked.  
The finding that a biomedical perspective was prominent on the 
pharmaceutical web sites was, in general, consistent with previous research on 
the framing of menopause in print magazine advertisements. However, my 
analysis of the reading level of information and the online self-diagnosing 
symptom tools offered new dimensions to research on the framing of menopause 
in advertisements. As a result of my findings, I propose that the high reading 
level of information contained in the advertisements is one more “test” signifying 
that medicalization was operating on the pharmaceutical web sites for HT. This 
finding pushes and extends the existing body of literature to include a new “test” 
for medicalization.  
Moreover, limited information was provided to consumers about the 
Women’s Health Initiative (WHI) study while pharmaceutical companies 
appeared to be re-positioning HT as a viable treatment by emphasizing “low-
dose options.” As noted, three pharmaceutical web sites highlighted positive 
benefits from the WHI study and consumers were encouraged to ask their health 
care providers if potential benefits of using HT may outweigh the risks. Given 
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these findings, my analysis suggests there is a need for better risk 
communication in online drug advertisements for HT. 
 
Limitations of the Study 
 
This study had some limitations. First, the dataset was only comprised of 
FDA-approved Estrogen and Estrogen-Progestin products for the treatment of 
postmenopausal women. While the degree of medicalization within the dataset 
was observed and analyzed, it was not clear how this compared with other online 
DTC advertisements for menopause such as herbs, supplements, and alternative 
therapies. Second, due to the subjective and interpretive nature of this qualitative 
research, two researchers might have arrived at different conclusions of the 
online advertisements for hormone therapies. Furthermore, the study sample 
was small and consisted of eight web sites for FDA-approved hormone therapies.  
At the time of the study, only eight pharmaceutical companies for FDA-approved 
hormone therapies had active web sites available for analysis. Further, this study 
was a cross-sectional observation and the dataset was collected at one point in 
time. Therefore, this study by design did not set out to investigate if online drug 
advertisements for HT have changed over time. Finally, this analysis was based 
on a particular perspective grounded in the sociology of health and illness and 
medicalization frameworks. Although the pharmaceutical web sites were 
analyzed from this perspective, my findings indicate that future research can help 
to examine the marketing decisions behind the development of such web sites 
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and how women have responded to the online drug advertisements for hormone 
therapies. 
 
Directions for Future Research  
 
This study demonstrates the need for further examination of gender and 
aging in online drug advertisements. This study focused on FDA-approved HT 
products for the treatment of postmenopausal women. Therefore, another 
productive area of future research might be analyzing online advertisements for 
other menopausal remedies, such as natural and herbal supplements. In 
addition, in-depth interviews with women users of the web sites could help 
illuminate how consumers search for and evaluate the credibility of information 
on the World Wide Web about menopause. A better understanding of the users 
of the web sites, such as their age, race, education level, and their use of the 
online symptom tools (i.e. do women print off the symptom assessment tools and 
share them with a health care provider?), would also be useful.  
Another possible study could investigate if the portrayal of menopause has 
changed over time in direct-to-consumer advertisements. Such an analysis would 
add an extra layer of complexity missing from past discussions of the 
representation of menopause in advertising. It might also be interesting to 
compare the portrayal of menopause across various types of media, including 
print, television, and online media.   
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Further research is also needed to examine online drug advertisements 
for “male” menopause and “female” menopause. With the advent of Viagra and 
other treatments aimed at male consumers, it would be interesting to explore 
how this portrayal is framed for different audiences. Hence, such a study could 
help elucidate the messages about gender and aging manifested in online drug 
advertisements.  
 
Policy Implications 
 
Three major implications arise from this study. First, there is a need for 
better risk communication in online drug advertisements for HT. In particular, the 
location of side effects information was observed only in the footer on one web 
site and in a smaller font size. Therefore, this important information is likely to be 
overlooked. Furthermore, an overlap between the “common” side effects and 
“serious but less common” side effects was noted across the web sites in the 
study sample which could be a source of potential confusion for patients. This 
study has also shown that there was little discussion of the concerns brought to 
light by Women’s Health Initiative (WHI) study for consumers on the web sites. In 
fact, three pharmaceutical web sites highlighted positive benefits from the WHI 
study and suggested to consumers that potential benefits of using HT may 
outweigh the risks. As noted, another distinguishing characteristic was the lack of 
scientific evidence provided for consumers to support various advertised benefits 
of HT. Given the vagueness of the statements about benefits and limited 
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discussion about risks, more information is needed for women to be able to 
weigh the benefits and risks of HT. Hence, the need for better communication 
and educational information for consumers in online advertisements for HT was 
evident. 
Second, this study revealed the promotion of an expanded list of “benefits” 
to consumers beyond what the HT products were originally FDA-approved for. By 
proposing such an expansive range of symptoms could be “fixed” with HT 
products, such as dry skin and irritability, the online advertisements proposed HT 
as a viable option for a range of so-called symptoms. Furthermore, the use of 
“hypothetical” women’s stories to support product claims of benefits and efficacy 
was another pattern observed on several of the web sites. Taken together, these 
patterns illustrated a process by which non-medical problems were being defined 
as medical problems along with proposed medical interventions (Conrad, 2007). 
Therefore, a closer examination of how online drug advertisements are making 
claims about their products is warranted. 
Third, data from this analysis also demonstrated that the reading level of 
the online symptoms tools and side effects information found on the 
pharmaceutical web sites far surpassed the reading level of the average adult in 
the United States (National Adult Literacy Survey, 1992). As such, this finding 
served as an important reminder. Clearly, safety and risk information in online 
drug advertisements must be written at an appropriate reading level and 
considerations for those with limited literacy skills should also be taken into 
account.  
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This research contributed to the critical reflection of direct-to-consumer 
advertising with implications for information literacy in the digital age. Women 
seeking health-related information about prescription drug products can use the 
following questions as a set of guidelines whenever evaluating pharmaceutical 
web sites. Moreover, this education can be further facilitated by nurses, 
physicians, health educators, and librarians when working with consumers 
seeking online health-related information: 
 
• Who is the intended audience (or audiences) of the pharmaceutical 
web site? 
• When was the web site last updated? 
• Who provided the information on the web site and what are their 
credentials? 
• Is contact information provided in case you have questions or need 
further information?  
• Does the web site provide a link to U.S. Food and Drug 
Administration (FDA) web site? 
• Were you able to locate both the benefits and side effects 
information about the pharmaceutical product being advertised?  
• Is a “fair balance” of the proposed benefits and potential risks 
provided on the web site? 
• Is any information on the web site provided in a smaller font size? If 
so, is this information difficult to read? 
246 
 
 
• Does the web site encourage you to ask a health care provider 
about a specific prescription drug product? 
• Does the web site provide an online self-diagnosing symptom tool 
to assess the frequency and severity of your symptoms? 
• If so, does the web site encourage you to print off and share your 
“symptom report” with a health care provider?  
• Does the pharmaceutical web site provide information about non-
medical options, such as exercise and diet modifications, that might 
help to reduce symptoms? 
• If claims about a prescription drug product are being made, are 
citations to scientific sources provided to support these claims? 
 
Summary   
  
Advertising deconstruction “is not trivial” (Cortese, 2008, p. 4). 
Pharmaceutical companies spend a substantial amount of money on direct-to-
consumer advertising. Since the FDA’s relaxation of its regulation in 1997, 
pharmaceutical industry spending on direct-to-consumer advertising (DTCA) has 
more than tripled reaching $4.2 billion in 2005 for American broadcast DTCA 
efforts (Conrad and Leiter, 2008). Additionally, advertisements are visually 
appealing, symbolic, and persuasive. To better understand the construction of 
menopause in online drug advertisements, the specific aim of this study was to 
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explore how menopause was being portrayed on direct-to-consumer web sites 
for HT sponsored by pharmaceutical companies.  
To accomplish this, I employed a qualitative content analysis approach to 
data collection and analysis in order to develop a fuller understanding of the 
phenomenon under investigation. By analyzing the information content and how 
menopause was portrayed on web sites for HT, my analysis offered insight into 
how menopause was constructed in online direct-to-consumer advertisements 
and addressed a knowledge gap in relation to representations of menopause on 
pharmaceutical web sites. This qualitative investigation provided evidence 
demonstrating how menopause was portrayed as a medical event necessitating 
medical treatment in the online advertisements for HT.  Overall, the online 
advertisements articulated a biomedical perspective of menopause.  
In conclusion, the findings of this study illuminated how menopause was 
being portrayed in online advertisements for HT and the means that were used to 
construct this portrayal. Findings from this research are useful for understanding 
how menopause was portrayed in drug advertisements for hormone therapies in 
the online environment. The bottom line is that negative language and visual 
images portrayed symptoms of menopause as “problematic” thereby effectively 
placing menopause under the rubric of medical supervision. In this way, the 
portrayal of menopause as “disease-like” set the stage for use of the HT products 
advertised on the pharmaceutical web sites to alleviate “problematic” and 
bothersome symptoms. Further, by suggesting to potential female consumers 
that their physical and emotional issues might fit medical models of menopause, 
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the online advertisements expanded the list of possible menopausal symptoms. 
Conrad (2007) identified “diagnostic expansion” as one way in which 
medicalization can occur (p. 47). As a result, my analysis of the pharmaceutical 
web sites revealed an expansion of definitional boundaries to include new 
problems and potentially new markets beyond what HT was originally designated 
for.  
Several of my findings reinforced the acceptance and dominance of the 
biomedical model of menopause in advertising. Additionally, one of the strengths 
of this study was my analysis of the reading level, online symptom tools, and the 
framing of the WHI in online pharmaceutical advertisements for HT. To this end, 
this research contributes to the existing body of literature to include analyses of 
representations of menopause on pharmaceutical web sites for HT. Indeed, while 
physicians are “still the gatekeepers for many drugs, the pharmaceutical 
companies have become a major player in medicalization” (Conrad, 2007, p. 
134). As online direct-to-consumer advertising becomes increasing prevalent, 
research that delves into the intersection of gender, aging, and consumer-
targeted prescription drug advertising on the World Wide Web is further 
warranted.  
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APPENDIX A 
CODE SHEET  
FOR DTC WEB SITE ADVERTISEMENTS 
 
 
 
Categories Examined: 
 
 
1. Type of product (tablet, lotion, ring, or patch) 
2. Name of product  
3. How menopause is defined 
4. “Causes” of menopause 
5. How symptoms are portrayed  
6. Presentation of benefit  
7. Presentation of side effects 
8. Prescription for action (action/behavior being advocated) 
9. Nature of portrayal of patients (characteristics) 
10.  Nature of portrayal of health care providers (characteristics) 
11.  Mention of WHI (yes or no? location?)  
12.  Web site characteristics: 
• Number of web sites with lay person and health provider portals 
• How are the portals labeled? (i.e. how many web sites portals use 
the term “health care providers”?) 
• Number of menu items on the site for consumers 
• Menu options for consumers (list by web site) 
• Number of menu items on the site for health care providers 
• Menu options for health providers (list by web site) 
• Slogans for consumers  
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• Slogans for health care providers  
• Information provided to health professionals to distribute to 
patients?  (On every web site? in PDF? need to order?) 
• How many web sites include references or citations? (If so, where 
are they located? Consumer pages or health provider pages?) 
• How many web sites show pictures of HT products? Packaging? 
• How many web sites have self-diagnosis tools? (symptom tools) 
• How many web sites have guide or list of questions to ask your 
health provider? 
• How many web sites have coupons or free samples? 
• Colors used on web site 
• Imagery: How many use flowers, nature, ribbons, etc. 
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CODE SHEET 
 
 
1. Type of product (tablet, lotion, ring, or patch) 
2. Name of product   
3. How menopause is defined Description: (describe how menopause 
is defined) 
 
4. “Causes” of menopause Description (check all that apply): 
• Aging 
• End of reproductive capacity 
• Other: 
________________________  
5. Portrayal of symptoms Description (check all that apply): 
• “Deficiency” 
• “Burden” 
• “End” 
• “Beginning” 
• “Transition” 
• “Natural” 
• “Inevitable” 
• Other: ___________________ 
6. Presentation of benefit  Description (check all that apply): 
• “effective”  
• “proven”  
• “works”  
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• “reliable” 
•  “cure” 
• “prevents”  
• “prolongs”  
• “controls” 
• “manages” 
• Other: _____________________ 
• Are testimonials / personal 
stories used to support benefit? 
(Yes/No) 
• Are studies cited to support 
benefit? (Yes/No) 
7. Presentation of side effects Description (language used) 
• Are potential side effects 
mentioned? (Yes/No) 
• How are potential side effects 
presented?  
o Font consistent with other 
sections of the Web site 
o Smaller font 
o Side effects are not 
mentioned 
8. Prescription for action  (action or behavior being advocated / 
encouraged) 
• See your doctor 
• Feel healthy again 
• Other: 
_______________________ 
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9. Nature of portrayal of 
patients/characters 
(characteristics) 
• Gender 
• Estimated age 
• Estimated race 
• Dress (business suit, jogging suit, 
etc.) 
• Primary setting 
• Primary behavior/activity 
10. Nature of portrayal of health 
providers 
(characteristics) 
• Gender 
• Estimated age 
• Estimated race 
• Dress 
• Primary setting 
• Primary behavior/activity 
• Are any credentials listed?  
11. WHI (mentioned / 
referenced?) 
• WHI mentioned? Yes/No 
• Location/where on web site? 
12. Web site characteristics  
• Number of web sites 
with lay person and 
health provider portals 
 
• How are the portals 
labeled? (i.e. how many 
web site portals use the 
term “health care 
providers”?) 
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• Number of menu items 
on the site for 
consumers 
 
• Menu options for 
consumers (list by web 
site) 
 
• Number of menu items 
on the site for health 
care providers 
 
• Menu options for health 
providers (list by web 
site) 
 
• Slogans for consumers  (Advertising message that appears in 
the largest font) 
 
• Slogans for health care 
providers  
(Advertising message that appears in 
the largest font) 
 
• Information provided to 
health professionals to 
distribute to patients?  
(On every web site? in 
PDF? need to order?) 
 
• How many web sites 
include references or 
citations? (If so, where 
are they located? 
Consumer pages or 
health provider pages?) 
 
• How many web sites 
show pictures of HT 
products? Packaging? 
 
• How many web sites 
have self-diagnosis 
tools? (symptom tools) 
• Symptom Tool: Yes/No 
 
• How many web sites 
have guide or list of 
• Guide to Talking with Health 
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questions to ask your 
health provider? 
Provider: Yes/No 
• How many web sites 
have coupons or free 
samples? 
• Coupons: Yes/No 
• Free samples: Yes/No 
• Colors used on web site  
• Imagery: How many use 
flowers, nature, ribbons, 
etc. 
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Consumer-targeted prescription drug advertising serves as an interesting 
lens through which we can examine the portrayal of menopause in online drug 
advertisements. The aim of this study was to explore the portrayal of menopause 
on web sites sponsored by pharmaceutical companies for hormone therapies 
(HT). To unravel this question, a qualitative content analysis of web sites for 
FDA-approved hormone therapies was employed. A total number of 608 printed 
pages of web site content from eight web sites (N=8) were analyzed. Key 
findings elucidated how menopause was portrayed on the pharmaceutical web 
sites. First, descriptions of menopause articulated a biomedical perspective of 
menopause. In adopting a biomedical perspective, menopause was described as 
a medical event requiring medical treatment. Second, the web sites employed 
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the terminology of illness, including the term “symptoms” which is a medically 
symbolic term. Women were told that their symptoms were to be assessed, 
tracked, and managed which related to a disease-like model of menopause. If left 
untreated, the web sites implied that symptoms could lead to hampered sex lives 
and a reduced sense of self. Third, the web sites were prescriptive and 
advocated consumer behaviors. Specifically, women were told to “ask” their 
health care provider about HT. Likewise, the “expert” role of the physician in 
providing a diagnosis was also reinforced. Fourth, another distinguishing 
characteristic was the lack of scientific evidence provided for consumers to 
support proclaimed benefits. The Women’s Health Initiative (WHI) was framed in 
a positive light and consumers were told that potential benefits of HT may 
outweigh the risks. Finally, the reading level of the pharmaceutical web sites far 
surpassed the reading level of the average adult in the United States. Overall, my 
findings reinforced the acceptance and dominance of the biomedical model of 
menopause in advertising. Additionally, one of the strengths of this study was the 
analysis of the reading level, online self-diagnosing symptom tools, and the 
framing of the WHI in online pharmaceutical advertisements. To this end, this 
research contributes to the existing body of literature to include analyses of 
representations of menopause on pharmaceutical web sites. 
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